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 SUMMARY  1 
1  Summary 
Tumor-associated  macrophages  (TAM)  are  a  major  supportive  component  within 
neoplasms  and  by  their  plasticity  promote  all  phases  of  tumor  development. 
Mechanisms of macrophage (M) attraction and differentiation to a tumor-promoting 
phenotype, defined among others by distinct cytokine patterns such as pronounced 
immunosuppressive interleukin 10 (IL-10) production, are largely unknown. However, 
a high apoptosis index within tumors and strong M infiltration correlate with poor 
prognosis. Thus, I aimed at identifying signaling pathways contributing to generation of 
TAM-like M by using supernatant of apoptotic cancer cells (ACM) as stimulus. 
To  distinguish  novel  factors  involved  in  generating  TAM-like  M,  I  used  an 
adenoviral  RNAi-based  approach.  The  primary  read-out  was  production  of  IL-10. 
However, mediators modulating IL-10 were re-validated for their impact on regulation 
of the cytokines IL-6, IL-8 and IL-12. Following assay development, optimization and 
down-scaling to a 384-well format, primary human M were transduced with 8495 
constructs of the adenoviral shRNA SilenceSelect® library of Galapagos BV, followed by 
activation to a TAM-like phenotype using ACM. I identified 96 genes involved in IL-10 
production  in  response  to  ACM  and  observed  a  pronounced  cluster  of  22  targets 
regulating IL-10 and IL-6. Principal validation of five targets of the IL-10/IL-6 cluster was 
performed using siRNA or pharmacological inhibitors. Among those, IL-4 receptor- 
and cannabinoid receptor 2 were confirmed as regulators of IL-10 and IL-6 secretion. 
One protein  identified  in the screen, the nerve growth factor (NGF) receptor 
TRKA was chosen for in-depth validation, based on its involvement in IL-10, IL-6 and 
IL-12 secretion from ACM-stimulated human M. TRKA possesses a cardinal role in 
neuronal development, but compelling evidence emerges suggesting participation of 
TRKA  in  cancer  development.  First  experiments  using  pharmacological  inhibitors 
principally confirmed the involvement of TRKA in IL-10 secretion by ACM-stimulated 
M and revealed PI3K/AKT and to a lesser extend MAPK p38 as important signaling 
molecules  downstream  of  TRKA  activation.  Signaling  through  TRKA  required  the 
presence of its ligand NGF, as indicated by NGF neutralization experiments. NGF was 
not  induced  by  or  present  in  ACM,  but  was  constitutively  secreted  by  M. 
Interestingly,  M  responded  to  authentic  NGF  with  neither  AKT  and  p38 
phosphorylation  nor  IL-10  production.  TRKA  is  well  known  to  be  transactivated  by SUMMARY  2 
other  receptors  and  in  neurons  its  cellular  localization  is  decisive  for  its  function. 
Inhibitors of common transactivation partners did not influence IL-10 production by 
human M. Rather, ACM-treatment provoked pronounced translocation of TRKA to 
the  plasma  membrane  within  10  minutes  as  observed  by  immunofluorescence 
staining. Consequently, I was intrigued to clarify mechanisms of TRKA trafficking in 
response to ACM.  
The bioactive lipid sphingosine-1-phosphate (S1P) has been previously identified 
as important apoptotic cell-derived mediator involved in TAM-like M polarization. 
Indeed, I observed S1P and src kinase involvement in ACM-mediated IL-10 induction. 
Furthermore,  inhibition  of  S1P  receptor  (S1PR)  signaling  or  src  kinase  activity 
prevented TRKA translocation, whereas a TRKA inhibitor or anti-NGF did not block 
TRKA  trafficking  to  the  plasma  membrane  in  response  to  ACM.  Thus,  autocrine 
secreted  NGF  activated  TRKA  to  promote  IL-10  secretion,  which  required  previous 
S1PR/src-dependent translocation of TRKA to the plasma membrane.  
Following  the  detailed  analysis  of  IL-10  regulation,  I  was  interested  whether 
other TAM phenotype markers were influenced by ACM and whether their expression 
was  regulated  through  TRKA-dependent  signaling.  Five  of  six  markers  were  up-
regulated on mRNA level by ACM, and secretion of IL-6, IL-8 and TNF- was triggered. 
S1PR-signaling  was  essential  for  induction  of  all  but  one  marker,  whereas  TRKA 
signaling  was  only  required  for  cytokine  secretion.  Interestingly,  none  of  the 
investigated TAM markers was regulated identically to IL-10, emphasizing a tight and 
exclusive regulation machinery of this potent immunosuppressive cytokine.  
Finally,  I  aimed  to  validate  the  in  vitro  findings  in  human  ACM-stimulated  M. 
Therefore,  I  isolated  murine  TAM  as  well  as  other  major  mononuclear  phagocyte 
populations  from  primary  oncogene-induced  breast  cancer  tissue.  Indeed,  TRKA-
dependent signaling was required for spontaneous cytokine production selectively by 
primary murine TAM. Besides IL-10, the TRKA pathway was decisive for secretion of 
IL-6, TNF- and monocyte chemotactic protein-1, indicating its relevance in cancer-
associated inflammation.  
In  summary,  my  findings  highlight  a  fine-tuned  regulatory  system  of  S1P-
dependent TRKA trafficking and autocrine NGF signaling in TAM biology. Both factors, 
S1P as well as NGF, might be interesting targets for future cancer therapy.  ZUSAMMENFASSUNG  3 
2  Zusammenfassung 
Tumor-assoziierte  Makrophagen  (TAM)  begünstigen  verschiedene  Phasen  der 
Tumorentwicklung. Bisher ist das Wissen über die Mechanismen der Rekrutierung und 
Differenzierung von Makrophagen (M) zu TAM, die sich unter anderem durch eine 
ausgeprägte Produktion von immunsuppressivem Interleukin 10 (IL-10) auszeichnen, 
unvollkommen. Eine Korrelation zwischen dem Ausmaß der M-Infiltration sowie der 
Zelltotrate innerhalb von Tumoren und einer schlechten Prognose für Krebspatienten 
wurde berichtet. Auf Grundlage dessen, untersuchte ich in der vorliegenden Arbeit 
Signalwege, die zur Entstehung von TAM-ähnlichen M führen. Dazu stimulierte ich 
humane primäre M mit Überständen von apoptotischen Tumorzellen (ACM). 
Zuerst führte ich ein RNAi-basiertes adenovirales Hochdurchsatzverfahren (HTS) 
zur Identifizierung unbekannter Faktoren, die zur Entstehung von TAM-ähnlichen M 
beitragen, durch. Als primären Endpunkt analysierte ich zunächst die Produktion von 
IL-10. Die identifizierten IL-10-regulierenden Faktoren wurden im nächsten Schritt auf 
ihre  Beteiligung  an  der  Synthese  von  weiteren  tumorfördernden  (IL-6,  IL-8)  und 
tumorinhibierenden  (IL-12)  Zytokinen  getestet.  M  wurden  mit  8495  adenovirale 
shRNAs der SilenceSelect Bibliothek der Firma Galapagos BV transduziert und mit 
ACM  zu  TAM-ähnlichen  M  polarisiert.  96  Gene,  die  eine  Rolle  in  der  ACM-
vermittelten  IL-10  Produktion  spielen,  wurden  identifiziert.  Davon  zeigten  22  Gene 
eine bisher nicht beobachtete Koregulation von IL-10 und IL-6 auf. Fünf Kandidaten aus 
dieser  Gruppe  wurden  mit  Hilfe  von  Inhibitoren  oder  siRNA  validiert  und  eine 
Beteiligung des IL-4 Rezeptors  sowie des Cannabinoid Rezeptors 2 an der IL-10 und 
IL-6 Regulation konnte bestätigt werden. In darauffolgenden Versuchen verifizierte ich 
im  Detail  die  Beteiligung  des  nerve  growth  factor  (NGF)  Rezeptors  TRKA  an  der 
Ausbildung TAM-ähnlicher M nach ACM-Behandlung. Die Ausschaltung des Gens im 
HTS hatte zu einer verminderten Sekretion von IL-10 und IL-6 sowie einer Zunahme 
von IL-12 geführt. TRKA ist essentiell an der Entwicklung des Nervensystems beteiligt 
und  neuere  Berichte  weisen  auf  seine  Beteiligung  in  der  Tumorbiologie  hin. 
Pharmakologische Inhibitoren bestätigten die Notwendigkeit von TRKA an der ACM-
vermittelten  IL-10  Produktion,  sowie  die  TRKA-abhängige  Aktivierung  der 
Signalmoleküle  PI3K/AKT  und,  wenn  auch  weniger  ausgeprägt,  MAPK  p38.  Die 
Neutralisation von NGF demonstrierte, dass von M konstitutiv autokrin sezerniertes ZUSAMMENFASSUNG  4 
NGF für die IL-10 Sekretion benötigt wurde. Synthetisches NGF zeigte jedoch keinen 
Effekt  auf  die  AKT  und  p38  Phosphorylierung  oder  auf  die  Produktion  von  IL-10. 
Interessanterweise  legten  Immunfluoreszenzaufnahmen  von  ACM-stimulierten  M 
eine  deutliche  Zunahme  von  TRKA  an  der  Plasmamembran  nach  10-minütiger 
Simulation offen, die durch Inhibition von TRKA oder Neutralisation von NGF nicht 
beeinflusst wurde. Dieses Phänomen war Anlass für weiterführende Studien.  
Sphingosine-1-Phosphat (S1P) wurde im Vorfeld als wichtiger Mediator in der 
ACM-vermittelten M Polarisierung identifiziert und ich konnte eine Abhängigkeit der 
IL-10  Produktion  von  S1P  und  Src  Kinasen  zeigen.  Des  Weiteren  wurde  die 
Anreicherung von TRKA an der Plasmamembran durch Inhibitoren von Src sowie S1P 
Rezeptoren verhindert. Diese Daten indizieren  eine komplexe Regulation der ACM-
vermittelten  IL-10  Produktion  in  primären  M.  S1P,  generiert  von  apoptotischen 
Krebszellen, vermittelt S1P Rezeptor- und Src Kinasen-abhängig die Translokalisation 
von TRKA an die Zelloberfläche von M. Der Rezeptor wird daraufhin von autokrin 
sezerniertem NGF aktiviert und initiiert darauffolgend die Produktion von IL-10. 
In einem weiteren Schritt untersuchte ich zusätzliche  biologische Marker,  die 
eine Rolle bei der Funktion von TAM spielen. ACM bewirkte eine starke Sekretion von 
IL-6, IL-8 und TNF-, sowie eine Hochregulation weiterer Marker auf mRNA-Ebene. Die 
S1P Rezeptoraktivität war für nahezu alle Marker essentiell. Die Zytokinsekretion war 
ebenfalls abhängig von TRKA, jedoch wurde keiner der untersuchten Faktoren analog 
zu IL-10 reguliert. Diese Befunde unterstreichen die fein abgestimmte und exklusive 
Regulation dieses hochpotenten immunsuppressiven Zytokins. 
Um  meine  in  vitro  Daten  zu  bestärken,  isolierte  ich  TAM  und  weitere 
mononukleare  Phagozytenpopulationen  aus  primärem  Onkogen-induzierten 
Brustkrebsgewebe der Maus und untersuchte die spontane Zytokinproduktion dieser 
Zellen. Auch in diesem Modell zeigte sich eine, auf TAM beschränkte, TRKA-abhängige 
Produktion von IL-10, IL-6, TNF- und monocyte chemotactic protein-1, und die Rolle 
von TRKA im Tumor-assoziierten Entzündungsgeschehen wurde bekräftigt. 
Zusammenfassend  konnte  ich  Mechanismen  der  S1P-  und  NGF-abhängigen  TRKA 
Signaltransduktion  und  deren  Funktion  im  Bezug  auf  Makrophagen  im 
Tumorgeschehen identifizieren. Sowohl S1P als auch NGF stellen somit interessante 
Zielmoleküle in der künftigen Krebstherapie dar. INTRODUCTION  5 
3  Introduction 
3.1  Cell death 
Cell death research is almost as old as the cell theory. The cell as the basic unit of life, 
was  proposed  by  Schleiden  and  Schwann  in  the  mid  nineteenth  century.  Virchow 
extended this model by stating, a cell cannot be created de novo, but has to derive 
from an existing one ‘omnis cellula e cellula’, resulting in the modern cell theory. Soon 
after declaration of the cell theory, Vogt described the physiological appearance of cell 
death (1-3). The foundation of cellular research on life and death was laid. 
Different modes of cell death are described. Apoptosis and necrosis, by far, are 
the best studied mechanisms of cell death mechanisms and the nomenclature is based 
on morphological features observed during the processes. Necrotic cell death leads to 
inflammatory responses due to ‘uncontrolled’ leakage of cell content. Harsh conditions 
such as heat or strong detergents lead to a poorly defined necrotic death characterized 
by cytoplasmic swelling, rupture of plasma membranes, loss of intracellular content 
and only moderate chromatin condensation. However, evidence is accumulating that 
necrotic  cell  death  is  finely  regulated  under  physiological  conditions  and  fulfils 
important roles in physiology and pathology (4-6). Contrarily, the fine-tuned apoptotic 
cell death is better understood and consequences for the organism are better defined. 
3.1.1  Apoptosis 
First described in 1972 by Kerr and colleagues (7), apoptosis is essential for embryonic 
development  and  maintenance  of  cellular  homeostasis  in  adult  organisms.  Highly 
controlled  apoptotic  death  is  associated  with  cell  rounding,  shrinkage,  plasma 
membrane bebbing, cellular fragmentation into apoptotic bodies, nuclear shrinkage 
and fragmentation, chromatin condensation and finally engulfment of the dying cell by 
resident phagocytes. The controlled destruction is mediated by a family of proteases – 
the caspases, which are activated by either the extrinsic or intrinsic apoptosis pathway 
(8). 
The extrinsic pathway is triggered by ligand-receptor binding on the cell surface. 
Upon ligand-binding (e.g. Fas-Ligand (FasL), TRAIL) the so-called death receptors (e.g. 
TNF-related  apoptosis-inducing  ligand  (TRAIL)  –R1  and  –R2)  trimerize  and  recruit 
adaptor  proteins  and  procaspase-8  to  form  the  death  inducing  signaling  complex INTRODUCTION  6 
(DISC). Procaspase-8 is cleaved to the active form caspase-8 and triggers the apoptotic 
effector caspase cascade ((8-10) and Figure 1). 
Stress, such as growth factor deprivation, heat, irradiation or DNA-damage by 
chemotherapeutic agents induces the intrinsic  pathway and leads to cytochrome c 
release from mitochondria into the cytosol. Subsequently, caspase adaptor molecule 
Apaf-1  (apoptotic  protease-activating  factor  1)  and  procaspase-9  are  recruited  and 
activated. Subsequently, interaction with cytochrome c leads to the formation of the 
holoenzyme complex called the apoptosome. Consequently, the proteolytic activity of 
caspase-9 cleaves and activates effector caspases 3, 6 or 7 leading to apoptosis by 
proteolysis of cellular substrates ((8, 10) and Figure 1). Cytochrome c is not the only 
pro-apoptotic factor released by mitochondria during stress. Apoptosis-inducing factor 
(AIF) and IAP-binding-motive (IBM)-domain proteins, like Smac/DIABLO, are released 
to fuel the apoptotic process. Smac/DIABLO inhibits IAPs (inhibitor of apoptosis), which 
are commonly overexpressed in tumors. The oncogenic IAPs are pro-survival proteins 
inhibiting  caspase  activation  and  promoting  their  degradation  (11).  Another 
mechanism  to  fine-tune  the  balance  between  cell  survival  and  death  provide  the 
members of the B-cell lymphoma (Bcl) -2 family. Anti-apoptotic family members, such 
as  Bcl-2  and  Bcl-XL,  are  membrane  proteins  especially  found  in  the  mitochondria, 
endoplasmatic reticulum (ER) and nuclear membranes. Pro-apoptotic members (e.g. 
Bax,  Bad,  Bim,  Bid)  are  mainly  localized  in  the  cytosol  and  upon  death  signals 
translocate to the mitochondria membranes. By forming heterodimers of anti- and 
pro-apoptotic  family  members,  the  pro-apoptotic  capacity  is  inhibited  and  thereby 
cytochrome c release prevented. Thus, the relative amount of the opposing family 
members influences the susceptibility of cells to death signals (12). INTRODUCTION  7 
 
Figure 1:  Apoptosis: the extrinsic and intrinsic pathway to caspase activation 
The extrinsic pathway is triggered by members of the death receptor family. After binding of 
ligands,  FADD  and  procaspase-8  are  recruited  and  form  the  active  DISC  complex  with 
functional caspase-8. Caspase-8 induces activation of pro-apoptotic Bid and of the effector 
caspases  (e.g.  caspase-3).  The  intrinsic  pathway  is  used  in  response  to  DNA  damage  and 
extracellular stress. It results in perturbation of mitrochondria leading to release of potent pro-
apoptotic proteins, such as cytochrome c, AIF and Smac/DIABLO. Smac/DIABLO inhibits the 
pro-survival properties of IAPs. Bcl-2 family members take part in regulating the release of 
cytochrome c. Cytosolic pro-apoptotic (e.g. tBid, Bax) or membrane bound anti-apoptotic (e.g. 
Bcl-2, Bcl-XL) family members compete in tuning cytochrome c release. Once released into the 
cytosol, cytochrome c binds to Apaf-1 and together with procaspase-9 forms the apoptosome 
complex, resulting in effector caspase activation. Subsequent cleavage of cellular substrates 
finally results in apoptotic cell death. Abbreviations: AIF, apoptosis inducing factor; Apaf-1, 
apoptotic protease activating factor 1; Bax, Bcl-2 associated protein x; Bcl-2, B-cell lymphoma 
2; Bcl-XL, B-cell lymphoma extra long; IAP, inhibitor of apoptosis; DISC, death-inducing signaling 
complex; FADD, Fas-associated death domain protein; tBid, truncated Bcl-2 interacting domain 
death  agonist;  Smac/DIABLO,  second  mitochondria-derived  activator  of  caspase/direct 
inhibitor of apoptosis-binding protein. 
3.1.2  Cell death in health and disease 
Disturbance  within  the  apoptotic  machinery  results  in  pathological  conditions. 
Insufficient  apoptosis  is  observed  in  cancer  and  autoimmune  diseases,  whereas 
accelerated cell death is pronounced in degenerative diseases, immunodeficiency and 
infertility. Low affinity or autoreactive T and B cells are eliminated through apoptosis INTRODUCTION  8 
to preserve a functional immune system. Defects in this mechanism result in B cell 
lymphomas and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, 
lupus erythematosus or diabetes (10, 13). Next to dysregulated apoptosis, insufficient 
clearance of apoptotic debris is a major factor in a variety of pathologies. Persistence 
of  apoptotic  debris  is  observed  in  atherosclerotic  plaques  and  results  in  pro-
inflammatory events fueling the disease (14). In regard to tumor biology, resistance to 
apoptosis is one of the hallmarks of cancer (Figure 41). Nevertheless, through rapid 
proliferation  and  lack  of  nutrients,  solid  tumors  show  marked  apoptosis,  and  a 
correlation between high apoptosis indices in tumors and poor prognosis for patients 
has been observed (15, 16).  
3.1.2.1  Soluble factors released by apoptotic cells and their implication in disease 
Dying cells expose various molecules on their surface and release a variety of soluble 
factors.  The  context,  in  which  cell  death  occurs,  thereby  determines  the  immune 
response. Apoptotic cells secrete ‘find-me’ signals, e.g. lysophosphatidylcholine (LPC), 
sphingosine-1-phosphate  (S1P),  adenosine  triphosphate  (ATP)  and  uridine 
triphosphate, to attract the major professional phagocytes – the macrophages (M) 
(16). On the other hand, so called ‘keep-out’ signals, such as lactoferrin, are described 
to  suppress  the  recruitment  of  neutrophiles  and  other  granulocytes,  which  would 
foster inflammatory responses (17). Once phagocytes have found the apopotic cell, 
distinct ‘eat-me’ signals are presented to enable effective recognition, phagocytosis 
and immunologically silent removal of the cell to restore tissue homeostasis (18-20). 
Noteworthy, silencing of an inflammatory immune response to apoptotic cells does 
not  necessarily  require  phagocytosis  of  the  apoptotic  cells.  Recognition  of 
phosphatidylserine  or  of  apoptotic  cell  mediators  was  shown  to  be  sufficient  for 
phagocytes to produce anti-inflammatory factors, such as transforming growth factor-
 (TGF-), interleukin 10 (IL-10) or prostaglandin E2 (PGE2). Of note, not  only the 
interaction  of  apoptotic  cells  with  phagocytes  establishes  an  immunosuppressive 
milieu, apoptotic cells themselves were shown to produce considerable amounts of 
the  anti-inflammatory  mediators  mentioned  above  (16).  Interestingly,  many  of  the 
signaling  molecules  exert  more  than  one  function  in  the  course  of  apoptotic  cell 
clearance. Their pluripotency is necessary to guarantee appropriate responses and re-
establishment of tissue function. Two of these versatile mediators are the ‘find-me’ INTRODUCTION  9 
signals lactoferrin and the sphingolipid S1P, which have been described to inhibit pro-
inflammatory  mediators,  promote  expression  of  anti-inflammatory  factors  and 
function as growth and differentiation factors (16, 21).  
3.2  Sphingosine-1-phosphate (S1P) 
Sphingolipids are a class of cell membrane lipids, important for membrane integity. 
Some derivatives evolve as important lipid mediators in a growing body of cellular 
functions.  One  important  member  is  the  phosphosphingolipid  S1P,  a  potent 
intracellular  second  messenger  and  extracellular  receptor  agonist,  which  has  been 
identified more than 20 years ago (22). S1P derives from sphingosine (Sph), named in 
1884 after the Greek mythological creature, the Sphinx, because of its enigmatic dual 
nature in structure as well as biological function. High S1P levels are found in the blood 
where it is mainly produced by erythrocytes and is bound primarily to chaperones such 
as HDL or albumin (23, 24). In other tissues its levels are generally very low, but can 
increase during injury and inflammation (25). 
 
Figure 2:  Sphingosine-1-phosphate (S1P) 
3.2.1  S1P synthesis and secretion 
De  novo  synthesis  of  sphingolipids  originates  at  the  cytoplasmic  side  of  the 
endoplasmatic reticulum. Several paths lead to ceramide formation and subsequent 
conversion to sphingosine (Sph). Two sphingosine kinase isoforms SK1 and SK2 finally 
phosphorylate Sph to S1P. To tightly regulate S1P levels, the phosphosphingolipid can 
be either irreversibly degraded by S1P lyase to hexadecenal and phosphoethanolamine 
or reversibly dephosphorylated by S1P phosphatase back to Sph (24, 26, 27). 
Certain  growth  factors,  hormones  and  cytokines  such  as  vascular  endothelial 
growth factor (VEGF) , nerve growth factor (NGF), estradiol, tumor necrosis factor  
(TNF-) or transforming growth factor  (TGF-) and others are known to stimulate 
SK1 activity (28). Activation and translocation of SK1 to the plasma membrane leads to 
S1P production and subsequent secretion of S1P was found to be facilitated by several 
transporters  such  as  ATP-binding  cassette  (ABC)-transporters  (29-31)  and  spinster 
homolog 2 (Spns2) (32). Furthermore, SK1-dependent S1P production and release by INTRODUCTION  10 
apoptotic cells was described as “come-and-get-me” signal for phagocytes to remove 
dying  cells  (33).  Work  from  our  group  demonstrated  the  necessity  of  SK2  for  the 
production of S1P by apoptotic cells (34), thereby release of a truncated form of SK2 
during apoptosis was crucial for S1P production (35). In line, catalytically active SK1 
was found in plasma from mice (36) and degradation of sphingomyelin to sphingosine 
at the outer leaflet of the plasma membrane is known ((37) and Figure 3). 
 
Figure 3:  Sphingosine-1-phosphate synthesis and export 
De novo synthesis of sphingolipids is initiated at the endoplasmatic reticulum (ER) through 
multiple  enzymatic  steps  forming  ceramide  (Cer).  Sphingosine  (Sph)  can  also  arise  from 
endocyclic recycling of the plasma membrane component sphingomyelin (SM). Both paths join 
in the conversion of Sph by sphingosine kinases 1 or 2 (SK1/2) to S1P, which can be either 
converted  back  to  Sph  or  irreversibly  degradated  by  S1P  lyase.  S1P  exerts  intracellular 
functions  or  is  transported  out  of  the  cell  by  ATP-binding  cassette  (ABC)  transporters  or 
Spinster homolog 2 (Spns2). Additionally, S1P can be synthesized at the outer leaflet of the 
plasma membrane. Extracellularly, it binds to ligand specific G protein-coupled S1P receptors 
(S1PR) to induce downstream signaling events and cellular responses. Adopted from (25, 26, 
35).  
3.2.2  S1P function  
S1P regulates diverse physiological and immunological processes by signaling through 
at least 5 G protein-coupled receptors (S1PR1-5) or by acting as second messenger on 
intracellular targets. In a physiological context, S1P is vital in embryonic development 
of the central nervous and cardiovascular system by orchestrating several complex 
biological circuits such as survival, proliferation and migration (38).  INTRODUCTION  11 
3.2.2.1  Intracellular functions of S1P 
One early discovered role of S1P was its negative regulation of cell death compared to 
the pro-apoptotic ceramide, termed the ‘sphingolipid rheostat’, determining the cell’s 
fate  (39).  The  two  S1P-producing  isoforms  SK1  and  SK2  differ  in  their  kinetic 
properties,  subcellular  localization  and  tissue  distribution.  They  show  some 
redundancy as single knockout mice are viable and reproduce whereas simultaneous 
knockout of both isoforms is lethal (40). Differential intracellular effects are reported 
for  S1P  derived  from  the  two  isoforms,  but  substantiated  studies  in  physiological 
contexts are lacking. Recently, detailed intracellular actions of SK1, SK2 and S1P were 
unravelled by Sarah Spiegel and coworkers. They indicated S1P as a co-factor for TNF- 
receptor-associated factor 2 (TRAF2), leading to activation of nuclear factor ‘kappa-
light-chain-enhancer’ of activated B cells (NFB) (41). Another study elucidated SK2 
and  S1P  assembly  with  histone  deacetylase  1  and  2  (HDAC1-2)  resulting  in  up-
regulation of p21 and c-fos (42). However, intracellular targets of S1P remain largely 
elusive. 
3.2.2.2  Extracellular receptor mediated functions of S1P 
After release, S1P selectively binds with affinities ranging from 2 nM to 63 nM to its 
receptors (S1PR1-5) for autocrine or paracrine signaling (43). S1PR1, 2 and 3 are nearly 
ubiquitously expressed, whereas S1PR4 and 5 show tissue-specific distribution. This 
correlates  with  the  observation  that  in  mice  only  knockout  of  S1PR1  or  double 
knockout  of  S1PR2  and  3  are  embryonically  lethal  (44).  S1PR1  and  2  show  similar 
expression  patterns,  S1PR3  is  highest  in  the  cardiovascular  system  (45),  S1PR4  is 
predominantly found on lymphoid cells (46) and S1PR5 seems to be restricted to NK 
cells (47), dendritic cell subsets (48) and the central nervous system (49). Downstream 
of the G protein-coupled S1P receptors activation of Gi for S1R1, Gi, Gq, G12/13 for 
S1PR2 and 3 and Gi, G12/13 for S1PR4 and 5 is reported. This results in multiple and 
complex downstream signaling cascades, including small GTPase modulation (Rac and 
Rho), adenylate cyclase (AC) activation or inhibition, phospholipase C (PLC) activation 
and  intracellular  calcium  mobilization,  together  with  AKT  and  extracellular  signal-
activated-kinase (ERK) phosphorylation events, as shown in Figure 4. Corresponding to 
differences in activated G proteins, stimulation of S1P receptors especially S1PR1 and 
S1PR2 sometimes triggers adverse effects. E.g. S1PR1 signaling stimulates migration INTRODUCTION  12 
through Rac activation, whereas S1P can inhibit cancer cell motility through S1PR2-
dependent regulation of Rho (50). Nevertheless, S1PR2-mediated cell invasiveness has 
also been reported (51). In addition to these various signals, transactivation of or by 
other signaling systems, or generation and secretion of additional factors are known, 
adding complexity to the S1P/S1PR system (25, 52). 
 
Figure 4:  S1P/S1P receptor signaling 
Extracellular S1P selectively binds to 5 S1P specific receptors S1PR1-5. Downstream of the 
receptors multiple signaling pathways are activated or inhibited, either directly or through G 
proteins (Gi, Gq or G12/13), resulting in a variety of cellular responses. Abbreviations: AC, 
adenylate cyclase; AKT, protein kinase B; ERK, extracellular signal-regulated kinases; JNK, jun 
N-terminal kinase; PI3K, phosphatidylinositol-3 kinase; PLC, phospholipase C; Rac, Rho, family 
members of Rho GTPase; S1P, sphingosine-1-phosphate. Adopted from (25, 50, 53).  
3.2.2.3  Physiological function of S1P receptor signaling  
S1P  is  a  key  player  in  neurogenesis,  cardiac  function,  maturation  of  the  vascular 
system, blood vessel permeability and pathophysiological angiogenesis.  
  Angiogenesis is strongly dependent on S1P, as knockout of S1PR1 is embryonic 
lethal  due  to  migration  failure  of  vascular  smooth  muscle  cells  (54).  Immune  cell 
migration is another critical attribute of this sphingolipid. Lymphoid organs show low 
S1P levels compared to high concentrations in the circulation. This gradient and the 
expression  of  S1PR1  on  lymphocytes  are  requisites  for  lymphocyte  egress  (55).  In 
contrast,  S1PR4  activity  was  not  connected  to  migration,  but  affected  cytokine 
secretion  of  S1P-stimulated  T  cells.  S1P  coupling  to  S1PR4  enhanced  IL-10,  which 
replaced  inflammatory  and  proliferative  cytokines  (IFN,  IL-2,  IL-4)  to  create  an INTRODUCTION  13 
immunosuppressive milieu (56). A newly FDA approved therapy for multiple sclerosis 
takes  advantage  of  this  S1P/S1PR1-mediated  T  cell  migration.  The  sphingosine 
analogue FTY720 (fingolimod, Gilenya™) is intracellularly phosphorylated by SK2 and 
released as FTY720-phosphate (FTY-P). The active derivative is then able to bind all S1P 
receptors except for S1PR2. It induces lymphopenia by receptor internalization and 
degradation, thereby inhibiting egress from lymph nodes. Consequently, an attack of 
autoreactive lymphocytes on the central nervous system is prevented. Additionally, 
FTY-P  reduces  inflammatory  cytokine  release  by  astrocytes  and  might  have  pro-
survival  functions  on  oligodendrocytes  and  neurons  (27,  57).  Other  immunological 
functions of S1P include enhancing dendritic cell (DC) localization at the site of antigen 
uptake (58) and anti-inflammatory properties of NK cells by inhibiting NK cell-mediated 
cell lysis and release of inflammatory cytokines (59). The detailed effects of S1P on M 
are summarized in 3.3.3 and in the presented experimental work herein.  
3.2.2.4  S1P and cancer 
In  most  cancer  cells  SK1  is  upregulated  by  diverse  mechanisms  such  as  activation 
through growths factor signaling, lack of nutrients, or hypoxia. S1P exerts powerful 
pro-tumor function e.g. protection from apoptosis, facilitation of cell transformation, 
induction of proliferation, migration and promotion of angiogenesis ((60) and Figure 
5). These effects are mediated either by intracellular actions of S1P, or by extracellular 
receptor-mediated  processes.  Several  mechanisms  of  transactivation,  functional 
complex formation, SK induction, or autocrine loops of growth factors interacting with 
S1P and the corresponding receptors are described (50). As one example, epidermal 
growth  factor  (EGF)  was  shown  to  stimulate  the  expression  of  SK1  and/or  SK2  to 
induce  cell migration (61,  62). S1P  in turn was reported to augment EGF receptor 
(EGFR) expression and to facilitate EGF release from cells for activation of EGFR (63, 
64).  INTRODUCTION  14 
 
Figure 5:  S1P action in cancer 
Multiple processes in the course of cancer are influenced by S1P, including cell transformation, 
cancer  cell  growth,  survival  and  motility.  Neovascularization,  immune  cell  attraction  and 
cancer  promoting  inflammation  are  further  attributed  to  S1P.  Abbreviations:  Bcl-2,  B-cell 
lymphoma 2; ras, rat sarcoma; S1P, sphingosine-1-phosphate. Adopted from (50).  
To  target  S1P  signaling  for  cancer  therapy,  a  S1P-neutralizing  antibody 
(sphingomab) was used in murine xenograft models. Diminished tumor volume and 
reduced pathology-associated parameters were achieved (65). The humanized highly 
specific anti-S1P antibody (sonepcizumab, ASONEP™) was recently investigated as a 
single  agent  in  a  Phase  I  trial  in  refractory  advanced  solid  tumor  patients. 
Sonepcizumab  is  also  tested  in  clinical  trials  for  age-related  macular  degeneration, 
caused by new leaky blood vessel growth, and shows superior effects to standard anti-
VEGF treatment (60). Additionally, phosphorylated FTY720 has been shown to have 
anti-cancer properties (66, 67), to provoke cancer cell-selective apoptosis (68) and to 
reduce  tumor  vascularization  (69,  70).  Interestingly,  also  the  prodrug  FTY720  was 
shown in vitro to have anti-proliferative effects on cancer cells, arguing for an S1PR-
independent effect (71). Unfortunately, referring to www.clinicaltrials.gov, no clinical 
trials in regard to FTY720 and cancer are performed or planned in the near future. 
To  add  an  additional  layer  of  complexity,  S1P  not  only  contributes  to  tumor 
growth by influencing tumor and stromal cells, but also by its impact on immune cells 
present in the tumor microenvironment (Figure 5). One major immune cell type in this 
context is the macrophage. 
3.3  Macrophages 
Inflammation is an immune response to exogenous or endogenous noxious stimuli, 
such as microbial products, allergens, or signals released from stressed or dead cells 
(72).  The  immune  response  is  divided  into  adaptive  and  innate  immunity.  Tissue-
resident macrophages (M) are the first innate immune cells encountering noxious 
stimuli. Through their large repertoire of receptors, M recognize pathogens, cellular INTRODUCTION  15 
danger signals or adaptive immunity-derived immunomodulators. Consequently, M 
produce of a wide array of inflammatory mediators such as chemokines and cytokines 
to evoke immune responses. Thus, additional innate immune cells, mainly neutrophils 
and monocytes, are recruited from the blood stream for further release of cytotoxic 
factors,  phagocytosis  and  clearance  of  the  inflammatory  stimulus.  Through 
phagocytosis, digestion and subsequent antigen presentation, M are an important 
link  between  the  immediate  unspecific  innate  immune  response  and  the  delayed, 
highly antigen-specific adaptive immunity mediated by T and B cells. Finally, when the 
noxious stimulus is eradicated, M adapt their machinery to repair tissue damage and 
to restore homeostasis by secreting proteases and growth factors (72-74). 
M originate from myeloid progenitor cells in the bone marrow. In the presence 
of myeloid cytokines as granulocyte macrophage colony-stimulating factor (GM-CSF) or 
macrophage colony-stimulating factor (M-CSF), the progenitor cells differentiate into 
monocytes. These migrate into the blood, from where they can be rapidly recruited to 
peripheral  tissues  where  they  finally  differentiate  into  mature  M  with  distinct 
features and functions depending on the microenvironment of their destination. Some 
tissues show 10-20% resident M, such as microglial cells in the brain or Kupffer cells 
in the liver. As summarized in Table 1, M exert vital function in almost every organ.  INTRODUCTION  16 
Table 1:  Diversity of tissue macrophages  
 
Tissue 
Tissue-specific 
designation 
Function  Ref. 
Bone  Bone marrow 
macrophage 
Erythropoiesis  (75) 
  Osteoclast  Bone remodelling   (76) 
Brain  Microglial cell  Neuronal development, survival and repair  (77) 
Epidermis  Langerhans cell 
(more dendritic cell 
phenotype) 
Immune surveillance  (78) 
Eye    Vascular modelling/ remodelling  (79) 
Gut    Immune-tolerance  (80) 
Kidney    Organ development, injury, repair  (81) 
Liver  Kupffer cell  Clearance of debris from blood and liver tissue, 
liver regeneration, pathogen killing 
(82) 
Mammary 
gland 
  Branching and ductal development, 
postpartum mammary involution 
(83, 84) 
Ovary    Steroid hormone production and ovulation  (76, 85) 
Pancreas    Islet development  (86) 
Uterine desidua    Maternal immune tolerance to fetus  (87) 
Uterus    Cervical ripening, remodeling  (88) 
3.3.1  Macrophage phenotypes  
The remarkable degree of heterogeneity in M and their specialized functions are due 
to the impact of microenvironmental factors they encounter at the site of residence 
(89). Two rather opposing microenvironments are the pathogen-rich gut and the blood 
brain  barrier-protected  brain.  In  the  pathogen-rich  milieu  of  the  gut,  the  immune 
response of the resident M is blunted, shown by defects in toll-like receptor (TLR) 
responses, while preserving their bactericidal capacity to establish tolerance (80). On 
the other hand, M in tissues with low pathogen exposure, such as microglia in the 
nervous system, are highly sensitive to environmental alterations. They respond to 
changes by chemokine release to orchestrate the infiltration of peripheral immune 
cells, phagocytic activity or cytokine or neurotrophin release for neuroprotection (77). 
These M rather function as sentinels as compared to the barrier-building intestinal or 
alveolar macrophages.  INTRODUCTION  17 
Although M are well adapted to the needs of distinct environments, they are 
still  highly  plastic.  At  sites  of  tissue  injury,  where  the  local  microenvironment  is 
disturbed, M are activated by recognition of danger signals and acquire a phenotype 
denoted as ‘classically activated M’, which was first described by Mackaness (90). 
Danger signals relevant in this process are microbial products, such as the TLR4 agonist 
lipopolysaccharide (LPS), adaptive immunity-derived cytokines such as interferone  
(IFN-), or mediators leaking from damaged cells, such as ATP (91) or high-mobility 
group box (HMGB)1 protein (92). In vitro, these M can be generated by stimulation 
with  the  microbial  cell  wall  component  LPS  or  tumor  necrosis  factor  (TNF)-  in 
combination with interferon (IFN)-γ. This results, amongst others, in the production of 
nitric oxide (NO) and superoxide, which are necessary for pathogen killing, as well as 
the release of proinflammatory cytokines such as TNF-, IL-1 and IL-12 to activate 
bystander immune cells (74).  
Identification  of  a  distinct  M  subpopulation,  which  was  generated  by  IL-4 
receptor activation led to coining the term ‘alternatively activated’ M, based on a 
different surface marker and secretome profile compared to classically activated M 
(93). This discovery of M heterogenicity resulted in extended mostly in vitro research 
on  different  M  populations  depending  on  stimulation  with  various 
immunomodulatory agents. To avoid the arising confusion regarding the different use 
of terminology to describe these M subpopulations, several attempts to develop a 
common  classification  were  undertaken  during  the  last  ten  years.  Gordon  and 
coworkers proposed five subclasses of M (74). Beside classically (LPS and IFN-γ) and 
alternatively  activated  (IL-4/IL-13)  M,  innate  activation  due  to  microbial  stimuli 
without  IFN-γ,  humoral  activation  by  Fc  or  complement  receptor  agonists  and 
deactivation by immunosuppressive cytokines such as IL-10 and transforming growth 
factor (TGF)- or apoptotic cells were proposed.  
Alternatively, Mantovani grouped M phenotypes in analogy to the T helper cell 
nomenclature along a linear scale into M1 macrophages (classically activated) or M2 
(alternatively activated) M (94). M1 M are generated (as classically activated M 
from Gordon) by stimulation with IFN- and LPS or TNF-and are characterized by an 
IL-12
high/IL-10
low  profile,  together  with  production  of  NO,  reactive  oxygen  species 
(ROS), IL-1, TNF-, IL-6 and expression of major histocompatibility complex class (MHC) INTRODUCTION  18 
II important for pathogen killing and tumor resistance. M2 M, which all share the IL-
10
high/IL-12
low  profile  and  show  immunoregulatory  and  tumor  promoting  functions, 
were further divided into M2a, M2b and M2c subclasses. M2a M match Gordon’s 
alternatively activated macrophages with expression of MHC II, mannose  receptor, 
scavenger receptor, production of polyamines and IL-1 receptor antagonist (IL-1ra). 
These  M2a  M  are  especially  involved  in  Th2  response  inflammation,  allergy  and 
helminth infection. M2b M are comparable to humorally activated cells (stimulated 
with  immune  complexes  and  TLR  or  IL-1  receptor  ligands)  and  show  enhanced 
secretion of inflammatory cytokines TNF-, IL-1 and IL-6 with concomitant high IL-10 
and low IL-12 expression. This M subset was shown to protect mice against LPS 
toxicity and promoted Th2 differentiation and antibody production. As the last M2-
family  subgroup,  M2c  M  were  proposed  to  arise  from  stimulation  with  IL-10 
(corresponding to deactivated macrophages). By secretion of IL-10, transforming TGF- 
and  matrix  components  these  M  are  thought  to  be  especially  involved  in 
immunoregulatory processes and tissue remodelling (94).  
The above described models, especially the rough M1/M2 classification, might 
be useful to avoid confusion. However, the focus of these classifications is on the 
mediators shaping distinct M phenotypes rather than on the physiological outcome, 
which might be similar for different ‘phenotyping’ stimuli. On this account, Mosser and 
Edwards recently classified M along three functional states in analogy to the three 
primary colors in a color wheel. They discriminated classically activated (analogous to 
M1) from wound healing (analogous to alternatively activated or M2a) and regulatory 
or anti-inflammatory macrophages. This model allows the occurrence of ‘hybrid-type’ 
macrophages corresponding to secondary colors in the color spectrum (95). Thereby, it 
depicts very nicely the infinite number of possible M subtypes, mirroring the in vivo 
situation  where  an  array  of  factors  influences  M  activation.  Figure  6  tries  to 
summarize the functional activation states of M. Noteworthy, a recent report on 
tumor-associated  M  in  a  murine  carcinoma  model  substantiates  the  proposal  of 
Mosser and Edwards, as these M showed simultaneous expression of ‘typical’ M1 
and M2 characteristics (96).  INTRODUCTION  19 
 
Figure 6:  Macrophage phenotypes 
Microenvironmental factors shape the functional phenotype resulting in a dynamic repertoire 
of  M  represented  by  all  secondary  color  variations,  with  rough  distinctions  between 
classically  activated  M  (primary  color  red)  expressing  inflammatory  mediators,  wound-
healing M (primary color blue) and regulatory, anti-inflammatory M (primary color yellow). 
Factors and cells mediating one of the basic M phenotypes are depicted, as well as typical 
factors/receptors/enzymes  expressed  by  these  M.  Characteristics  marked  with  *  are 
common  for  tumor-associated  M.  Abbreviations:  APC,  antigen-presenting  cell;  ATP, 
adenosine triphosphate; ECM, extracellular matrix; GPCR, G protein-coupled receptor; HMGB1, 
high-mobility  group  box  1;  IFN-,  interferon  gamma;  IL,  interleukin;  IL-1ra,  IL-1  receptor 
antagonist; LPS, lipopolysaccharide; M, macrophage; NK cell, natural killer cell; NO, nitric 
oxide;  ROS,  reactive  oxygen  species;  PGE2,  prostaglandin  E2;  TGF-,  transforming  growth 
factor beta; Th1/2, type 1/2 T helper cell; TLR, toll-like receptor; TNF-, tumor necrosis factor 
alpha; Treg, regulatory T cell. Adopted from (95, 97, 98).  
3.3.2  Cancer-immunoediting and tumor-associated macrophages 
3.3.2.1  Cancer-immunoediting 
In  1909  Paul  Ehrlich  introduced  a  connection  between  immunology  and  cancer  by 
stating that the immune system scans the body for transformed cells to eliminate 
them (99). Unfortunately, this proposal of protective immunosurveillance was proven 
not to be true. By the 1990s, sophisticated mouse models permitted to reassess the 
role of immunity in cancer, which led to the term ‘immunoediting’ to describe the INTRODUCTION  20 
sequential  phases  of  cancer  elimination,  equilibrium  and  escape  (100).  In  the 
elimination phase, characterized by cancer immunosurveillance, innate and adaptive 
immune cells detect and destroy transformed cells before the tumor becomes clinically 
apparent. Expression of tumor antigens, release of IFN-, or HMGB1 activate innate 
immune cells to release pro-inflammatory cytokines and to develop a tumor-specific 
adaptive immune response (101). In this early stage of carcinogenesis, M show an 
inflammatory  anti-tumoral  M1  phenotype  with  pronounced  IL-12,  TNF-  and  ROS 
production (102, 103). If some tumor cells persist and escape the initial elimination 
phase,  they  may  enter  the  so-called  equilibrium  phase  where  tumor  growth  and 
adaptive anti-tumor responses are in balance resulting in cancer dormancy. This phase 
is thought to be the longest in the cancer immunoediting process and may, in many 
cases,  extend  throughout  life  of  an  individual  and  may  explain  years  of  latency 
between  first  cancer  prognosis,  therapy  and  final  metastatic  outgrowth  (104). 
Nevertheless,  some  poorly  immunogenic  and  highly  proliferative  tumor  cells  may 
escape the equilibrium phase. Constant selection of transformed cells leads to reduced 
immune  recognition  and  increased  resistance  to  cytotoxic  immune-derived  factors. 
These  tumor  cells  arise  as  aggressively  growing  tumors,  often  characterized  by 
expression  of  pro-oncogenic  transcription  factors,  such  as  signal  transducer  and 
activatior of transcription (STAT) 3 or anti-apoptotic proteins of the Bcl-2 family (101). 
The  pro-tumoral  microenviroment  in  the  escape  phase  is  predominated  by  tumor-
associated-macrophages (TAM) fostering a tumor-supportive milieu ((98) and Figure 
7). 
3.3.2.2  Tumor-associated macrophages 
In many human tumors, especially breast cancer, M can make up to 50% of the 
tumor  mass  and  a  high  density  of  tumor-associated  macrophages  (TAM)  often 
correlates with poor prognosis (105). A variety of signals were shown to be implicated 
in the recruitment and differentiation of these tumor-promoting M, among them are 
factors  released  by  tumor  cells  such  as  IL-10,  M-CSF  or  TGF-(103).  Additionally, 
overexpression of the primary monocyte/M proliferation and differentiation factors 
M-CSF and monocyte chemoattractant protein-1 (MCP-1, CCL2) have been linked to 
disease progression and poor prognosis (106-109). Furthermore, CD4
+ T cells were 
shown  to  release  IL-4  to  promote  TAM  generation  in  pulmonary  metastases  of INTRODUCTION  21 
mammary carcinomas (110). IL-10 and TGF- derived from regulatory T cells further 
fuel  the  immunosuppressive  tumor  microenvironment  and  TAM  generation  (111). 
Hypoxia  within  tumors  is  another  important  feature.  Many  tumor-promoting  and 
immunomodulatory  genes  are  regulated  through  hypoxia-inducible  factors  (HIFs) 
thereby  facilitating  further  tumor  growth  (112).  Manifold  factors  in  the  tumor-
environment lead to TAM generation and TAM exert manifold functions in promoting 
the  malignancy,  e.g.  immunosuppression,  angiogenesis,  tumor  cell  survival, 
proliferation  and  invasion  (98).  To  simplify,  I  will  only  concentrate  on  the  best 
described and most pronounced functions and factors released by TAM.  
In general, TAM have a phenotype similar to alternative M2 M with a typical IL-
10
high/IL-12
low  expression  pattern,  which  is  mainly  responsible  for  establishing  and 
maintaining  the  immunosuppressive  environment  (Figure  6).  Additionally,  immuno-
suppression is achieved by induction of indoleamin 2,3-dioxygenase (IDO) in tumor 
cells,  DCs  and  TAM  (113).  IDO  converts  tryptophan  into  metabolites  known  as 
kynurenines  and  thereby  tryptophan  in  the  vicinity  is  depleted.  IDO  activity  has 
fundamental consequences for T cell populations. Clonal expansion of CD8
+ and CD4
+ T 
cells  as  well  as  the  generation  and  activation  of  cytotoxic  T  cells  and  Th1  cells  is 
blocked, due to the lack of tryptophan. Conversely, de novo Treg differentiation is 
promoted, shifting T cell populations to tumor-promoting subsets (114). Furthermore, 
enhanced secretion of TGF- and prostaglandin E2 (PGE2) add to suppression of the 
adaptive  immune  response  (115).  To  nourish  solid  tumor  growth,  established 
immunosuppression cooperates with further pro-tumoral functions of TAM. Among 
others,  angiogenesis  is  a  decisive  step  in  the  progression  of  cancer,  as  the  highly 
proliferative  cancer  cells  need  abundant  oxygen  and  nutrients.  TAM  produce  and 
release high amounts of angiogenic factors, such as VEGF, EGF and IL-8. Moreover, 
many TAM-derived factors directly promote cancer cell survival and proliferation, the 
best described are EGF, IL-6, IL-8 and other growth factors. To substantiate disease 
progression, TAM engage in the remodelling of the extracellular matrix (ECM) and the 
breakdown  of  the  basement  membrane  surrounding  pre-metastatic  tumors,  thus, 
facilitating  local  growth,  invasion  and  distant  metastases.  (97,  98,  116-119).  In 
conclusion  TAM  express  a  multitude  of  factors  promoting  all  aspects  of  tumor 
progression, as summarized in Figure 6 and Figure 7.  INTRODUCTION  22 
 
Figure 7:  Macrophages in the tumor environment 
By secretion of various chemotactic factors, cancer cells recruit monocytes from the blood 
stream to the tumor site. In the course of tumor-immunoediting tumor cells succeed to evade 
the cytotoxic immune response, and a tumor-promoting immune environment is established. 
Differentiated  macrophages  acquire  an  anti-inflammatory,  immunosuppressive,  tumor-
promoting phenotype. These so called TAM foster cancer cell survival, proliferation, invasion, 
metastasis,  angiogenesis,  facilitate  ECM  remodeling  and  inhibit  the  anti-tumor  immune 
response  by  the  release  of  various  factors.  Abbreviations:  ECM,  extracellular  matrix;  EGF, 
epidermal  growth  factor;  IL,  interleukin;  MCP-1,  monocyte  chemotactic  protein-1;  M-CSF, 
macrophage colony-stimulating factor; MMP, matrix metalloproteinase; PGE2, prostaglandin 
E2;  TAM,  tumor-associated  macrophages;  TGF-,  transforming  growth  factor  beta;  VEGF, 
vascular endothelial growth factor. 
3.3.3  Function of S1P on macrophages  
Inflammatory  as  well  as  regulatory  M  were  shown  to  express  high  levels  of  SK1 
mRNA (120, 121). However, functional significance is on modulation of SK activity. 
Inflammatory mediators, such as TNF- or LPS, activate SK1 in M as a component of 
inflammatory responses (122-124)  by TRAF2-dependent NF-B activation (41, 125). 
The relevance and mechanistics of SK1 in inflammatory diseases requires extensive 
research.  Divergent  effects  in  different  disease  models  might  be  explained  by  its 
localization,  interaction  with  other  factors,  transcription  factors  and  finally  the 
localization  and  effect  of  S1P,  either  acting  as  intracellular  signaling  molecule, 
intracellular receptor ligand or by exhibiting extracellular functions (21, 126). INTRODUCTION  23 
  M express S1P receptors to different extents depending on the species and 
maturation state. Murine M express S1PR1, S1PR2 (127) and S1PR3 (128), whereas 
S1PR1-4  are  expressed  in  the  human  counterparts  (129).  In  this  context,  M 
attraction, protection from apoptosis and M phenotyping has been assigned to the 
potent  phospholipid  S1P  (21,  38).  In  contrast  to  the  primarily  inflammatory 
intracellular  properties  of  S1P,  binding  of  extracellular  S1P  to  S1PR1  blocked  LPS-
mediated  NF-B  activation  and  the  concomitant  production  of  TNF-  and  IL-12  in 
murine and human M. In addition, induction of anti-inflammatory IL-10 as well as 
TGF-  was  observed  through  S1PR  signaling  (127,  130).  For  long,  STAT3  has  been 
recognized for its central role in oncogenic signaling pathways, being constitutively 
active in tumor cells as well as immune cells of the tumor environment. By a ‘vicious 
circle’ IL-10, as well as IL-6, activate STAT3 signaling. STAT3, in turn, promotes the 
production  of  immunosuppressive  factors  and  restrains  inflammatory  responses 
leading to a tumor-promoting environment (131). Recently, STAT3 activation in tumors 
was  shown  to  enhance  S1PR1  expression  and  in  turn  S1P/S1PR1  led  to  persistent 
STAT3 activation in both tumor cells and tumor-associated myeloid cells, promoting 
tumor growth and metastasis (132). In human M STAT3 activation was achieved by 
apoptotic  cell  (AC)-derived  S1P  binding  to  S1PR1,  leading  to  induction  of  heme 
oxygenase-1 and adenosine receptor A2A (ADORA2A) (133). In the same model of M 
stimulated with apoptotic cell supernatant (ACM), S1P together with TGF- induced 
HIF-1  mRNA  under  normoxia,  concomitant  with  augmented  VEGF  mRNA  and 
differentiation of embryonic stem cells to CD31
+ cells (134). Other studies showed S1P-
mediated  increase  in  arginase  1  and  2  via  cyclic  AMP  (cAMP)  /cAMP  responsive 
element binding (CREB) signaling as characteristics of alternative M activation (127, 
135).  Elevation  of  cAMP  and  subsequent  decrease  in  inflammatory  responses  of 
different M cell lines have also been reported for catecholamines, dopamine and 
other  neuromediators,  signaling  through  Gs-coupled  receptors  (136).  These  reports 
collaborate with the notion of cAMP being a major determinant of anti-inflammatory 
M activation in mice (137). On the other hand, studies demonstrated that S1PR2-
deficient M from apoE knockout mice showed reduced NF-B activity and reduced 
inflammatory cytokine production (138, 139).  INTRODUCTION  24 
In  summary,  S1P  exerts  a  powerful  impact  on  M  activation,  either  by 
intracellular inflammatory actions or by binding to its receptors provoking pro- or anti-
inflammatory  responses.  Whether  S1P  drives  M  to  an  inflammatory  or  anti-
inflammatory phenotype depends on the expression pattern of S1P receptors on M 
and  other  factors  influencing  M  activation,  which  are  present  in  the 
microenvironment of the chosen disease model or in the in vitro used combination of 
stimuli e.g. ACM.  
The work on apoptotic cell-derived S1P and reports from others with the same 
notion of S1P screwing M population towards an anti-inflammatory or alternatively 
activated phenotype, highlights the potential impact of S1P on M function in tumors.  
3.4  Interleukin 10 
Cytokines  are  a  heterogeneous  group  of  secreted,  soluble  polypeptides  and 
glycoproteins.  They  are  pleiotropic  mediators  promoting  growth,  differentiation, 
activation and migration. Immune cells are the major source. Nontheless, other cells 
have the capability to produce cytokines as means of communication. Depending on 
the source and the microenvironment, the secreted factors have either pro- or anti-
inflammatory/immunosuppressive  effects.  Thus,  cytokines  are  engaged  in  all 
inflammation-associated  diseases,  such  as  rheumatoid  arthritis,  multiple  sclerosis, 
inflammatory bowel disease, diabetes and cancer (140). 
Interleukins (IL) belong to the superfamily of cytokines (141). IL-10 was originally 
discovered by Mosmann and colleagues as product of  Th2 cells  inhibiting cytokine 
synthesis of Th1 cells and was named cytokine synthesis inhibitory factor (CSIF) (142). 
IL-10 is expressed by a wide range of cells of the adaptive and innate immune system 
and even non-immune cells including epithelial and tumor cells (143). The IL-10 gene 
encodes a polypeptide of 178 amino acids and functional IL-10 protein is a noncovalent 
homodimer  of  two  18  kDa  subunits  (144,  145).  The  functional  receptor  complex 
consists of two subunits of IL-10 receptor 1 (IL-10R1) and IL-10R2 and is expressed by 
most cells of hematopoetic and non-hematopoetic origin. IL-10 binds to two IL-10R1 
and  through  recruitment  of  IL-10R2  the  functional  complex  is  formed  and  signal 
transduction, mainly via the janus kinase JAK/STAT3 pathway, can occur (146). INTRODUCTION  25 
3.4.1  Function of IL-10 
IL-10 influences expression of cytokines, growth factors and cell surface molecules and 
has strong anti-inflammatory, immunosuppressive properties. The relevance of IL-10 is 
drastically  shown  in  IL-10  deficient  mice,  which  spontaneously  develop  chronic 
enterocolitis (147) and IL-10 receptor mutations were found in colitis patients (148). 
Along this line, IL-10 null mice were shown to succumb to CNS inflammation (149). 
During infection with viruses, bacteria, fungi, protozoa or helminths IL-10 serves as key 
immunoregulator.  Excessive  T  cell  responses  are  suppressed  by  IL-10  through 
inhibition of IL-2 production, important for T cell development and activation, and 
through suppression of pro-inflammatory cytokines. On the other hand, IL-10 strongly 
induces  regulatory  T cell differentiation and function. Furthermore, IL-10 acts as a 
potent B cell stimulator, enhancing activation, proliferation and differentiation of B 
cells. Looking at the various effects of IL-10 on immune cells, over- or mistimed IL-10 
production  might  lead  to  immune  evasion  of  pathogens,  resulting  in  fast  disease 
progression with either fatal outcome or chronic manifestation (150). 
One major attribute of IL-10 is the ability to diminish antigen presentation by 
monocytes, M and DCs and subsequent T cell activation. Cell surface expression of 
major histocompatibility complex class 2 (MHC-II) and costimulatory CD80 and CD86 
molecules, among others, are reduced (151). Interestingly, the phagocytic capacity of 
monocytes  and  M  is enhanced  by  IL-10,  although  the  ability  to  kill  the  ingested 
pathogen is hampered, due to decreased production of ROS and NO. The reduced 
antigen presentation and killing capacity creates a niche for specialized intracellular 
pathogens,  such  as  the  cytomegalovirus  and  mycobacterium  tuberculosis  (152).  In 
regard to soluble factors, such as cytokines and chemokines, IL-10 potently inhibits the 
production of pro-inflammatory cytokines and enhances the production of IL-1ra as 
well as soluble TNF receptors by M. Together with the suppressed production of a 
wide array of chemokines implicated in recruitment of inflammatory immune cells, IL-
10 establishes an anti-inflammatory, immunosuppressive environment (151) important 
in gut homeostasis, chronic infection and cancer promotion.  
3.4.2  Regulation of IL-10 expression 
IL-10 employs a multitude of mechanisms to control inflammatory responses and is 
expressed by various cells. Due to this, its expression needs to be tightly regulated and INTRODUCTION  26 
kept at a beneficial level for the organism. In M, its production is triggered by diverse 
stimuli,  through  signal  transduction  downstream  of  TLR  (153),  Fc  receptor  ligation 
(121), activation of receptor tyrosine kinases (154, 155), G protein-coupled receptors 
such as adenosine receptors (156), various neuromediator receptors (136), as well as 
interaction with apoptotic cells (AC) (157, 158) or apoptotic cell derived factors e.g. 
S1P (130). Consequently, a multitude of signaling pathways and post-transcriptional 
regulations are described to influence IL-10 expression (143, 159, 160). Transcription 
factors such as STAT3 (161, 162), specificity protein (SP)1 and SP3 (163, 164), activator 
protein (AP)-1 (165), CCAAT/enhancer-binding proteins (C/EBP) (166, 167) and CREB 
(168)  are  reported  for  IL-10  promoter  activation.  Furthermore,  immune  complex-
binding to Fc receptors led to ERK-dependent modification of histone H3 within the 
IL-10 promoter  rendering the promoter more accessible for SP1 and STAT3, which 
resulted  in  very  rapid  IL-10  production  (169).  Feed-forward  loops,  such  as  the 
autocrine induction of IL-10 by itself (162) or regulatory circuits involving inflammatory 
cytokines like TNF- (170) add additional levels to the regulation of IL-10. The most 
established regulators are summarized in Figure 8.  
 
Figure 8:  IL-10 regulation in macrophages 
Summary of well known ligands, receptors, signaling molecules and TFs in IL-10 transcriptional 
regulation.  Abbreviations:  AKT,  protein  kinase  B;  AP-1,  activator  protein-1;  cAMP,  cyclic 
adenosine monophosphate; C/EBP, CCAAT/enhancer-binding protein; CREB, cAMP response 
element  binding;  ERK,  extracellular  signal-regulated  kinases;  FcR,  fragment  crystallizable 
gamma receptor; GPCR, G protein-coupled receptor; JAK, janus kinase; LPS, lipopolysaccharide; 
IL, interleukin; nAChR, nicotinic acetylcholine receptor; p38, mitogen-activated protein kinase 
p38; PI3K, phosphoinositide 3-kinase; S1P, sphingosine-1-phosphate; SP1, specificity protein 1; 
src,  sarcoma  tyrosine  kinase;  STAT,  signal  transducer  and  activator  of  transcription  3;  TF, 
transcription factor TLR4, toll like receptor 4. INTRODUCTION  27 
3.4.3  Therapeutic interventions in regard to IL-10 
Given  the  importance  of  IL-10  in  immune  regulation,  many  studies  have  been 
performed, especially in the 1990s, administering IL-10 or using neutralizing antibodies 
in animal studies. Beneficial effects of IL-10 application in various inflammatory animal 
models raised the hope for a therapeutic option in human diseases, such as colitis, 
arthritis  or  pancreatitis.  Administering  IL-10  in  clinical  phase  1  trials  in  healthy 
volunteers was well tolerated and showed IL-10 specific effects, such as reduction of T 
cells and induction of monocytes with decreased expression of MHC II in the white 
blood cell count. Unfortunately, large multicenter trials on IL-10 therapy of Crohn’s 
Disease, a form of chronic colitis, were unsatisfying. Similar discouraging results were 
obtained for psoriasis and rheumatoid arthritis treatment (171).  
In the context of cancer, production of IL-10 by TAM in non-small cell lung cancer 
correlated  with  poor  anti-tumor  response  and  poor  prognosis  for  patients  (172). 
Current  tumor  therapy  strives  for  new  adjuvants  in  combination  with  classical 
immunotherapy. One evolving approach is the activation of potent anti-tumor T cell 
responses  by  DC-based  vaccines  or  antigen  presenting  cell-activators  (e.g.  TLR-9 
agonist CpG). Anti-IL-10 in combination with these new strategies might enhance and 
prolong  the  tumoricidal  immune  response  (173).  This  theory  was  strengthened  by 
elegant murine tumor models showing drastic effects of combinatorial treatment with 
chemokine  (C-C  motif)  ligand  (CCL)  16,  CpG  and  anti-IL10.  CCL16  promoted 
accumulation of Mand DC at the site of established tumors. Intratumoral injection of 
CpG, together with systemically administered anti-IL-10 led to activation of DC with 
pronounced  IL-12  and  TNF-  production,  migration  to  lymph  nodes  and  adaptive 
immunity responses. TAM were shown to be redirected from a tumor-promoting to an 
inflammatory tumor-rejecting phenotype with pronounced production of IL-12, TNF- 
and NO and were likely the major cell type responsible for dramatic tumor lysis within 
16  h  (174).  Whether  these  promising  results  hold  true  in  humans  remains  to  be 
investigated. 
3.5  Neurotrophin tyrosine kinase receptor 1 (TRKA, NTRK1)  
In 1986 the Nobel prize in physiology or medicine was awarded for the discovery of 
growth factors, namely EGF and nerve growth factor (NGF) to Stanley Cohen and Rita 
Levi-Montalcini. NGF belongs to the neurotrophin protein family, which consists of INTRODUCTION  28 
four members: NGF, brain-derived neurotrophic factor (BDNF) and neurotrophin (NT)3 
and 4/5. Neurotrophins signal through neurotrophic tyrosine kinase receptors (TRK A-C 
or NTRK1-3), TRKA is the preferred receptor for NGF, TRKB has high affinity for BDNF 
and NT-4/5, while NT-3 mainly signals through TRKC. They are essential for neuronal 
survival, growth and differentiation (175) and recent work emphasizes their role in 
neuronal  and  non-neuronal  cancer  (176,  177),  immunity  (178,  179)  and 
psychopathology (180).  
Mature NGF is a glycoprotein of 118 amino acids. NGF protein is translated from 
two major transcripts, resulting in inactive pre-pro-NGF with molecular weights of 34 
and 27 kDa. Within the ER, the pre-pro from is cleaved to pro-NGF (32 and 25 kDa) 
(181). Pro-NGF itself has been recognized as a pro-apoptotic effector by binding to 
P75
NTR, a member of the TNF receptor family, but is unable to activate TRKA signaling 
(182). To form mature NGF (13 kDa), pro-NGF is cleaved intracellularly by furin or pro-
convertases and extracellularly by matrix metalloproteinases. Active NGF is comprised 
of  two  -subunits,  forming  a  stable  non-covalently  bound  homodimer,  which 
preferentially binds TRKA. The TRK receptors are composed of an extracellular domain 
containing leucine-rich motifs with cysteine clusters and two immunoglobulin-like C2 
type domains, which are important for ligand binding. Additionally, the C2 domains are 
thought  to  stabilize  the  monomeric  receptors  to  prevent  auto-activation  through 
spontaneous  dimerization.  Upon  ligand  binding,  the  receptors  dimerize  and 
autophosphorylate specific tyrosine residues. For TRKA the phosphorylation sites Y490 
and  Y785  serve  as  major  docking  sites  for  different  adaptors  and  enzymes.  Y490 
primarily recruits Shc followed by activation of  the PI3K/AKT and MAPK pathways, 
whereas Y785 recruits PLC leading to calcium release ((183, 184) and Figure 9).  INTRODUCTION  29 
 
Figure 9:  TRKA signaling 
Ligand-binding of NGF to TRKA or transactivation by GPCR induces phosphorylation of different 
tyrosine kinase residues within the intracellular region of TRKA. Signaling through multiple 
adaptor proteins leads to differentiation and survival signaling through ERK1/2 and PI3K/AKT 
and  calcium  release.  NGF-dependent  or  independent  transactivation  of  TRKA  is  mediated 
through  GPCRs  and  src,  leading  to  AKT  activation.  Abbreviations:  AKT,  protein  kinase  B; 
ERK1/2, extracellular signal-regulated kinase 1/2; gab1/2, grb-2-associated binder-1/2; GPCR, 
G protein-coupled receptor; grb-2, growth factor receptor-bound protein-2; MEK1/2, mitogen-
activated protein kinase kinase 1/2; NGF, nerve growth factor; PI3K, phosphatidylinositol 3-
kinase;  PKC,  protein  kinase  C;  PLC,  phospholipase  C;  raf,  murine  leukemia  viral  oncogene 
homolog 1; ras, rat sarcoma; shc, src homologous; sos, son of sevenless; src, sarcoma tyrosine 
kinase ; TRKA, neurotrophin tyrosine kinase receptor A. 
  Neuronal  survival  largely  depends  on  TRKA  signaling  through  activation  of 
PI3K/AKT and MAPK pathways, resulting in the induction of anti-apoptotic Bcl-2 family 
proteins.  Furthermore,  Raf  and  PLCγ/PKCδ/ERK  cascades  were  described  to  be 
important  for  neurite  outgrowth  and  differentiation  (175).  As  tyrosine  kinase 
receptors, TRKs are usually activated by ligand binding, but can be transactivated, 
often src-dependent, by G protein-coupled receptors like ADORA2A (185) and  α2-
adrenoceptor  (186).  In  addition  to  neuronal  functions,  TRKA  and  its  ligand  have 
previously been associated with supporting or suppressing tumor growth (187). It was 
shown that especially breast cancer cells can benefit from NGF signaling (188, 189). A 
multitude  of  trials  employing  interference  with  neurotrophins  are  currently  under 
way.  Anti-NGF  antibodies  are  tested  in  e.g.  breast  cancer,  as  NGF  contributes  to 
mammary tumor cell growth, angiogenesis and metastasis (177). However, producers 
and targets of neurotrophins in cancer are ill defined, and neurotrophin effects vary INTRODUCTION  30 
between tumors, as in neuroblastoma high TrkA expression was favourable for patient 
survival (190, 191). On the other hand, high BDNF/TRKB indicated aggressiveness in 
neuroblastoma (192).  
  Furthermore, cells of the immune system broadly expressed neurotrophins and 
their receptors. Especially NGF affects differentiation, survival and chemotaxis of most 
immune  cells,  stimulates  antibody  synthesis  in  B  cells  and  enhances  phagocytosis 
(193,  194).  Despite  these  observations,  the  role  of  neurotrophins  in  M  biology 
remains elusive with only a very limited number of studies performed in this context. 
3.6  Aims of the study 
Due  to  rapid  proliferation,  scarcity  of  oxygen,  nutrients  and/or  therapeutic 
interventions solid tumors show a high rate of apoptosis. Macrophages as professional 
phagocytes clear the apoptotic debris and respond to apoptotic cells by phenotypical 
changes.  Over  the  last  years tumor-associated  macrophages  and  their  pronounced 
secretion of IL-10 have been recognized as key components in establishing a tumor-
promoting milieu, but molecular mechanisms remain ill-defined. Detailed elucidation 
of immune cell function and regulation within tumors is critical to understand disease 
initiation and progression and will be of value for future cancer therapy. 
Thus, the aim of this study was to elucidate the influence of apoptotic cancer cell 
supernatants on primary human macrophages in regard to TAM-related phenotypical 
changes, with special focus on IL-10 regulation. 
In the first part of my studies I performed an adenoviral shRNA high-throughput 
screen to find novel regulators of IL-10 production. Additionally, regulation of three 
other cytokines related to cancer was investigated.  
The  aim  of  the  second  part  of  my  thesis  was  the  in-depth  validation  of  one 
selected target identified in the screen. Thus, I performed experiments to clarify the 
underlying mechanistic principles of IL-10 induction after ACM treatment in regard to 
the chosen target. To analyse, if the identified regulatory pathway was unique for IL-10 
regulation or a conjoint event for macrophage polarization by apoptotic cancer cell 
supernatant,  an  array  of  markers  was  investigated.  Furthermore,  tumor-associated 
macrophages  of  murine  breast  cancer  tissue  were  examined  for  inter-species 
homology of cytokine regulation. MATERIAL AND METHODS  31 
4  Material and Methods 
4.1  Material 
4.1.1  Cells  
MCF-7 breast carcinoma cells 
MCF-7 human breast adenocarcinoma cells were established from the pleural effusion 
of a 69-year-old Caucasian woman with metastatic mammary carcinoma after radio- 
and hormone therapy in 1970 (195). 
 
A549 lung carcinoma cells 
A549  human  alveolar  adenocarcinoma  cells  were  developed  from  cancerous  lung 
tissue of a 58-year-old Caucasian male in 1972 (196). 
 
DU145 prostate cancer cells 
DU145 human prostate adenocarcinoma cells were derived from brain-metastatic cells 
of a 69-year-old Caucasian male in 1978 (197). 
 
HEK293 embryonic kidney cells  
HEK293  cells  were  generated  by  transformation  of  human  embryonic  kidney  cell 
cultures with sheared adenovirus 5 DNA and were first described in 1977 (198). 
 
PC-12 rat pheochromocytoma cells  
PC-12 rat pheochromocytoma cells were obtained from New England Deaconess 
Hospital strain white rats bearing a subcutaneously rat adrenal pheochromocytoma 
solid tumor and were established as cell line in 1976 (199). 
 
PER.C6E2A cells 
PER.C6 cells were derived from a human embryonic retinoblast in 1998 and function 
as  helper  and  packaging  cell  line  for  generation  of  replication-incompetent 
adenoviruses (200). 
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Primary human monocytes 
Primary  human  monocytes  were  isolated  from  buffy  coats  obtained  from  DRK-
Blutspendedienst  Baden-Württemberg-Hessen,  Institut  für  Transfusionsmedizin  und 
Immunhämatologie,  Frankfurt  am  Main  or  from  Sanquin  Bloedbank  Region  South 
West, Rotterdam, The Netherlands. 
 
Primary murine leukocytes 
Primary  murine  leukocytes  were  isolated  from  PyMT  mammary  tumor  tissue  of 
C57BL/6J  mice  carrying  the  PyMT  oncogene  under  the  control  of  the  MMTV  LTR 
promoter  (FVB/N-TgN(MMTV-PyVT)634Mul/J)  (201).  All  procedures  performed  on 
these mice followed the guidelines of the Hessian animal care and use committee.  
4.1.2  Bacteria 
Competent  bacteria  strains  were  provided  by  Stratagene  GmbH  (Amsterdam,  The 
Netherlands). XL1-Blue® supercompetent cells were used for amplification, showing 
the genotype recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZ.M15 
Tn10(Tetr)].  
4.1.3  Stimulants and inhibitors 
Table 2:  Stimulants and inhibitors 
 
Stimulants and inhibitors  Target  Provider 
AG1478  EGFR inhibitor  Avanti Polar Lipids (Alabaster, USA) 
AM630  CBR2 antagonist  Cayman Chemical (Ann Arbor, USA) 
Atorvastatin  HMGCR inhibitor  Tocris Bioscience (Ellisville, MO) 
BDNF (human)  TRKB ligand  ImmunoTools GmbH (Friesoythe) 
Cerivastatin  HMGCR inhibitor  Sigma-Aldrich GmbH (Steinheim) 
CSC (8-(3-
Chlorostyryl)caffeine) 
A2A adenosine receptor 
antagonist 
Sigma-Aldrich GmbH (Steinheim) 
Etoposide  Topoisomerase 2 inhibitor  Sigma-Aldrich GmbH (Steinheim) 
GW441756   TRKA inhibitor  Sigma-Aldrich GmbH (Steinheim) 
Janus kinase (JAK) inhibitor 1  JAK1 inhibitor  Merck KGaA (Darmstadt) 
JTE-013  S1PR2 and 4 antagonist  Santa Cruz Biotechnology (Santa Cruz, 
USA) 
K252a  TRK inhibitor  Sigma-Aldrich GmbH (Steinheim) 
LFM-A13   BTK inhibitor  R&D Systems GmbH (Wiesbaden) MATERIAL AND METHODS  33 
NT3 (human)  TRKC ligand  ImmunoTools GmbH (Friesoythe) 
NT4 (human)  TRKB ligand  ImmunoTools GmbH (Friesoythe) 
PP2  Src inhibitor  Enzo Life Sciences GmbH (Lörrach) 
Propranolol hydrochloride  -adrenoceptor 
antagonist 
Sigma-Aldrich GmbH (Steinheim) 
Rapamycin  mTOR inhibitor  Sigma-Aldrich GmbH (Steinheim) 
SB203580   P38 inhibitor  Sigma-Aldrich GmbH (Steinheim) 
SP600125  JNK inhibitor  Sigma-Aldrich GmbH (Steinheim) 
S1P  S1PR ligand  Biomol GmbH (Hamburg) 
STA-21  STAT3 inhibitor  Enzo Life Sciences GmbH (Lörrach) 
Staurosporine (Sts)  Protein kinase inhibitor  Sigma-Aldrich GmbH (Steinheim) 
UO126  ERK1/2/5 inhibitor  Enzo Life Sciences GmbH (Lörrach) 
VPC23019  S1P1 antagonist  Avanti Polar Lipids (Alabaster, USA) 
Wortmannin  PI3K inhibitor  Sigma-Aldrich GmbH (Steinheim) 
Yohimbine hydrochloride  -adrenoceptor 
antagonist 
Sigma-Aldrich GmbH (Steinheim) 
-NGF (human)  TRKA ligand  ImmunoTools GmbH (Friesoythe) 
4.1.4  Chemicals and kits 
All chemicals were of the highest grade of purity, commercially available and usually 
purchased from Sigma-Aldrich GmbH (Steinheim, Germany), Roth GmbH (Karlsruhe, 
Germany) or Merck (Darmstadt, Germany). Cell culture media and supplements were 
from PAA (Cölbe, Germany). Special reagents and kits are listed in Table 3.  
Table 3:  Special reagents and kits 
 
Chemical/Kit  Provider 
Absolute™ qPCR SYBR® Green Fluorescein Mix  Fisher Scientific GmbH (Schwerte) 
Accutase  PAA Laboratories GmbH (Cölbe) 
Agarose  peqLab Biotechnologie GmbH (Erlangen) 
Annexin-V-FITC  ImmunoTools GmbH (Friesoythe) 
Brome phenol blue  Fluka GmbH (Buchs) 
CD11b Microbeads (mouse)  Miltenyi Biotec GmbH (Bergisch-Gladbach) 
CD14 Microbeads (human)  Miltenyi Biotec GmbH (Bergisch-Gladbach) 
Collagen R  Serva GmbH (Heidelberg) 
Collagenase 1A  Sigma-Aldrich GmbH (Steinheim) 
DC Protein Assay Kit  BioRad GmbH (Munich) 
DNAse 1  Promega GmbH (Mannheim) 
Dynabeads Protein G  Life Technologies GmbH (Darmstadt) MATERIAL AND METHODS  34 
HiPerFect  Qiagen GmbH (Hilden) 
Human Inflammation Kit (CBA)  BD Biosciences GmbH (Heidelberg) 
Human serum (AB positive), inactivated  DRK-Blutspendedienst Baden-Württemberg-
Hessen (Frankfurt) 
Human Soluble Protein Master Buffer Kit  BD Biosciences GmbH (Heidelberg) 
Human Th1/Th2 Cytokine Kit II (CBA)  BD Biosciences GmbH (Heidelberg) 
IL-10 (human)  BD Biosciences GmbH (Heidelberg) 
IL-10 Flex Set (human)  BD Biosciences GmbH (Heidelberg) 
IL-6 (human)  ImmunoTools GmbH (Friesoythe) 
JetPEI™ transfection reagent  Biomol GmbH (Hamburg) 
Lymphocyte separation medium (Ficoll)  PAA Laboratories GmbH (Cölbe) 
MA6000 Human IL-10 384 Tissue Culture Kit  Meso Scale Discovery (Gaithersburg, USA) 
Maxima® First Strand cDNA Synthesis Kit   Fermentas GmbH (St. Leon-Rot) 
M-CSF  ImmunoTools GmbH (Friesoythe) 
Mouse Inflammation Kit (CBA)  BD Biosciences GmbH (Heidelberg) 
MA6000 Human IL-10 384 Tissue Culture Kit  Meso Scale Discovery (Gaithersburg, USA) 
MS6000 384 4 Spot HB, Cytokine Plate-Human TC 
4-Plex 
Meso Scale Discovery (Gaithersburg, USA) 
Neomycin (G 418)  PAA Laboratories GmbH (Cölbe) 
Nonidet P-40   ICN Biomedicals Gmb ( Eschwege) 
NucleoBond Xtra Midi/Maxi Kit  Machery-Nagel GmbH (Düren) 
ON-TARGETplus SMARTpool siRNA (human 
HMGCR, IL4R, THBS3) 
Fisher Scientific GmbH (Schwerte) 
Paraformaldehyde (PFA)  Sigma-Aldrich GmbH (Steinheim) 
PBS (Instamed 9.55 g/ml)   Biochrom AG (Berlin) 
peqGOLD RNAPure™  PeqLab Biotechnologie GmbH (Erlangen) 
PhosSTOP  Roche GmbH (Grenzach) 
Propidium iodide  Sigma-Aldrich GmbH (Steinheim) 
Protease inhibitor mix (PIM)  Roche GmbH (Grenzach) 
Proteinase K  New England Biolabs (Frankfurt) 
Triton X100  Serva GmbH (Heidelberg) 
Vectashield H-1400 mounting medium  Vector Labs (Burlingame, USA) 
4.1.5  Antibodies 
All antibodies were directed against human proteins (if not stated otherwise) and were 
used  for  neutralization  (NEUTR),  Western  blotting  (WB),  immunoprecipitation  (IP), 
immunofluorescence (IF), ELISA or FACS-based cell sorting as listed below in Table 4. MATERIAL AND METHODS  35 
Table 4:  Antibodies 
 
Antibody  Provider  Application  Dilution 
Anti-AKT  Cell Signaling Tech. Inc. (Danvers, USA)  WB  1:2000 
Anti-CD11b-FITC clone 
M1/70.15.11.5 (mouse) 
Miltenyi Biotec GmbH (Bergisch-
Gladbach) 
Cell Sorting  1µl/200µl/ 
10
6cells 
Anti-CD36 FITC   ImmunoTools GmbH (Friesoythe)  IF  1:100 
Anti-CD45-Vioblue 
clone 30-F11.1 (mouse) 
Miltenyi Biotec GmbH (Bergisch-
Gladbach) 
Cell Sorting  4µl/200µl/ 
10
6cells 
Anti-F4/80-PE-Cy7 clone 
BM8 (mouse) 
eBioscience (Frankfurt)  Cell Sorting  2µl/200µl/ 
10
6cells 
Anti-HA.11  Covance Laboratories GmbH (Münster)  WB  1:1000 
Anti-HLR-DR-APC clone 
M5/114.15.2 (mouse) 
Miltenyi Biotec GmbH (Bergisch-
Gladbach) 
Cell Sorting  4µl/200µl/ 
10
6cells 
Anti-Ly6C-PerCP-Cy5.5 
clone AL-21 (mouse) 
BD Biosciences GmbH (Heidelberg)  Cell Sorting  1µl/200µl/ 
10
6cells 
Anti-Ly6G-PE clone 1A8 
(mouse) 
BD Biosciences GmbH (Heidelberg)  Cell Sorting  4µl/200µl/ 
10
6cells 
Anti-mouse Alexa Fluor 
488 
Life Technologies GmbH (Darmstadt)  IF  1:200 
Anti-mouse IRDye680-
labelled  
Li-COR Biosciences GmbH (Bad 
Homburg) 
WB  1:5000 
Anti-mouse IRDye800-
labelled  
Li-COR Biosciences GmbH (Bad 
Homburg) 
WB  1:5000 
Anti-NGF (H-20)  Santa Cruz Biotechnology (Heidelberg)  WB  1:250 
Anti-p38 MAP Kinase  Cell Signaling Tech. Inc. (Danvers, USA)  WB  1:2000 
Anti-phospho-AKT 
(Ser473) (D9E) XP 
Cell Signaling Tech. Inc. (Danvers, USA)  WB  1:2000 
Anti-phospho-p38 MAP 
(Thr 180/Tyr 182) 
Cell Signaling Tech. Inc. (Danvers, USA)  WB  1:2000 
Anti-phospho-TRKA (Tyr 
490) 
Cell Signaling Tech. Inc. (Danvers, USA)  WB  1:1000 
Anti-rabbit DyLight 594  Jackson ImmunoResearch Laboratories 
(Suffolk, UK) 
IF  1:200 
Anti-rabbit IRDye680-
labelled  
Li-COR Biosciences GmbH (Bad 
Homburg) 
WB  1:5000 
Anti-rabbit IRDye800-
labelled  
Li-COR Biosciences GmbH (Bad 
Homburg) 
WB  1:5000 
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Anti-TRKA  Santa Cruz Biotechnology (Heidelberg)  IF, IP  IP: 4µg/1000µg 
protein 
IF: 1:100 
Anti-tubulin  Sigma-Aldrich GmbH (Steinheim)  IF  1:250 
Anti--NGF  R&D Systems GmbH (Wiesbaden)  NEUTR  5µg/ml 
CD16/32 blocking ab, 
clone 93 (mouse) 
BD Biosciences GmbH (Heidelberg)  Blocking for 
cell sorting 
4µl/200µl/ 
10
6cells 
IgG1 Isotype Control  R&D Systems GmbH (Wiesbaden)  NEUTR  5µg/ml 
IL-10 matched paired   ImmunoTools GmbH (Friesoythe)  ELISA  1:750 
IL-6 matched paired  ImmunoTools GmbH (Friesoythe)  ELISA  1:1000 
4.1.6  Plasmids 
For  overexpression  of  hemagglutinin  (HA)-tagged  TRKA,  the  CMV-HA-TRKA  plasmid 
with ampicillin, neomycin resistance was kindly provided by Prof. Y-A Barde (202) 
4.1.7  Oligonucleotides 
Oligonucleotides were purchased from Biomers GmbH (Ulm) and described in Table 5. 
QuantiTect  primers  from  Qiagen  GmbH  (Hilden)  were  used  for  human  ADORA2A, 
IDO1, IL-6, IL-8, IL4RA, HMGCR, THBS3. 
Table 5:  Oligonucleotides 
 
Primer  Forward  Reverse 
annealing 
temperatur 
18S rRNA (human)  5’-GTAACCCGTTGAACCCCATT-3’  5’-CCATCCAATCGGTAGTAGCG-3’  55°C 
HIF-1 (human)  5’-CTCAAAGTCGGACAGCCTCA-3’  5’- CCCTGCAGTAGGTTTCTGCT-3’  60°C 
IL-10 (human)  5’-AAGCCTGACCACGCTTTCTA-3’  5’-TAGCAGTTAGGAAGCCCCAA-3’  55°C 
IL-1ra (human)  5’-ACCAATATGCCTGACGAAGG-3’  5’-CCTGTGACCAGGTTGTTGTG-3’  60°C 
MRC-1 (human)  5’-GGCGGTGACCTCACAAGTAT-3’  5’-ACGAAGCCATTTGGTAAACG-3’  60°C 
NGF (human)  5’-CATCATCCCATCCCATCTTC-3’  5’-CTCTCCCAACACCATCACCT-3’  60°C 
TRKA (human)  5’-CAGCCGGCACCGTCTCT-3’  5’-TCCAGGAACTCAGTGAAGATG 
AAG-3’ 
60°C 
VEGF (human)  5’-TACCTCCACCATGCCAAGTG-3’  5’-AAGATGTCCACCAGGGTCTC-3’  60°C MATERIAL AND METHODS  37 
4.1.8  Consumables 
Table 6:  Consumables 
 
Material  Provider 
BZO Seal Film  Biozym Scientific GmbH (Hessisch Oldendorf) 
Cover slips  Menzel GmbH (Braunschweig) 
ELISA microplates, high binding   Greiner bio-one GmbH (Frickenhausen) 
Hard-Shell® Full-Height 96-Well Semi-Skirted 
PCR Plates 
Bio-Rad Laboratories GmbH (Munich) 
Eppendorf Cups (0.5 ml; 1.5 ml; 2 ml)  Eppendorf GmbH (Hamburg) 
FACS tubes  Sarstedt AG & Co. (Nürnbrecht) 
Filcon (70 µm)  BD Biosciences GmbH (Heidelberg) 
Filter paper  Whatman GmbH (Dassel) 
Medicons  BD Biosciences GmbH (Heidelberg) 
Microscope slides  Süsse Labortechnik (Gudensberg) 
Pipet tips (10 µl; 100 µl; 1000 µl; 5000 µl)  Eppendorf GmbH (Hamburg) 
Leucosep tubes  Greiner bio-one GmbH (Frickenhausen) 
Plastic material (cell culture)  Greiner Bio-One GmbH (Frickenhausen) 
Steril filters (0,22 µm)  Millipore GmbH (Schwalbach) 
Tissue culture dishes  Sarstedt AG & Co. (Nürnbrecht) 
Vivaspin 4 PES membrane falcons   Satorius AG (Goettingen) 
Whatman PROTRAN® nitrocellulose 
membrane 
Whatman GmbH (Dassel) 
4.1.9  Instruments and software 
Used instruments and software are listed in Table 7 and Table 8.  
Table 7:  Instruments  
 
Instruments  Provider 
12-channel Eppendorf Research (200 µl)  Eppendorf GmbH (Hamburg) 
16-channel Finnpipette (50µl]  Fisher Scientific GmbH (Schwerte) 
AIDA Image Analyzer  Raytest GmbH (Straubenhardt) 
Apochromat 64x/1.40 oil lense  Carl Zeiss MicroImaging GmbH (Jena) 
Apollo-1 LB 911 photometer  Berthold Technologies GmbH & Co. KG (Bad Wildbad) 
Autoclave HV 85   BPW GmbH (Süssen) 
AutoMACS™ Separator  Miltenyi Biotec GmbH (Bergisch-Gladbach) 
AxioCam MRm  Carl Zeiss MicroImaging GmbH (Jena) MATERIAL AND METHODS  38 
AxioVert 200M fluorescence microscope 
equipped with the ApoTome 
Carl Zeiss MicroImaging GmbH (Jena) 
B250 Sonifier   Branson Ultrasonics (Danbury, USA) 
Bacteria clean bench Hera guard  Heraeus GmbH (Hanau) 
Bacteria incubator B5042   Heraeus GmbH (Hanau) 
Bacteria incubator Innova®44  New Brunswick Scientific GmbH (Nürtingen) 
CASY®   Schärfe System GmbH (Reutlingen) 
Centrifuge 5415 R and 5810 R  Eppendorf GmbH (Hamburg) 
DynaMag Magnet for 1.5-2 ml tubes  Life Technologies GmbH (Darmstadt) 
FACSAria  BD Biosciences GmbH (Heidelberg) 
Galaxy Mini  VWR International GmbH (Darmstadt) 
Hera cell 150 (Lamina)   Fisher Scientific GmbH (Schwerte) 
LabLine Orbit Shaker   Uniequip GmbH (Martinsried) 
LSRIIFortessa  BD Biosciences GmbH (Heidelberg) 
Magnetic stirrer Combimag RCH  IKA Labortechnik GmbH & Co. KG (Staufen) 
Mastercycler®   Eppendorf GmbH (Hamburg) 
Medimachine   Keul GmbH (Steinfurt) 
Mini-PROTEAN 3 System   Bio-Rad Laboratories GmbH (Munich) 
Multidrop 384  Thermo Fisher Scientific GmbH (Dreieich) 
MyiQ iCycler system  Bio-Rad Laboratories GmbH (Munich) 
NanoDrop ND-1000   Peqlab Biotechnologie GmbH (Erlangen) 
Neubauer improved counting chamber  Labor Optik GmbH (Friedrichsdorf) 
Odyssey infrared imaging system  Li-COR Biosciences GmbH (Bad Homburg) 
Pipetboy  Hirschmann Laborgeräte GmbH & Co.KG (Eberstadt) 
Pipettes (10 μl, 100 μl, 1.000 μl)   Eppendorf GmbH (Hamburg) 
Power washer 384  Tecan Deutschland GmbH (Crailsheim)   
Pure water system Purelab Plus   ELGA LabWater GmbH (Siershahn) 
Reax Top  Heidolph Instruments GmbH & Co. KG (Schwabach) 
Roller Mixer SRT1  Bibby Scientific Ltd. (Staffordshire, UK) 
SECTOR Imager 6000  Meso Scale Discovery (Gaithersburg) 
TeMO 384 Genesis robotic system  Tecan Deutschland GmbH (Crailsheim) 
Thermomixer compact   Eppendorf GmbH (Hamburg) 
Trans-Blot SD blotting machine   Bio-Rad Laboratories GmbH (Munich) 
Table 8:  Software 
 
Software  Provider 
AxioVision Release 4.7  Carl Zeiss MicroImaging GmbH (Jena) 
BD Biosciences’ FCAP software  BD Biosciences GmbH (Heidelberg) 
CorelDRAW Graphics Suite X4  Corel Cooperation (Ottawa, Canada) MATERIAL AND METHODS  39 
EndNote X2  Thomson Reuters Endnote (Carlsbad, USA) 
FlowJo V7.6.1.  FlowJo (Ashland, USA) 
Gemini
TM  Tecan Deutschland GmbH (Crailsheim) 
Microsoft Office 2007  Mikrosoft Deutschland GmbH (Unterschleißheim) 
MSD DISCOVERY WORKBENCH software  Meso Scale Discovery (Gaithersburg, USA) 
MyiQ Optical Systems, Software 1.0  Bio-Rad Laboratories GmbH (Munich) 
ND-1000 V3.2.1  Peqlab Biotechnologie GmbH (Erlangen) 
Odyssey 2.1  Li-COR Biosciences GmbH (Bad Homburg) 
Photo Read V1.2.0.0  Berthold Technologies GmbH & Co. KG (Bad Wildbad) 
Prism 4  GraphPad Software (La Jolla, USA) 
4.2  Methods 
For all experiments except for the HTS, cells were starved over night in culture medium 
without FCS or human serum. Control cells, which were not stimulated with ACM, 
were  treated  with  control  medium  containing  equal  amounts  of  FCS  compared  to 
ACM. Buffers and Solutions used for experimental procedures are listed and described 
in the Appendix. 
4.2.1  Cell culture 
MCF-7 breast carcinoma cells were cultured in RPMI 1640 medium supplemented with 
1 x non-essential aminoacids, 10% heat-inactivated fetal calf serum (FCS) and 10 µg/ml 
bovine insulin. A549 lung carcinoma cells were cultured in high-glucose DMEM, 10% 
heat-inactivated  FCS.  DU145  prostate  cancer  cells  were  grown  in  MEM  with  1  x 
nonessential amino acids, 10% FCS. HEK293 embryonic kidney cells were grown  in 
RPMI  1640  supplemented  with  10%  heat-inactivated  FCS.  PC-12  rat 
pheochromocytoma  cells  were  cultured  on  collagen  R  in  DMEM  high  glucose 
supplemented with 5% heat-inactivated FCS, and 5% horse serum. PER.C6E2A cells 
were cultured in DMEM supplemented with 10% FCS and 5 mM MgCl2. All media were 
supplemented with 5 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
Cells  were  kept  in  a  humidified  atmosphere  of  5%  CO2  in  air  at  37°C  and  were 
transferred twice a week. Cell numbers were determined using the cell counter system 
Casy
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4.2.2  Isolation and culture of human monocytes 
Human monocytes were isolated from buffy coats using Ficoll-Hypaque gradients as 
described previously (203). In brief, two 50 ml Leukosep® tubes per buffy were layered 
with 15 ml lymphocyte separation media, blood cells were added followed by density 
gradient centrifugation (440 x g, 35 min, break off, RT). PBMCs were collected, washed 
twice with leukocyte washing buffer, seeded in RPMI and were allowed to adhere to 
tissue culture dishes for 2 h at 37°C. Non-adherent cells were removed. Monocytes 
were then differentiated into M with RPMI 1640 containing 5% heat-inactivated AB
+ 
human serum, 5 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin for 7 
days, medium was changed every second day. Cells were then used up to 3 weeks 
after isolation at cell densities between 60 – 90% confluency. 
4.2.3  Monocyte isolation and M culture for screening procedure 
Peripheral blood mononuclear cells were isolated as described in 4.2.2, and CD14
+ cells 
were extracted using MACS CD14 microbeads and the AutoMACS Separator (4.2.5.). 
Cells were resuspended in RPMI 1640 supplemented with 10% heat-inactivated FCS, 
5 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 100 ng/ml M-CSF 
and were differentiated for 4 days in 384-well plates at a density of 1 x 10
4/well before 
adenoviral transduction (4.2.8.2) was performed. 
4.2.4  Isolation of murine lymphocytes of PyMT breast cancer tissue  
Mice carrying the Polyoma middle T-antigen (PyMT) oncogene under the control of the 
mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter (FVB/N-
TgN(MMTV-PyVT)634Mul/J)  were  a  kind  gift  of  Thomas  Reinheckel  (University  of 
Freiburg,  Germany).  Mice  were  backcrossed  for  at  least  six  generations  into  the 
C57BL/6J background. 20 week-old tumor-bearing mice were sacrificed and the tumors 
extracted  by  Benjamin  Weichand.  1  g  of  tumor  tissue  was  minced  with  a  scalpel 
followed by lysis in 2 ml tumor lysis buffer for 30 min at 37°C. Lysis was stopped with 6 
ml DMEM + 10% FCS and the lysate was further processed using Medicons and the 
Medimachine. After centrifugation, erythrocyte lysis in 6 ml erythrocyte lysis buffer 
was performed for 4 min at 4°C. Cells were resuspended in 10 ml leukocyte running 
buffer, brought to a single cell suspension using a Filcon (70 µm), counted and CD11b-
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were stained and sorted for distinct immune cell populations (4.2.6). Immediately after 
isolation 400,000 CD11b
+ cells per well were seeded in 24-well plates. For distinct 
populations 6,000 cells or 20,000 cells per well were seeded in 96-well plates. Cells 
were  cultured  in  RPMI  1640  supplemented  with  1%  heat-inactivated  FCS,  5  mM 
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
4.2.5  Magnetic cell sorting 
Human CD14
+ cells and murine CD11b
+ were sorted using the AutoMACS Separator. 
According  to  the  manufacturer’s  protocol,  cells  were  washed  and  resuspended  in 
leukocyte  running  buffer  (80 µl/1  x  10
7  cells).  For  magnetic  labelling,  10 µl beads 
/1 x 10
7 cells of CD14 or CD11b microbeads were added and incubated at 4°C for 15 
min. Cells were washed with 25 ml leukocyte running buffer, centrifuge at 300 x g for 
10 min, 4°C and re-suspended in 2ml leukocyte running buffer. Cells were sorted using 
the AutoMACS program <posselD> for positive selection. The eluted positive fraction 
was washed with 20 ml leukocyte running buffer and centrifuged at 300 x g for 10 min. 
Supernatant  was  discarded  and  cells  were  resuspended  in  appropriate  culture 
medium. The cell concentration was determined with help of the Neubauer counting 
chamber, and cells were seeded at appropriate cell densities in either 24, 96 or 384-
well plates.  
4.2.6  Multi-color FACS cell sorting 
Single cell suspensions of murine PyMT tumors (4.2.4) were divided into 6 tubes à 10
6 
cells in 200 µl. To minimize unspecific binding, Fc-receptors were blocked for 15 min, 
4°C  with  CD16/CD32  blocking  antibody,  followed  by  staining  with  CD45-Vioblue, 
CD11b-FITC, HLR-DR-APC, F4/80-PE-Cy7, Ly6G-PE, Ly6C-PerCP-Cy5.5 antibodies for 30 
min  on  ice.  Cells  were  pooled,  singled  out  using  a  Filcon  and  CD45
+CD11b
+Ly6G
+ 
granulocytes,  CD45
+CD11b
+F4/80
-HLR-DR
-Ly6C
+  monocytes,  CD45
+CD11b
+F4/80
-HLR-
DR
-Ly6C
- monocytes and CD45
+CD11b
+F4/80
+HLR-DR
+ macrophages were sorted using 
a BD FACSAria. Cells were seeded and stimulated after 15 min with inhibitors.  
4.2.7  Generation of apoptotic cancer cell supernatant (ACM) 
To  generate  apoptotic  cancer  cell  supernatant  from  MCF-7  cells  (ACM)  cells  were 
cultured  in  FCS-free  medium  and  stimulated  with  0.5 µg/ml  staurosporine  for  2 h 
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washed twice with medium to remove staurosporine and were incubated over night 
with  fresh  medium  containing  10%  heat-inactivated  FCS,  glutamine,  penicillin  and 
streptomycin. For A549-ACM and DU145-ACM, etoposide (250 µM, 3 h) was applied to 
induce  apoptosis.  Apoptotic  cell  death  (%)  was  comparable  to  staurosporine.  The 
volume of medium was adjusted to cell number to obtain ACM with a concentration of 
approximately 2.5 x 10
6 cells/ml. The generated ACM was centrifuged (1000 g, 10 min, 
4°C) and filtered through a 0.22 µm filter to remove cell debris and apoptotic bodies. 
For generation of viable cell supernatant (VCM), the same procedure was followed, 
without induction of apoptosis. A 5:1 ratio of apoptotic/viable cells to M was used 
when stimulating M with ACM.  
4.2.7.1  Verification of cell death in cells used for ACM generation 
For  determination  of  cell  death,  cells  were  detached  from  culture  dishes  using 
accutase and stained with propidium iodide and annexin-V-FITC in Annexin-V binding 
buffer for 20 min. Samples were acquired on a BD LSRIIFortessa flow cytometer, and 
analyzed  using  FlowJo  V7.6.1..  Cells  used  for  ACM  showed  at  least  35%  apoptosis 
(Annexin V
+/PI
-) compared to a basal level of not more than 13% of apoptosis in viable 
cells used for VCM. 
4.2.7.2  Generation of deproteinated ACM 
ACM  was  treated  for  1  h  with  50  µg/ml  proteinase  K  at  37  °C  followed  by  1  h 
incubation at 100°C. The obtained deproteinated ACM (Deprot-ACM) was then filtered 
through a 0.22 µm filter and used for stimulation.  
4.2.8  Transduction and transfection procedures 
4.2.8.1  Repropagation of adenoviruses and IU determination 
Replication defective adenoviruses, lacking the E1 and E2A region in their genome, 
were repropagated in the packaging cell line Per.C6/E2A (200, 204), containing the two 
required regions for virus replication. In brief, PER.C6/E2A cells were seeded in a 96-
well format and at 80% confluency were transduced with virus and cultured for 7 – 10 
days at 34°C and 10% CO2. The cytopathogenic effect (CPE), cell lysis due to production 
of adenoviral particles, was determined by eye. When cells reached full CPE, cells were 
frozen (-20°C) to completely permeabilize, than thawn and spun down to remove cell 
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(-80°C),  sequencing  and  infectious  unit  (IU)  concentration  titration.  For  IU 
determination PER.C6/E2A were transduced with serial dilutions of viruses and 48 h 
later stained for virus specific hexon protein to determine the transduction efficiency 
(performed by BioFocus). The average IU per ml of the used library was 7 x 10
7, for the 
rescreen 4.5 x 10
7. 
4.2.8.2  Adenoviral transduction 
CD14
+  M  (4.2.3)  were  transduced  for  24h  at  day  4  after  monocyte  isolation. 
Transduction  of  controls  using  Ad5C01-shRNA  constructs  and  empty  vector  from 
BioFocus/Galapagos  BV  (Leiden,  The  Netherlands)  was  performed  at  an  IU  of  85. 
Library viruses were used at an optimized volume (5.2.1). Medium was replaced and 
after additional 5 days transduced M were treated with ACM for 24 h. Supernatants 
were harvested and stored at -80°C until cytokine measurement (4.2.11.1). 
4.2.8.3  Transient transfection 
For overexpression experiments in HEK293 cells, cells were seeded on cover slips in 6-
well plates at a density of 5 x 10
4 cells per well. 24 h later, cells were transfected with 3 
µg HA-tagged TRKA expression plasmid using JetPEI transfection reagent, following the 
manufacture's  transfection  protocol. After  24  h,  cells  were  starved  over  night  and 
stimulated with ACM or control medium for 30 min. Thereafter, immunoflourescence 
staining  (4.2.12)  was  performed.  For  knockdown  studies  in  primary  human  M, 
monocytes were isolated as described in 4.2.2 and seeded in 6-well plates at 80-90% 
confluency.  For  transfection  with  siRNA,  ON-TARGETplus  SMARTpool  siRNA  and 
transfection reagent HiPerFect were used. In detail, cells were treated for 6 h with 
16.8 µl HiPerFect and 150 µM siRNA in 500 µl RPMI 1640, thereafter 1 ml RPMI 1640 
was added and incubation continued over night. The next day, M were treated with 
ACM or control medium for 24 h. Knockdown efficiency was controlled by qRT-PCR 
(4.2.9.3) in control medium-treated cells. 
4.2.9  mRNA expression analysis 
4.2.9.1  RNA isolation 
Total RNA was isolated using peqGold RNAPure™ Kit as described by the manufacturer. 
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5 min and transferred to a 1.5 ml tube. After addition of 200 µl chloroform, samples 
were vortexed thoroughly and incubated at RT for 5 min. Subsequently, samples were 
centrifuged at 12,000 x g for 10 min to separate the RNA containing water phase from 
the phenol- and inter-phase. To precipitate RNA, 0.5 ml 2-propanol was added to the 
collected  water  phase,  incubated  for  20 min  at  RT  or  over  night  at  -20°C  and 
centrifuged (12,000 x g, 15 min, 4°C). Precipitated RNA was washed twice with 75% 
ethanol in DEPC-H2O, dried (5 min, 70°C) and finally dissolved in 20-50 µl DEPC-H2O for 
45 min at 60°C. RNA concentration was determined using the NanoDrop ND-1000 and 
optical density (OD) at 260 nm. An OD260 of 1 is equivalent to 40 ng/µl RNA.  
4.2.9.2  Reverse transcription 
To  determine  the  amount  of  specific  RNA  transcripts,  reverse  transcription  was 
performed according to the provided manual using Maxima® cDNA Synthesis Kit. In 
brief,  1 µg  of  isolated  mRNA  was  mixed  with  4 µl  5  x  reaction  mix,  2 µl  Maxima® 
reverse transcriptase and nuclease-free H2O was added to 20 µl. The reaction mix was 
incubated for 10 min at 25°C, 15 min at 50°C and finally 5 min at 85°C for inactivation 
of the enzyme. The resulting cDNA was diluted to 1 µg/800µl.  
4.2.9.3  Quantitative real-time polymerase chain reaction (qRT-PCR) 
For qRT-PCR, 8 µl of cDNA (4.2.9.2) was used and mixed with either 2 µl QuantiTect 
Primer Assay or 0.5 µl forward and reverse primer (5 µM) each and 10 µl Absolute™ 
qPCR SYBR ® Green Fluorescein Mix. The volume was adjusted to 20 µl with distilled 
H2O. The mixtures were transferred to a qRT-PCR compatible plate. The plate was 
briefly centrifuged and sealed with BZO Seal Film, an optical adhesive seal. QRT-PCR 
was performed using the MyiQ Single-Color Real-time PCR Detection System and the 
following thermal cycling program.  
Enzyme activation:     95°C, 15 min 
Denaturation:     95°C, 15 s 
Annealing:       55-60°C, 30 s        35 – 45 cycles 
Extension:      72°C, 30 s 
 
To confirm specificity of the multiplication, a  melting curve was created using the 
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Denaturation:     95°C, 30 s 
Starting temperature:  60°C, 30 s 
Melting step:      60°C, 10 s, + 0.5°C per cycle, 80 cycles 
4.2.10  Protein analysis by Western blotting and Immunoprecipitation  
4.2.10.1  Protein determination (Lowry) 
The protein content of cell lysates was determined using the DC Protein Assay Kit, 
based on the Lowry method (205). Briefly, a standard dilution series of bovine serum 
albumin (BSA) in urea lysis buffer was prepared (0.625 to 10 mg/ml). 2 µl of each 
sample as well as of the standard dilutions were pipetted in duplicates into a clear flat-
bottom 96-well plate, 20 µl solution A were added, and the colorimetric reaction was 
started  by  adding  160  μl  of  solution  B.  After  incubation  for  15  min  (shaking;  RT), 
extinction was measured at 750 nm using the Apollo-8 LB 912 photometer. 
4.2.10.2  SDS-PAGE/Western analysis 
For Western analysis 60-90% confluent M or PC12 cells on 6- or 10-cm dishes were 
stimulated, washed with ice-cold PBS and scraped off in 200 - 400 µl urea lysis buffer 
at 4°C and sonicated for 15 x 1 s on ice. After centrifugation (16,000 x g, 10 min, 4°C), 
protein  concentration  was  determined  (4.2.10.1).  100 µg  protein  was  mixed  with 
4 x SDS  (sodium  dodecyl  sulfate)  sample  buffer  and  denatured  at  95°C  for 10 min. 
Proteins were separated on 6 or 10% SDS-polyacrylamide gels – depending on the size 
of the protein to detect. 1 x SDS-running buffer and the Mini-PROTEAN 3 system were 
used. Seperated proteins were transferred onto a nitrocellulose membrane by semi-
dry  blotting.  To  minimize  unspecific  binding,  membranes  were  blocked  with  5% 
BSA/TBS or 5% milk/TBS, depending on the thereafter used antibody, for 1 h at RT. 
Membranes were incubated with primary antibodies in 5% BSA/TBS at 4°C over night 
at indicated concentrations (4.1.5). For protein detection, membranes were washed 3 
times with TBS or TTBS for 7 min and incubated with IRDye secondary antibodies in 5% 
BSA/TBS for 1 h at RT. The membrane was washed again 3 times for 7 min (2 x TBS, 1 x 
TTBS) and proteins were detected and densitometrically analysed using the Odyssey 
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4.2.10.3  Immunoprecipitation (IP)  
Primary human M of two 10-cm  dishes per sample were stimulated for 30 min, 
washed with ice-cold PBS, scraped off in 600 µl NP40 Cell Lysis Buffer and lysed in 1.5 
ml tubes for 30 min at 4°C while shaking. Lysates were centrifuged at 10,000 g, 10 min, 
4°C to remove remaining cell debris and protein amount was determined (4.2.10.1) 
and conventional Western blotting samples were taken (4.2.10.2) and stored at -20°C. 
For IP, the DYNAL IP Kit - Dynabeads® Protein G protocol was followed. Briefly, 50 µl 
beads per sample were incubated with 4 µg polyclonal rabbit anti-TRKA (763) ab per 
sample  in  IP  buffer  for  90 min,  RT,  rotating.  After  formation  of  the  Dynabead-ab 
complex, the liquid phase was removed with the help of the DynaMag magnet. The 
complex was washed with 200 µl IP buffer and 1 mg protein lysate in 500 µl NP40 
buffer  was  added  to  the  complex  and  incubated  rotating  at  4°C  over  night.  The 
following day, the Dynabeads-ab-TRKA complex was washed three times with 200 µl 
PBS, with help of the DynaMag magnet. The complex was then transferred in 100 µl 
PBS into a fresh tube. Using the DynaMag, the complex was separated from PBS and 
TRKA protein was eluted by using 30 µl 2 x SDS sample buffer at 70°C. The liquid phase, 
containing TRKA was collected and the elution repeated twice (1 x 70°C, 1 x 95°C). 
After combining the three elutions, 1/3 of the IP samples and crude cell lysates were 
loaded onto 6% SDS-polyacrylamide gels and proceeded as in 4.2.10.2. Membranes 
were stained with polyclonal rabbit anti-phospho-TRKA (Y490) ab as well as polyclonal 
rabbit anti-TrkA (763) ab. 
4.2.11  Analysis of secreted proteins 
4.2.11.1  Cytometric Bead Array (CBA) and Meso Scale Discovery (MSD) 
Cytokine measurement in the supernatant of primary human M was performed by 
FACS analysis using the CBA Flex Set for IL-10, CBA Human Th1/Th2 Cytokine Kit II and 
CBA  Human  Inflammation  Kit  for  multi-cytokine  measurements,  following  the 
manufacturer’s instructions. For PyMT tumor leukocytes, cytokines were measured 
with the CBA Mouse Inflammation Kit. In brief, 50 µl supernatant and standards were 
incubated  with  beads,  coated  with  specific  antibodies  and  a  PE-labeled  detection 
reagent for 3 h. Samples were acquired with the LSR Fortessa flow cytometer and 
analyzed with BD Biosciences’ FCAP software. MATERIAL AND METHODS  47 
Cytokine measurement during the HTS at BioFocus/Galapagos, was performed 
using the MSD System, an immunoassay using electro-chemiluminescence. 384-well 
plates were purchased pre-coated with anti-IL-10 ab (MA6000 Human IL-10 384 Tissue 
Culture Kit), or anti-IL-6, IL-8, IL-12p70, IL-13 antibodies in 4-spot wells (MS6000 384 4 
Spot HB, Cytokine Plate-Human TC 4-Plex). The provided MSD protocol was followed. 
In brief, 10 µl of M supernatant or standards was transferred to MSD plates, either 
by hand or using the TeMO 384 robot. Plates were incubated for 2 h, RT, shaking. 10 µl 
detection antibody (1 µg/ml) was added to each well, using a 16-channel pipette. After 
incubation  (2 h,  RT,  shaking),  plates  were  washed  three  times  with  50 µl  washing 
buffer using the Tecan Power Washer 384. Wells were emptied and 35 µl Read Buffer T 
was added with the Multidrop 384. Plates were measured with the SECTOR Imager 
6000  following  the  manufactures  protocol  and  analyzed  with  MSD  DISCOVERY 
WORKBENCH software.  
4.2.11.2  Enzyme-linked immunosorbent assay (ELISA) 
For validation experiments of the screening data, IL-10 and IL-6 protein measurement 
in supernatant of primary human M was performed by ELISA, using IL-10 and IL-6 
matched antibody pairs and standards from ImmunoTools. The assays were performed 
following  the  ImmunoTools’  protocol  on  96-well  ELISA  microplates.  In  brief, 
microplates were coated with coating antibodies diluted 1:1000 in ELISA coating buffer 
over night at 4°C. Following five washing steps with PBS, unspecific binding of samples 
was diminished by 1 h incubation with ELISA blocking buffer at RT, shaking. Plates were 
washed five times with ELISA washing buffer and incubated with 100 µl sample or 
standard  for  1  h,  RT,  shaking.  Washing  as  before  was  repeated  and  biotinylated 
detection antibody in ELISA dilution buffer was added for 1 h. Plates were washed and 
incubated  for  30  min  with  streptavidin-HRP  (1:200)  in  ELISA  dilution  buffer.  After 
thorough  washing,  color  substrate  (Substrate  Reagent  Pack  containing 
Tetramethylbenzidine and H2O2) was added for 5 to 30 min. Reaction was stopped by 
an equal volume of 1 M H2SO4. Absorbance was measured on the Apollo-1 LB 911 
photometer  within  15  min,  measuring  at  450  nm  and  subtracting  background 
absorbance at 560 nm. Samples for the IL-6 ELISA had to be diluted 1:5 to be within 
the standard range (0 – 100 ng/ml), for IL-10 samples were within the standard range 
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4.2.11.3  Western blotting of secreted NGF 
For detection of NGF, primary human M were starved over night and then incubated 
for 20 min with ACM or with control medium C with equal amounts of FCS. After 
stimulation,  supernatants  were  harvested,  filtered  through  0.22 µm  pores  and 
concentrated  to  50  µl  using  Vivaspin  4  PES  membrane  falcons  with  an  molecular 
weight cut off of 10,000 Da. Concentrates were mixed with equal volume of 4 x SDS 
sample buffer and heated for 10 min at 95°C. Samples were then subjected to 15% 
SDS-polyacrylamide gels (see 4.2.10.2). Before blotting, gels were cut above the 40 kDa 
marker to remove albumin overload, which interfered with blotting and detection.  
4.2.12  Immunofluorescence (IF) staining 
Primary human M were trypsinized 7d after isolation, reseeded at a density of 1 x 10
5 
cells on a sterile cover slip in 6-well plates and cultured for additional 3 days. After 
over-night starvation, cells were stimulated, washed with PBS and fixed in 4% PFA for 2 
h at RT. Mouse anti-human-CD36 FITC (1:100) in PBS was added for 2 h, followed by 3 
washing  steps  with  IF  washing  buffer  and  incubation  for  30  min  with  IF 
permeabilization  buffer.  Cover  slips  were  blocked  for  1  h  with  IF  blocking  buffer, 
followed by over-night incubation with polyclonal rabbit anti-TrkA (763) ab, mouse 
anti-tubulin  or,  regarding  HEK293  cells,  mouse  anti-human  HA.11  ab  in  IF  binding 
buffer at 4°C. After 3 x washing, cells were incubated for 2.5 h with anti-mouse DyLight 
594 ab and anti-rabbit Alexa Fluor 488 ab in IF binding buffer. Finally, cover slips were 
washed 5 times and mounted on microscope slides using Vectashield H-1400 mounting 
medium.  For  image  acquisition,  AxioVert  200M  fluorescence  microscope  equipped 
with an ApoTome, a Plan Apochromat 63x/1.40 Oil lens and a charge-coupled device 
camera was used at RT together with AxioVision 4.7 software. 
4.2.13  Microbiology 
4.2.13.1  Transformation of bacteria by heat-shock 
Bacteria were transformed with plasmid DNA by heat-shock. 50 µl of bacteria glycerol 
stocks were thawn on ice, plasmid DNA was added and incubated for 30 min on ice. 
After a heat-shock for 30 s at 42°C, bacteria were incubated for 5 min on ice. For initial 
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at 250 rpm. 200 µl were inoculated on a LB agar plate containing 100 µg/ml ampicillin 
and incubated over night at 37°C to select positive, plasmid carrying bacteria clones.  
4.2.13.2  Bacterial culture and plasmid preparation 
For  preparation  of  plasmids  a  single  clone  was  picked  from  the  LB  agar  plate, 
transferred into 2 ml LB medium with 100 µg/ml ampicillin and cultured over night at 
37°C with shaking (250 rpm). The next day, the culture was transferred into 150 ml LB 
medium  containing  100 µg/ml  ampicillin  and  again  incubated  over  night  at  37°C. 
Isolation of plasmids was performed according to the manufacturer’s protocol using 
the NucleoBond Xtra Midi/Maxi Kit. DNA content was measured with the NanoDrop 
ND-1000.  
4.2.14  Data analysis of screening procedure 
4.2.14.1  Quality criteria  
Donor and experimental performance 
Control plates with controls evenly distributed over the plates were taken along during 
the  screen  at  the  start  and  end  of  a  batch.  Donor  performance  and  consistency 
throughout the assay procedure were controlled. No differences in cytokine secretion 
between  start  and  end  control  plates  were  observed,  although  processing  of  a 
complete batch needed up to  4 hours. In the rescreen cells of  one donor  did  not 
respond to ACM and cells were dismissed from analysis.  
 
Conformity between wells and plates 
Heat maps of MSD IL-10 signal intensity throughout the library plates were created, to 
visualize edge effects (performed by BioFocus/Galapagos). Edge effects were observed 
for plates of one batch. For this batch, hit calling was performed separately between 
inner and outer wells. Consequently, the two outer rows of wells were left empty 
during the rescreen to avoid edge effects. Consistency between duplicate plates was 
monitored  using  kappa  statistics  (206).  The  kappa  values  were  calculated  as:  2x 
[(duplicate hits x non hits) - (single hits plate 1 x single hits plates 2)] / [((single hits 
plate 2 + duplicate hits) x (single hits plate 2 + non hits)) + ((single hits plate 1 + 
duplicate hits) x (single hits plate 1 + non hits))]. A kappa value of 1 shows perfect 
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agreement than by chance. Duplicate plates had to pass a kappa value greater than 0.3 
(quality  standard  at  BioFocus/Galapagos).  During  the  screen,  two  duplicate  plates 
failed this quality criteria, they were dismissed and rescreened. 
4.2.14.2  Hit calling and statistical analysis 
For hit calling in the primary screen the IQR method was used, as signals showed a 
non-Gaussian  distribution.  The  top  5%  of  shRNAs  which  showed  reduction  (or 
induction for final target verification) of IL-10 signal intensity on both replicate plates 
were selected as hits. This percentage was reached on all plates at a cut off below 
< 1.6 IQR. In the rescreen, controls were included on the screening plates, and for hit 
calling the cut-off was based on negative controls, with a cut-off at  2 standard 
deviation from the mean of the negative controls. For screening of the three additional 
cytokines, shRNAs passed as hits at a cutoff  1.5 IQR for reduction and  1.5 IQR for 
induction  of  the  cytokine.  Target  sequences  and  gene  names  were  mapped  to 
Ensembl 61 (performed by J. K. Hériché, EMBL, Heidelberg). Target sequences, which 
did not exactly target one Ensembl 61 protein-coding gene, were dismissed from final 
analysis. 
4.2.15  Non-screening statistical analysis 
All experiments were performed at least three times using different donors unless 
stated otherwise. Data in bar graphs are presented as mean values  standard error of 
the mean (SEM). Statistical analysis was performed using one-way analysis of variance 
(ANOVA) followed by Bonferroni’s post test, or paired or unpaired two-tailed student’s 
t-test as specified in figure legends. Differences were considered significant at *
/#, p  
0.05; **
/##, p  0.01; ***
/###, p  0.001.  
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5  Results 
At  sites  of  inflammation  or  in  tumors,  M  encounter  dying  cells.  Cell-cell  contact 
beween M and dying cells or soluble factors of apoptotic cells induce a phenotype 
shift in M characterized by enhanced IL-10 secretion (130, 157). IL-10 might be a 
major immunosuppressant in tumors. Thus, by limiting anti-tumor immunity, it might 
present an obstacle for successful cancer therapy. Therefore, in-depth analysis of IL-10 
regulation is mandatory to understand its full importance and to evolve possible new 
cancer treatment strategies.  
Throughout  the  experimental  work,  I  used  two  distinct  M  maturation 
protocols. Initial experiments to establish an adenoviral shRNA screening procedure 
for novel regulators of IL-10 and the post-screen target validation experiments were 
performed using M differentiated from adhesion-selected human monocytes with 
AB
+ human serum. This set-up generates macrophage populations with a rather high 
functional and genetic variability, dependent on the donor cell as well as the donor 
serum. I deemed this set-up more suitable to identify meaningful targets that have a 
chance to affect cytokine production on a whole population scale. Nonetheless, for the 
shRNA screen I differentiated magnetic bead-selected CD14
+ monocytes to M using 
M-CSF to generate a more homogenous setting that allowed for higher reproducibility 
in the screening procedure. 
5.1  The nature of IL-10 induction by ACM-stimulated macrophages 
5.1.1  S1P as modulator of IL-10 production 
Supernatants of apoptotic MCF-7 breast cancer cells (ACM), as compared to viable cell 
supernatant (VCM), were sufficient to  induce IL-10 mRNA and protein secretion  in 
human (Figure 10) and murine (135) M. Importantly, ACM from other solid tumor 
cell lines, driven into apoptosis alternatively with etoposide instead of staurosporine, 
induced IL-10 expression to a comparable level as ACM from MCF-7 cells. For the work 
presented  here,  I  chose  MCF-7  breast  cancer  cells,  as  strong  M  infiltration  and 
correlation with poor prognosis has been extensively described for breast cancer (105).  RESULTS  52 
 
Figure 10:  Apoptotic cell supernatant induces IL-10 in primary human macrophages 
(A) M were incubated for 3 h with supernatants of viable (VCM) or apoptotic (ACM) MCF-7 
cells. IL-10 mRNA and ribosomal 18S RNA were quantified by qRT-PCR. The ratio of IL-10 mRNA 
versus ribosomal 18S RNA in untreated control cells C was set to 1, n = 4. (B) M were 
stimulated for 24 h as in (A) and secreted IL-10 protein was measured by CBA and C was set to 
1, n = 5 - 14. Statistics were performed using one-way ANOVA and Bonferroni’s post test. (C) 
M were incubated with ACM from etoposide-treated DU145 and A549 cells and secreted 
IL-10 was measured, n = 6. Statistics were performed using paired two-tailed student’s t-test. 
All data are means ± SEM; *, p  0.05; **, p 0.01; ***, p  0.001. 
Prior  work,  which  lead  to  my  studies,  identified  the  sphingolipid  S1P  to  be 
released  from  dying  tumor  cells  to  promote  M survival  (34).  Additionally,  it  was 
observed that S1P release from dying tumor cells established an alternative, TAM-like 
M  phenotype  with  pronounced  IL-10  and  IL-8  and  reduced  TNF-  and  IL-12 
production (130). Corroborating these observations, ACM from MCF-7 cells carrying a 
knockdown  of  sphingosine  kinase  2  (SK2)  (ACM-siSK2)  generated  less  S1P  after 
induction of cell death (207) and dampened IL-10 mRNA induction in M compared to 
ACM from control MCF-7 cells (Figure 11 A). The diminished potency of ACM-siSK2 
compared to ACM on IL-10 mRNA was reproducible on IL-10 protein level after 24 h 
ACM/ACM-siSK2 treatment, but to a lesser extend. In another approach, I compared 
ACM  to  VCM  supplemented  with  or  without  S1P  or  S1P  alone.  S1P  alone  or  in 
combination with VCM did not show synergistic effects on IL-10 mRNA or protein level 
(Figure 11 B and C). This implies that, besides S1P, other apoptotic cell-derived factors 
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Figure 11:  S1P is involved in IL-10 induction by ACM 
(A) M were treated for 3 h with ACM or ACM of MCF-7 cells with a knockdown for SK2 (ACM-
siSK2). IL-10 mRNA and ribosomal 18S RNA were quantified by qRT-PCR. The ratio of IL-10 
versus ribosomal 18S in ACM treated cells was set to 1, n = 8. (B) M were stimulated for 3 h 
with ACM, VCM with or without S1P or S1P alone. IL-10 mRNA and ribosomal 18S RNA were 
quantified by qRT-PCR. The ratio of IL-10 versus ribosomal 18S in ACM-treated cells was set to 
1, n = 7. (C) M were incubated for 24 h as described in (B) and secreted IL-10 was measured 
in the supernatant by CBA, n = 4 – 5. Statistics were performed using one-way ANOVA and 
Bonferroni’s post test. Data are means ± SEM. *, p  0.05; **, p  0.01; ***, p  0.001. 
5.1.2  Src, MAPK p38 and PI3K/AKT/mTOR are involved in IL-10 regulation 
Numerous signaling pathways are acknowledged to contribute to IL-10 production by 
immune cells (159). As S1P seemed to be only one of the required mediators released 
from apoptotic cells, I investigated common signaling pathways and their involvement 
in  ACM-induced  IL-10  production  in  primary  human  M.  Well-described 
pharmacological  inhibitors  of  major  signal  transducers  were  evaluated  for  their 
potency to repress ACM-dependent IL-10 mRNA induction. Expression of IL-10 often 
requires activation of STAT3 (162), a pathway activated downstream of S1P1 in M in 
the tumor context in vitro (133) and  in vivo (132). However, a non-selective janus 
kinase (JAK) inhibitor (JAK inhibitor I) as well as the STAT3 inhibitor STA-21 did not 
repress ACM-induced IL-10 mRNA (Figure 12 A). For the MAPK family, only the p38 
inhibitor  SB203580  significantly  attenuated  IL-10  mRNA  levels,  whereas  ERK1/2 
(UO126) and JNK (SP600125) inhibition did not alter IL-10 expression induced by ACM 
(Figure 12 B). Further experiments revealed that IL-10 production was also dependent 
on signaling through the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway. 
This was demonstrated by use of the PI3K inhibitor wortmannin as well as the mTOR 
inhibitor rapamycin, which markedly decreased ACM-triggered IL-10 induction (Figure RESULTS  54 
12  C).  Nonetheless,  the  most  striking  effect  was  observed  when  applying  PP2,  an 
inhibitor of src family tyrosine kinases (Figure 12 C). 
 
Figure 12:  IL-10 induction requires PI3K/AKT and p38 MAPK signaling 
(A-C) IL-10 mRNA and ribosomal 18S RNA were quantified by qRT-PCR after 3 h of incubation 
with ACM and inhibitors JAK-Inhibitor 1 (1 µM), STA-21 (10 µM), UO126 (10 µM), SB203580 (5 
µM), SP600125 (10 µM), PP2 (10 µM), Wortmannin (100 nM), Rapamycin (50 nM). The ratio of 
IL-10 mRNA versus ribosomal 18S RNA in ACM-treated cells was set to 1, n  3. All data are 
means ± SEM. *, p  0.05; **, p  0.01; **, p  0.001. Statistics were performed using one-way 
ANOVA and Bonferroni’s post test. 
Next,  I  was  interested  if  the  missing  factor  might  be  a  protein.  I  therefore 
degraded proteins in the apoptotic cell supernatant (Deprot-ACM) by incubation of 
ACM with proteinase K for 1 h at 37°C followed by 1 h at 100°C. IL-10 levels only 
reached  50%  when  cells  were  stimulated  with  Deprot-ACM  compared  to  ACM. 
Interestingly, the MAPK p38 inhibitor SB203580 together with ACM showed the same 
effect  as  Deprot-ACM  alone,  whereas  there  was  no  further  significant  attenuation 
when  using  Deprot-ACM  with  SB203580  (Figure  13).  This  strengthened  the 
assumption, that an ACM-derived protein factor was required for signaling through 
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Figure 13:  Deproteinated ACM shows reduced activity compared to ACM 
M  were  incubated  for  3  h  with ACM  or  deproteinated  ACM,  with  or  without  SB203580 
(5 µM). IL-10 mRNA and ribosomal 18S RNA were quantified by qRT-PCR. The ratio of IL-10 
versus 18S RNA in ACM-treated cells was set to 1, n = 4. Statistics were performed using one-
way ANOVA and Bonferroni’s post test. Data are means ± SEM. *, p  0.05; **, p  0.01; ***, p 
 0.001. 
5.2  Adenoviral shRNA high-throughput screen 
5.2.1  Establishing a high-throughput shRNA screen in primary human M 
In  order  to  distinguish  and  investigate  the  contribution  of  other  factors  in  the 
polarization of M, I collaborated with the company BioFocus/Galapagos in Leiden, 
The  Netherlands.  The  collaboration  was  supported  by  the  European  Commission 
within  the  Proligen  project.  The  company  has  in  depth  expertise  in  high-content 
screening.  One  division  is  specialized  in  adenoviral  copy  (c)DNA  and  short-hairpin 
(sh)RNA libraries focusing on the druggable human genome (208). For identification of 
novel  factors  involved  in  M  polarization  through  ACM,  I  performed  a  shRNA 
adenoviral  high-throughput  screen  (HTS).  The  employed  recombinant  adenoviral 
library is based on the adenovirus serotype 5 genome (Ad5C01Att01/A150100), from 
which  the  E1  and  E2A  regions  have  been  deleted,  to  render  them  replication-
incompetent in hosts (204). By using adenoviruses, gene knockdown in difficult-to-
transfect cells such as M can be efficiently achieved. Thus, adenoviral transduction 
enabled me to knockdown individual genes of interest and exploit their function in M 
biology. I performed an adenoviral shRNA screen using a selected library of druggable 
targets including GPCRs, RTKs, secreted factors, ion channels, transporters, kinases and 
others.  
First, I established the experimental set-up for screening in a 96-well format. The 
optimized protocol is indicated in Figure 14.  RESULTS  56 
 
Figure 14:  Time sequence of experimental steps during the screening procedure 
CD14
+  cells  were  isolated  from  buffy  coats  at  day  0  and  differentiated  to  M  in  M-CSF 
containing growth medium. 24 h transduction with shRNA viruses took place at day 4. At day 
10 M were stimulated with ACM for 24 h before supernatants were harvested and analyzed 
for secreted cytokines.  
I  determined  optimal  virus  concentrations  (infectious  units  (IU)/M)  and 
evaluated the respective robustness of the assay (Figure 15). CD14-expressing PBMC 
were isolated, 4.5 x 10
5 cells were seeded in individual wells of 96-well plates and 
differentiated to M with 100 ng/ml M-CSF. At day 4 after isolation, cells were first 
transduced with virus containing a luciferase insert (luc_v13) as a negative control or 
containing shRNA against IL-10 (shIL10_v2) as the positive control at different IU per 
M for 24 h (Figure 15 A). Following medium exchange, cells were maintained for 
another six days to reach optimal knockdown efficiency (208). Thereafter, M were 
stimulated with ACM for 24 h, followed by collection of supernatants, which were 
stored at -80°C. IL-10 protein in the supernatant of M was determined using CBA flex 
sets.  
At an IU of 200 the luciferase construct showed non-specific reduction of IL-10, 
indicating  unspecific  virus  effects.  However,  transduction  with  virus  containing 
shIL10_v2  at  an  IU  of  100  significantly  and  robustly  reduced  IL-10  levels  to  20%. 
Importantly,  the  luciferase  construct  was  inert  regarding  ACM-induced  IL-10 
production at this IU (Figure 15 A), providing a suitable window between the negative 
and positive control at an IU of 100. RESULTS  57 
 
Figure 15:  Implementation of screen controls 
(A) Virus titration for optimal infectious units (IU) amount. M were treated as shown in 
Figure 14 on a 96-well plate format, n = 2 – 4. (B) Further control viruses were assessed at an 
optimized IU of 100. Negative control: luc_v13, positive controls: shIL10_v5, shMAPK14_v17 
and _v20, n = 3. IL-10 protein was measured by CBA. All data are means ± SEM. P-values were 
calculated using two-tailed student’s t-test. *, p  0.05; **, p  0.01; ***, p  0.001. 
As observed in previous experiments, MAPK p38 seems to be involved in ACM-
depended IL-10 production and to function downstream of an unknown protein factor 
within the ACM (Figure 12 and Figure 13). Having this in mind, I included two virus 
constructs targeting MAPK14/p38 as second positive controls. Both constructs reduced 
IL-10 secretion to a level comparable to the unstimulated control. In addition, a shRNA 
targeting a different sequence (version v_5) within the IL-10 mRNA was used to ensure 
specificity (Figure 15 B).  
Since I observed high reproducibility in the 96-well format, I transfered the assay 
to BioFocus. Employing robotic systems, I down-scaled the assay to a 384-well format 
(10
4 cells per well), thereby drastically reducing the screening time, the number of 
donors needed for the primary screen and thereby limiting inter-donor variations. To 
substantiate the robust screening procedure in a 384-well format, additional negative 
control luciferase constructs and an empty vector were tested together with positive 
controls  in  three  different  IUs  (75,  85,  100).  A  satisfying  and  highly  reproducible 
window  between  positive  and  negative  controls  was  achieved  with  all  virus 
concentrations (Figure 16 A). To exclude a non-specific effect of transduction on IL-10 
secretion by M at an IU of 85, I transduced cells without ACM-stimulation. Although I 
observed significantly reduced IL-10 secretion from unstimulated M when using virus 
expressing IL-10 shRNA, as could be expected, no drastic alterations with the control 
constructs or virus containing shRNA against MAPK14/p38 were observed (Figure 16 RESULTS  58 
B). Thus, I decided to perform the primary screen in a 384-well format and an IU of 85 
for the controls.  
 
Figure 16:  Control virus titration on a HT platform and basal effect on unstimulated M 
(A) Experimental procedure was followed as in Figure 14. Additional negative (luc_v13, _v20, 
_v21, empty) and positive controls were tested at different IUs on a 384-well plate. (B) The 
effect of control viruses on unstimulated M was tested at an IU of 85. For both experiments, 
IL-10 protein was measured by MSD. Data from one donor are shown as representative result, 
with 4 – 12 individually obtained data points. Data are means ± SEM. P-values were calculated 
using two-tailed student’s t-test. *, p  0.05; **, p  0.01; ***, p  0.001. 
The last question, which had to be answered before proceeding to the screen, 
was the optimal transduction volume for the library. The average IU of the library was 
7 x 10
7/ml. Calculating with the optimal IU of 85 for the controls, 12.14 µl would have 
been the corresponding transduction volume for the library. Considering that virus 
repropagation was performed in different formats for the library (96-well plate) and 
controls  (flasks)  with  possible  effects  on  the  properties  of  the  virus  suspensions,  I 
tested three different transduction volumes on M to obtain the optimal volume to 
be used for the screen. Consequently, one random library plate, reformatted to 384-
well, was chosen. From this, M cultures were transduced, as duplicate plates, with 4, 
8 or 16 µl virus lysate. The experimental procedure was performed as shown in Figure 
14. IL-10 protein in the supernatant was assessed by MSD and extinction signals of the 
replicates  were  plotted  against  each  other  to  visualize  signal  distribution  between 
duplicate plates. No drastic differences were observed between the three transduction 
volumes (Figure 17 A). Hit calling was performed (please refer to 4.2.14.2) in order to 
identify the amount of overlapping hits between the volumes. At the chosen cut-off, to 
obtain  approximately  5%  hits  per  plate  (  20  hits),  the  three  volumes  showed  11 RESULTS  59 
common hits (white bars) and 9 (8 µl, black) to 12 (16 µl, red) hits, which were only 
found in one or two of the volumes (Figure 17 B).  
 
Figure 17:  Determination of optimal library transduction volume 
One virus library plate served as virus reservoir for transducing M in a 384-well format with 
three different transduction volumes (4, 8. 16 µl), in duplicate plates. The procedure depicted 
in Figure 14 was followed. IL-10 was measured by MSD in the supernatant. (A) Obtained IL-10 
signal intensities of both replicate plates for each transduction volume are plotted. (B) Number 
of shRNA constructs which passed hit calling. White bars: hits correspond between different 
volumes, shaded: Hits found in one or two of the three transduction volumes. 
  Thus, four-fold changes in virus concentration did not drastically influence the 
hits identified, confirming the stability of the experimental system. To be assured not 
to lose hits, due to low virus load, or to deal with too many unspecific targets, due to 
toxicity of high virus concentrations, I chose 8 µl as transduction volume of the library. 
5.2.2  Screen yields 96 genes involved in IL-10 secretion 
Having established controls and optimal virus load for transduction, the screen was 
performed.  8495  adenoviral  shRNA  constructs  targeting  2825  genes  (usually  3 
different  shRNA  sequences/versions  (v_)  targeting  one  gene)  were  screened  on 
duplicate plates, transduced from the same virus source plate (Figure 18). The screen 
was divided into 3 batches and M from 4 donors were used. Throughout the screen, 
the percentage of IL-10 inhibition between shIL-10 and negative controls was above 
65%, and above 30% for shMAPK14 and negative controls. In the primary screen, 459 
out  of  the  screened  8495  shRNA  constructs,  targeting  434  protein-coding  genes, 
diminished  ACM-induced  IL-10  release  based  on  the  chosen  hit  calling  and  quality 
criteria (refer to 4.2.14.1 and 4.2.14.2). To substantiate the results, shRNA sequences, 
which did not unambiguously target a unique protein-coding gene in Ensembl 61, were 
excluded from further analysis (Ensemble 61 analysis was performed by J.K. Hériché, RESULTS  60 
EMBL, Heidelberg). In a next step, I used the 459 shRNA virus constructs for a rescreen 
to  validate  their  ability  to  inhibit  ACM-induced  IL-10  production  in  M  from  two 
additional donors. Therefore, the viruses were cherry-picked and formatted on 12 96-
well  plates  for  repropagation,  which  resulted  in  three  384-well  plates  for  M-
transduction. The two outer rows of the 384-well plates were left empty to avoid edge 
effects and controls were distributed over the plates. Following the formatting, the 
optimal  transduction  volume  (12  µl)  was  determined  as  described  for  the  primary 
screen. In the rescreen a shRNA construct was considered to reduce IL-10 secretion, 
when in 2 donors, screened in duplicates (total of 4 data points), 3 data points were 
below the assigned cut-off. For details on the hit calling procedure, see 4.2.14.2. 131 
shRNA  constructs  emerged  from  the  rescreen  and  were  validated  by  sequencing. 
Additionally,  13  targets  were  dismissed,  as  differential  shRNAs  targeting  the  same 
genes showed IL-10 induction in the primary screen. This resulted in the identification 
of 98 unique targeting sequences that reduced IL-10 release in the used system These 
98 sequences corresponded to 96 biological targets, which were required for IL-10 
secretion from M stimulated with dying tumor cells (Figure 18).  RESULTS  61 
 
Figure 18:  Screening workflow and outcome 
In the primary screen, 8495 adenoviral shRNA constructs targeting 2825 individual genes were 
screened for reduction of ACM-induced IL-10 in primary human M as depicted in Figure 14. 
The strongest 5% were considered hits and were taken into the rescreen. Constructs were 
repropagated and screened in M from two additional donors. Hit calling resulted in 131 
shRNAs  which  reduced  IL-10  secretion.  These  were  sequenced  and  compared  to  shRNAs 
inducing IL-10 in the primary screen to ensure specificity. 98 unique targeting sequences were 
found, leading to 96 genes important for IL-10 production. Additionally, three other cytokines 
(IL-6,  IL-8  and  IL-12p70)  were  measured  in  the  supernatant  of  the  rescreened  samples, 
resulting in 45 hits showing coregulation of IL-10 reduction and expression of one or more of 
the other cytokines. 22 of these shRNAs reduced IL-6 and IL-10. 
5.2.3  IL-6 and IL-10 are highly co-regulated in ACM-stimulated macrophages 
Tumor-associated  macrophages  (TAM)  produce  a  variety  of  tumor-promoting 
cytokines and chemokines, e.g. IL-10, IL-6 or IL-8, but lack the production of factors 
potentially  inducing  protective  immunity  such  as  IL-12.  This  cytokine  signature 
maintains a tumor-promoting milieu, finally supporting tumor outgrowth (97). Thus, 
identification of a common target globally changing this functional pattern would be 
desirable. I was therefore interested in clarifying whether the identified targets for IL-
10  affected  the  cytokines  mentioned  above.  Selection  of  the  three  cytokines  was 
based on previous findings showing that IL-10, IL-6 and IL-8 were strongly induced in RESULTS  62 
M interacting with apoptotic cancer cells, whereas IL-12 was repressed ((130), Figure 
19). 
 
Figure 19:  IL-6 and IL-8 induction by ACM 
(A) M were treated for 3 h with or without ACM or VCM. IL-6 mRNA and ribosomal 18S RNA 
were quantified by qRT-PCR. The ratio of IL-6 versus ribosomal 18S in ACM-treated cells was 
set to 1, n = 10. (B, C) ACM, VCM or control medium were incubated on M and IL-6 (B) and 
IL-8 (C) protein was measured in supernatant or in ACM alone after 24 h by CBA, n = 4 - 5. All 
data are means ± SEM and Statistics were performed using one-way ANOVA and Bonferroni’s 
post test. ***, p  0.001. 
  Thus, I determined IL-6, IL-8 and IL-12 contents in the M supernatants from the 
rescreen, i.e. of M transduced with viruses containing shRNAs that emerged from the 
primary screen. Within the screening procedure, mean concentrations of cytokines 
secreted by ACM-stimulated M were 150 pg/ml for IL-10, 10 ng/ml for IL-6, 11 ng/ml 
for IL-8 and 130 pg/ml for IL-12p70. When I evaluated the expression pattern of IL-6, 
IL-8 and IL-12 from the supernatants obtained in the rescreen and compared them to 
regulation of IL-10, I unfortunately was unable to identify a single gene affecting the 
production of all four cytokines (Figure 20). A major functional pattern of TAM, and 
regulatory M in general, is high IL-10 expression but repressed release of IL-12 (95). 
Only  few  of  the  targets  efficiently  reduced  IL-10  secretion  while  simultaneously 
elevating  IL-12  levels.  A  reason  for  this  might  be  the  absence  of  a  classical  pro-
inflammatory stimulus in ACM that would be required to trigger IL-12 production, such 
as IFN-(130). However, a prominent co-regulation pattern of IL-10 and IL-6 secretion 
from ACM-stimulated human M emerged (Figure 20).  RESULTS  63 
 
Figure 20:  Heat map of final hits of HTS 
Cytokine  regulation  by  unique  target  shRNAs,  which  passed  hit  calling  criteria  for  IL10 
reduction  in  the  primary  screen and  the  rescreen. Additional  regulation  of  IL6,  IL8  and 
IL12p70  in  supernatants  is  depicted.  Red:  cytokine  reduction,  green:  cytokine  induction. 
Boxed shRNAs were verified in subsequent experiments. NTRK1_v2 was validated in detail for 
IL-10 induction. The heat map was created by J.K. Hériché, EMBL, Heidelberg using clusters 
obtained with the DBScan algorithm rearranged manually to visualize regulation patterns. 
5.2.4  Validation of selected targets co-regulating IL-10 and IL-6 
For validation of the screening results, I focused on the pronounced cluster of genes, 
whose knockdown diminished IL-10 and IL-6 production after ACM-stimulation. This 
regulation pattern was rather surprising, as a co-regulation of IL-10 and IL-6 is not 
described in literature. However, both IL-6 and IL-10 are capable of activating STAT3 in 
cancer cells and in M in an autocrine manner, which is highly linked to tumorigenesis 
(131).  Interrupting  this  vicious  cycle  in  tumor-associated  inflammation  might  be 
beneficial for cancer therapy.  RESULTS  64 
  Confirmation of the screening results was performed by using a pool of target-
specific  siRNA  (ON-TARGETplus  SMARTpool)  and/or  common  pharmacological 
inhibitors.  Furthermore,  I  validated  the  screening  results  not  only  by  applying 
alternative techniques interfering with the targets, but also by using an alternative M 
generation  protocol.  Mwere  selected  by  adherence  and  differentiated  with  AB
+ 
human  serum  from  different  donors,  as  it  was  performed  for  all  screen-preceding 
experiments and subsequent validation assays. I selected 5 targets, which allowed a 
rational link to IL-10 or IL-6 generation. I chose IL-4 receptor alpha (IL-4RA, IL-4R), 
cannabinoid receptor 2 (CNR2, CB2), 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-
CoA)  reductase  (HMGCR),  bruton’s  tyrosine  kinase  (BTK)  and  thrombospondin  3 
(THBS3, TSP3). For CBR2 and BTK I applied pharmacological antagonists/inhibitors and 
for IL-4RA, HMGCR and THBS3 I used a knockdown strategy for evaluation. Primary 
human  M  were  transfected  with  target-specific  or  non-targeting  siRNA  using 
Hiperfect for 24 h, followed by stimulation with ACM for 24 h. Knockdown efficacy was 
evaluated  by  qRT-PCR  in  transfected,  non-stimulated  cells,  after  harvesting  M 
supernatants. In average, IL4-RA knockdown reached 80%, HMGCR knockdown 69% 
and THBS3 73% compared to non-targeting siRNA.  
  By binding to the IL-4 receptor, IL-4 and IL-13 are well established modulators of 
M biology. IL-4 was the first stimulus described for alternative macrophage activation 
(74)  and  accounts  for  a  wound-healing  M  phenotype  with  pronounced  IL-10 
expression (95). As observed in the screen, the knockdown of IL4-RA compared to non-
targeting  siRNA  significantly  reduced  IL-10  and  IL-6  secretion  after  24  h  of  ACM-
stimulation  (Figure  21  A,  B).  Regarding  the  cannabinoid  system,  CNR2  is  primarily 
expressed by immune cells and anti-inflammatory properties have been assigned to 
this  receptor  before.  In  addition,  under  inflammatory  conditions  endocannabinoid 
synthesis  in  M  has  been  observed  (209-212).  Indeed,  I  was  able  to  confirm  the 
screening results. CNR2 antagonist/reverse agonist AM630 (213) reduced IL-10 and IL-
6 secretion at concentrations of 10 µM in ACM-stimulated M (Figure 21 C, D).  RESULTS  65 
 
Figure 21:  Hit validation: IL-4RA and CNR2 regulate IL-10 and IL-6 expression 
(A, B) M were transfected with a target specific pool of siRNAs against human IL-4RA or non-
targeting siCtrl for 24 h. After medium exchange, cells were stimulated for additional 24 h with 
or  without  ACM  and  IL-10  and  IL-6  protein  in  the  supernatant  were  measured  by  ELISA. 
Transfected (siIL4RA and siCtrl) unstimulated extinction signals were set to 1, n = 11 – 12. (C, 
D) M were left untreated or preincubated for 45 min with AM630 (at given concentrations in 
µM) and stimulated with ACM with or without AM630 for 24 h. IL-10 and IL-6 protein in the 
supernatant were measured by ELISA and extinction signals of ACM-treated cells were set to 1, 
n = 7 – 13. All data are means ± SEM. P-values were calculated using two-tailed student’s t-
test. *, p  0.05; **, p  0.01; ***, p  0.001. 
  The third candidate chosen for validation was HMGCR. The reductase is the key 
enzyme in the mevalonate pathway generating isoprene moieties, which are required 
for synthesis of steroids, cholesterol, ubiquinones, and prenylation of GTPase proteins, 
important for cell function and survival (214). Drugs of the statin family inhibit HMGCR. 
They are widely used in the therapy of hypercholesterolemia and anti-inflammatory 
effects are reported (215). I did not observe this anti-inflammatory effect of statins 
with regard to IL-10, as knockdown of HMGCR during the screen, through siRNA or by 
pharmacological intervention (Cerivastatin and Atorvastatin) diminished IL-10 release 
in ACM-stimulated M (Figure 22 A, C). Unfortunately, the reduction of IL-6 in the 
screen was not reproducible by knockdown or statins (Figure 22 B, D).  RESULTS  66 
 
Figure 22:  Validation of HMGCR on IL-10 and IL-6 production 
(A, B) M were transfected with a target specific pool of siRNAs against human HMGCR or 
non-targeting siCtrl for 24 h. After medium exchange, cells were stimulated for additional 24 h 
with or without ACM and cytokines were measured by ELISA, n = 3. Transfected (siHMGCR or 
siCtrl)  unstimulated  extinction  signals  were  set  to  1.  (C,  D)  M  were  left  untreated  or 
preincubated  for  45  min  with  Cerviastatin  or  Atorvastatin  (at  given  concentrations)  and 
stimulated with ACM with or without statins for 24 h, n = 4 - 11. Cytokines were measured by 
ELISA and extinction signals of ACM-treated cells were set to 1. All data are means ± SEM. 
Statistical analysis was performed using two-tailed student’s t-test. *, p  0.05; **, p  0.01; 
***, p  0.001. 
  Targeting BTK with the pharmacological inhibitor LFM-A13 drastically reduced IL-
6 but had no effect on IL-10 (Figure 23 A, B). I had chosen this candidate, as several 
reports link the kinase to M function, e.g. HO-1 induction and cytokine production 
(216, 217). The only chosen candidate that failed validation completely was THBS3, a 
largely uncharacterized family member of thrombospondins which have been linked to 
tumor angiogenesis and prognosis (218). Knockdown of THBS3 significantly affected 
neither IL-10 nor IL-6 (Figure 23 C, D). Although I was not able to reproduce all effects 
observed  in  the  screen,  the  level  of  reproducibility  was  encouraging  for  further 
detailed analysis, especially, as I used differentially generated M for the validation RESULTS  67 
experiments,  which  can  have  an  impact  on  the  cell’s  transcriptome  and  thus  on 
functionality of the highly versatile human M (219).  
 
Figure 23:  Validation of BTK and THBS3 
(A,  B)  M  were  left  untreated  or  preincubated  for  45  min  with  LFM-A13  (at  given 
concentrations) and stimulated with ACM with or without LFM-A13 or EtOH as solvent control 
for 24 h. IL-10 and IL-6 protein in the supernatant were measured by ELISA. Extinction signals 
of ACM-treated cells were set to 1, n = 3. (C, D) M were transfected with a target specific 
pool of siRNAs against human THBS3 or non-targeting siCtrl for 24 h. After medium exchange, 
cells were stimulated for additional 24 h with or without ACM and IL-10 and IL-6 protein in the 
supernatant  were  measured  by  ELISA,  n = 6.  Transfected  (siTHBS3  or  siCtrl)  unstimulated 
extinction signals were set to 1. All data are means ± SEM. P-values were calculated using two-
tailed student’s t-test. *, p  0.05; **, p  0.01; ***, p  0.001. 
  The  above  mentioned  studies  brought  forward  a  robust  screening  assay  for 
primary human M, which are highly resistant to transfection and identified putative 
targets  for  intervention  with  tumor-induced  macrophage  polarization.  One  target 
particularly  caught  my  attention,  the  nerve  growth  factor  receptor  TRKA,  which  is 
crucial  in  neuronal  development and which  has been linked to tumor growth  in a 
murine breast cancer model (220). 
5.3  Detailed validation of TRKA signaling in regard to IL-10 production 
Of the targets that reduced IL-10 and IL-6 protein secretion, unexpectedly knockdown 
of TRKA stood out both regarding the magnitude and reproducibility of IL-10 reduction 
(60% compared to negative controls) (Figure 24 A). Reports of TRKA being related to 
breast cancer progression (220, 221), its described interaction with S1P receptors (222, 
223) and studies showing TRKA involvement in inflammatory responses of monocytes/ 
M (136, 224) strengthened my interest to validate this specific candidate.  
  To verify the involvement of TRKA in IL-10 regulation by AC, I first asked whether 
TRKA was activated by ACM. Therefore, I stimulated primary human M with ACM for RESULTS  68 
30  min  and  immunoprecipitated  TRKA,  followed  by  staining  for  the  specific 
autophosphorylation-site  (Y490)  of  the  receptor.  Immature  (80  and  110  kDa)  and 
mature forms (140 kDa) of TRKA monomers as well as dimers (225, 226) were detected 
using the pan-TRKA antibody (ab) in the loading controls. Importantly, following IP a 
specific band for TRKA autophosphorylation was observed in ACM-treated M at a 
molecular weight corresponding to TRKA dimers, whereas it was completely absent in 
unstimulated cells (Figure 24 B).  
 
Figure 24:  ACM induces TRKA-dependent IL-10 secretion in primary human M 
(A)  Raw  data  from  the  HTS  and  rescreen.  IL-10  signal  intensity  of  ACM  with  or  without 
adenoviral empty control vector, shIL10 and shTRKA are depicted. 4 donors were screened. 
Data are means ± SEM. ***, p  0.001. Statistics were performed using one-way ANOVA and 
Bonferroni’s  post  test.  (B)  Human  M  were  stimulated  for  30  min  with  ACM.  TRKA  was 
immunoprecipitated from cell lysates, subjected to 6% SDS-PAGE and stained for phospho-
TRKA (Y490). Additionally, TRKA was stained in the input controls, n = 3.  
  Next, I confirmed the involvement of TRKA in IL-10 up-regulation through ACM 
by using two TRKA inhibitors. K252a, a TRK family inhibitor (227), markedly decreased 
IL-10 mRNA after 3 h and protein up-regulation induced by ACM after 24 h. This was 
also  achieved  when  using  GW441756,  a  putatively  selective  TRKA  activity  inhibitor 
(228), although to a lesser degree (Figure 25 A, B).  RESULTS  69 
 
Figure 25:  Pharmacological TRKA inhibition verifies screening result 
(A) IL-10 mRNA and ribosomal 18S RNA were quantified by qRT-PCR after 3 h of incubation 
with ACM and the inhibitors K252a, GW441756 (concentrations in µM). The ratio of IL-10 
mRNA versus ribosomal 18S RNA in ACM-treated cells was set to 1, n  6. (B) ACM with or 
without inhibitors K252a (250 nM), GW441756 (1 µM) was added to M and IL-10 protein was 
measured in supernatant after 24 h by CBA. Inhibitors were pre-incubated for 45 min before 
ACM treatment, n  5. All data are means ± SEM. Statistical analysis was performed using one-
way ANOVA and Bonferroni’s post test. *, p  0.05; **, p  0.01; ***, p  0.001.  
5.3.1  IL-10 production downstream of TRKA requires PI3K and p38 MAPK 
In order to investigate the contribution of TRKA in signaling pathways involved in IL-10 
induction (Figure 12), I closely monitored p38 and AKT phosphorylation. Supportive 
argumentation for these two pathways downstream of TRKA is well established and 
was  summarized  in  a  review  by  Arevalo  and  Wu  (183).  First,  I  assessed  the  time 
kinetics of p38 and AKT phosphorylation in ACM-stimulated M by Western blotting. 
AKT phosphorylation was rapidly induced by ACM and remained stable over 1 h (Figure 
26 A). P38 MAPK phosphorylation was also rapidly initiated, but increased over time 
(Figure 26 C). At 30 min of ACM stimulation, ACM-induced p38 phosphorylation was 
reduced to about 50% using the TRK inhibitor K252a, but was unaffected by either src 
tyrosine kinase or PI3K inhibitors (Figure 26 D). In contrast, phosphorylation of AKT 
was completely abolished with the src inhibitor PP2 as well as with K252a. The PI3K 
inhibitor Wortmannin served as positive control (Figure 26 B).  RESULTS  70 
 
Figure 26:  ACM-induced AKT and p38 phosphorylation depends on TRKA 
(A, C) Mwere incubated for indicated times with ACM and Western analysis was performed. 
Graphs  show  quantification  of  ACM-mediated  phospho-AKT  and  phospho-p38  protein 
expression, with unstimulated control set to 1, n  11. (B, D) Cells were stimulated for 30 min 
with  ACM  and  inhibitors  PP2  (10  µM),  K252a  (250  nM),  Wortmannin  (100  nM).  For 
quantification ACM stimulation was set to 1, n  4. Inhibitors were pre-incubated for 45 min 
before ACM treatment. All data are means ± SEM. Statistics were performed using one-way 
ANOVA and Bonferroni’s post test.*, p  0.05; **, p  0.01; ***, p  0.001.  
  In summary, p38 phosphorylation was only dependent on TRKA, whereas AKT 
activation  needed  functional  TRKA  and  src.  This  behaviour  and  the  distinct  time 
kinetics argue for differential regulation of the two pathways, with PI3K/AKT being of 
major importance. 
5.3.2  Constitutive NGF secretion takes part in IL-10 induction 
In the following experiments I reached out to understand the molecular basis of TRKA 
activation. Activation of TRKA is reported to depend either on the availability of its 
ligand  NGF  and/or  transactivation  e.g.  by  other  receptor  tyrosine  kinases  without 
requiring NGF, but may also be regulated by the availability of the receptor itself (183). RESULTS  71 
In a first approach, I scavenged NGF in ACM and in supernatants of M. Using a 
neutralizing antibody significantly, but not completely, inhibited ACM-induced IL-10 
protein secretion after 24 h compared to isotype control (Figure 27). Thus, I searched 
for the source of NGF.  
 
Figure 27:  Neutralization of NGF reduces IL-10 secretion 
Mwere incubated  for  24  h  with  ACM  and  neutralizing  anti-NGF  ab (aNGF)  (5  µg/ml)  or 
control IgG1 (5 µg/ml). ACM was pre-incubated with antibodies for 45 min at 37°C prior to 
addition to the cells. IL-10 protein was measured in supernatant by CBA and ACM treatment 
was set to 1, n = 8. Data are means ± SEM. *, p  0.05; **, p  0.01; ***, p  0.001. One-way 
ANOVA followed by Bonferroni’s post test was used for statistical validation. 
  Existing literature points to cancer cells, as well as monocytes/M, as potential 
sources of NGF. Especially for breast cancer, strong NGF release has been described 
(188, 189) and the same holds true for M (194, 229). To investigate whether dying 
MCF-7 or M were the source of NGF, I performed qRT-PCR for NGF mRNA induction 
and  Western  blotting  for  intracellular  protein  expression  in  the  course  of  ACM 
generation (Figure 28 A and B) or in stimulated M (Figure 28 C and D). Changes in 
NGF  mRNA  or  protein  levels  were  observed  neither  in  MCF-7  cells  nor  in  M. 
Interestingly, Western analysis of cell lysates for NGF revealed different maturation 
states of NGF. MCF-7 lysates showed a pronounced band at the size of the immature 
pro-NGF form, whereas M revealed a band at the size of matured monomeric NGF 
(Figure 28 B and D).  RESULTS  72 
 
Figure 28:  NGF is not induced in MCF-7 nor in M 
(A,  B)  MCF-7  cells  were  treated  as  for  preparation  of  ACM  with  or  without  induction  of 
apoptosis by staurosporine (Sts). Cells were harvested after different incubation periods with 
growth medium after Sts treatment. (A) NGF mRNA and ribosomal 18S RNA were quantified by 
qRT-PCR. The ratio of NGF versus ribosomal 18S in non-sts treated cells was set to 1, n = 5. 
(B) Western blotting of MCF-7 cell lysates was performed, n = 1. (C) M were stimulated for 3 
h with our without ACM. NGF mRNA and ribosomal 18S RNA were quantified by qRT-PCR. The 
ratio of NGF versus ribosomal 18S in unstimulated cells was set to 1, n = 2. (D) M were 
incubated with ACM or without C for 20 min after medium exchange or no medium exchange 
took place after 16 h-starvation (16h starve). Whole cell lysate expression of NGF and p38 was 
followed by Western blotting. Authentic NGF served as control. For quantification the ratio of 
NGF to p38 was calculated with C set to 1, n = 4. Data are means ± SEM. 
  It  remained  elusive,  which  cell  type  produced  NGF  as  no  induction  through 
stimulation  was  observed.  To  clarify  this,  I  analyzed  NGF  content  in  ACM,  in 
supernatants of M treated with or without ACM for 20 min, as well as in normal 
growth medium. The monomeric form as well as the active dimer of NGF was present 
in ACM in low quantities, but to a similar extent as in growth medium containing the 
same amount of FCS. However, human M constitutively secreted high levels of NGF 
as  indicated  by  the  presence  of  the  active  dimer  already  20  min  after  medium 
exchange and its prominent accumulation over time in the supernatant of 16 h-starved 
M. Surprisingly NGF release was not affected by the addition of ACM (Figure 29). 
Thus, although ACM-induced IL-10 release was clearly dependent on the presence of 
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Figure 29:  Macrophages constitutively secrete high levels of NGF 
NGF was detected in control medium C and ACM alone or after 20 min incubation on starved 
M. Additionally, supernatant of 16 h-starved M and authentic NGF (100 ng/ml) in control 
medium were measured by Western blotting. Graphs show quantification of monomeric and 
dimeric NGF, n = 4. Data are means ± SEM. ***, p  0.001. Statistics were performed using 
one-way ANOVA and Bonferroni’s post test. 
  As  the  availability  of  NGF  was  not  the  rate-limiting  step  in  TRKA  activation, 
transactivation of TRKA or the availability of TRKA at the plasma membrane had to be 
considered  as  potential  modes  of  actions.  Transactivation  of  TRKA  is  frequently 
observed and was reported downstream of adrenergic receptor 2A (186), adenosine 
receptors (230), epidermal growth factor receptor (EGFR), formyle peptide receptor 
(231) and other receptors. Based on the finding that neutralization of NGF did not 
completely prevent ACM-induced IL-10 secretion, I suspected transactivation of TRKA 
to be  involved. However, pharmacological  inhibition of potential  receptors did not 
significantly  interfere  with  ACM-mediated  IL-10  production  (Figure  30),  although  a 
tendency was observed for the EGFR inhibitor AG1478.  RESULTS  74 
 
Figure 30:  Common transactivation partners of TRKA are not involved in IL-10 production 
(A – C) M were pre-incubated with inhibitors for 45 min followed by stimulation for 3 h with 
ACM with or without EGFR inhibitor AG1478 (1 µM), -adrenoceptor antagonist yohimbine (Y, 
10  µM),  -adrenoceptor  antagonist  propranolol  (P,  1  µM),  or  A2A  adenosine  receptor 
antagonist CSC (10 µM). IL-10 mRNA and 18S RNA were quantified by qRT-PCR. The ratio of IL-
10 versus 18S RNA in ACM-treated cells was set to 1 and statistics were performed using 
student’s t-test, n  3. All data are means ± SEM. *, p  0.05; **, p  0.01; ***, p  0.001. 
  Finally, I hypothesized that TRKA-dependent increase of IL-10 by ACM might be 
due  to  the  regulation  of  TRKA  availability  in  human  M.  This  hypothesis  was 
strengthened by the observation that neither NGF nor any other TRK family member 
induced  IL-10  mRNA  in  M  (Figure  31  A).  Furthermore,  NGF  did  not  induce 
phosphorylation of p38 and AKT, while this occured in ACM-treated M (Figure 31 B). 
In contrast, PC-12  rat pheochromocytoma cells, the gold-standard for  investigating 
TRKA signaling, due to high expression of TRKA at the plasma membrane, responded to 
both ACM and, although to a lesser extent, also to NGF with phosphorylation of AKT 
and p38 MAPK (Figure 31 C). This response was specific for NGF, as it was not observed 
with other neurotrophins (Figure 31 D). These findings suggested that in M, and to a 
lesser extent in PC-12 cells, ACM increased the bioavailability of TRKA. With the notion 
that ACM induces a rapid response, I did not expect regulation at the expression level 
of TRKA. This assumption was preliminarily confirmed at least by the lack of mRNA-
increase within 3h of M-stimulation. RESULTS  75 
 
Figure 31:  NGF activates p38 and AKT in PC12 cells 
(A) M were stimulated for 3 h with NGF (200 ng/ml), BDNF (50 ng/ml), NT3 (20 ng/ml), NT4 
(100 ng/ml) or ACM and IL-10 mRNA and ribosomal 18S RNA were quantified by qRT-PCR. The 
ratio of IL-10 versus ribosomal 18S in ACM-treated cells was set to 1, n  3 if not stated 
otherwise. Data are means ± SEM. ***, p  0.001. Statistics were performed using one-way 
ANOVA and Bonferroni’s post test. (B, C) M (B) and PC-12 cells (C) were treated with ACM or 
NGF (100 ng/ml) for 10 min and relative expression of phosphorylated p38 and AKT to p38 and 
AKT content was followed by Western blotting, n  3. (D) PC12 cells were treated for 10 min 
with  neurotrophins  NGF,  BDNF,  NT3  and  NT4  at  given  concentrations.  P38  and  AKT 
phosphorylation was analyzed by Western blotting, n = 1. 
5.3.3  S1P-dependent  redistribution  of  TRKA  to  the  plasma  membrane  is 
required for autocrine NGF signaling 
The above described hints pointed to an ACM-induced translocation of TRKA to the 
plasma membrane for its activation and downstream signaling in M. This assumption 
was supported by the highly regulated trafficking of TRKA in neurons (232). Therefore, 
I  investigated  the  localization  of  TRKA  in  primary  human  M  before  and  after 
stimulation with ACM. Indeed, immunofluorescence staining of TRKA and tubulin, as a 
cell  body  marker,  revealed  a  very  rapid  redistribution  of  TRKA  to  the  plasma 
membrane, reaching full manifestation at 10 min of ACM incubation (Figure 32 A). A 
similar pattern was observed in HEK293 cells overexpressing HA-tagged TRKA (Figure 
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Figure 32:  ACM-induced trafficking of TRKA to the plasma membrane 
(A) Time kinetics of ACM effect on TRKA localization. M were incubated with or without ACM 
and stained for TRKA (red), Tubulin (green) and DAPI (blue). Cells from 3 individual donors 
were  used  and  at  least  6  pictures  per  stimulation  were  acquired.  (B)  HEK293  cells  were 
transfected with HA-tagged TRKA, stimulated for 20 min with ACM and stained for HA (green). 
At  least  8  pictures  per  stimulation  from  2  individual  experiments  were  acquired  and 
representative pictures are shown. Scale bars represent 10 µm. 
  With the intention to characterize the cell organelle of TRKA translocation, I used 
CD36 as membrane marker for the following experiments. By staining for CD36 before 
permeablization of the cells, I was able to nicely depict the delicate and typical M-
pseudopodia and to show potential colocalization of CD36 and TRKA at the plasma 
membrane.  Staining  of  CD36  and  TRKA  revealed  remarkable  differences  between 
unstimulated  and  ACM-stimulated  M.  Control  cells  with  pronounced  CD36
+ 
pseudopodia showed no accumulation of TRKA at the plasma membrane. In contrast, I 
observed  strong  TRKA  staining  at  the  plasma  membrane  in  ACM-stimulated  M, 
accompanied  by  remarkably  reduced  pseudopodia  (Figure  33).  This  effect  was 
abrogated neither by neutralization of NGF nor by the TRK inhibitor K252a (Figure 33), 
which  underscored  the  assumption  of  another  factor  being  involved  in  TRKA 
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Figure 33:  Trafficking of TRKA to the plasma membrane is NGF/TRKA-independent 
M were stimulated for 20 min with or without ACM and inhibitor K252a (250 nM) or anti-
NGF  neutralizing  ab  (aNGF)  (5  µg/ml).  K252a  was  pre-incubated  for  45  min  on  cells  and 
neutralizing ab in ACM before ACM treatment. Cells were stained for CD36 as membrane 
marker (green) and TRKA (red). Scale bars represent 10 µm, cells from 6 individual donors 
were used and at least 10 pictures per donor and stimulation were taken.  
5.3.3.1  ACM activates S1PR to induce src-dependent TRKA shuttling  
The question of the factor responsible for TRKA translocation arose. This led me back 
to S1P, which had been previously identified to be involved in IL-10 regulation (Figure 
11,  (130)).  S1P  and  its  five  receptors  are  known  for  their  ability  to  influence  and 
transactivate  receptor  tyrosine  kinases,  as  exemplified  for  S1PR4  and  human 
epidermal growth factor receptor 2 (Her2/neu) (233) as well as S1P1 and platelet-
derived growth factor receptor (234). Among others, platelet-derived growth factor 
receptor and TRKA cross-activate S1P1/2 (222, 223). Considering this information, I 
investigated the effect of pharmacological inhibitors of S1P receptors on ACM-induced 
IL-10 production, p38 and AKT phosphorylation and finally on trafficking of TRKA. 
  First, I elucidated the effects of S1P receptor antagonists on ACM-induced IL-10 
production.  JTE-013,  described  as  a  S1P2  antagonist  (half  maximal  inhibitory 
concentration (IC50) 1.5 µM) and a S1PR4 antagonist (IC50 4.5 µM) (235), reduced 
ACM-mediated IL-10 production only when used at high concentrations (20 µM vs. 1 RESULTS  78 
µM), whereas the S1P1/3 antagonist VPC23019 (236) did not (Figure 34 A). As only 
high concentrations of JTE-013 showed  inhibitory effects, S1PR4 activation is likely 
required  to  induce  IL-10  secretion  from  M.  This  is  in  line  with  previous  findings 
showing enhanced IL-10 secretion in T cells via S1PR4 signaling (56). Nevertheless, a 
synergistic effect with S1PR2 or other S1P receptors cannot be excluded. 
 
Figure 34:  Antagonism of S1PR reduces IL-10, AKT and src phosphorylation 
(A) ACM with or without inhibitors JTE-013 (20 µM), VPC23019 (1 µM) was incubated on M 
and IL-10 protein was measured in supernatant after 24 h by CBA. ACM treatment was set to 
1, n  5. (B, C) M were treated with ACM with or without JTE-013 (20 µM), PP2 (10 µM), 
K252a (250 nM) for 30 min and relative expression of phosphorylated p38, AKT or src to p38 
and AKT content was followed by Western blotting. For quantification, ACM treatment was set 
to 1, n  5. Inhibitors were pre-incubated for 45 min on cells. Data are means ± SEM and 
statistics were performed using student’s t-test. **, p  0.01; ***
/###, p  0.001. 
  To further substantiate S1P signaling in IL-10 regulation, I investigated the two 
required  signaling  pathways  and  observed  S1PR-dependent  AKT  phosphorylation 
(Figure 34 B), which, as described above, was strongly TRKA-dependent (Figure 26 B). 
Interestingly, JTE-013 had no influence on p38 activation (Figure 34 B). These data 
corroborate  the  observation  that  TRKA  inhibition  showed  weaker  effect  on  p38 
phosphorylation compared to AKT (Figure 26 D) and that p38 signaling likely required a 
yet unidentified protein factor (Figure 13). Prior results had indicated an important 
role of src in AKT phosphorylation and IL-10 production (Figure 12 C, Figure 26 B). 
Intriguingly, src phosphorylation was markedly  reduced with JTE-013, but not with 
K252a (Figure 34 C) indicating a putative link involving src between S1PR and TRKA 
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  In a next step, I was intrigued to know whether TRKA trafficking was influenced 
by S1PR and src. Indeed, stainings revealed ablated ACM-depended translocation of 
TRKA to the plasma membrane when S1PR and src were blocked by JTE-013 and PP2 
respectively (Figure 35).  
 
Figure 35:  TRKA translocation depends on S1P and src signaling 
M were stimulated for 20 min with or without ACM and inhibitors JTE-013 (20 µM), PP2 
(10 µM). Inhibitors were pre-incubated for 45 min on cells before ACM treatment. Cells were 
stained for CD36 as membrane marker (green) and TRKA (red). Scale bars represent 10 µm, 
cells from 6 individual donors were used and at least 10 pictures per donor and stimulation 
were taken.  
  In conclusion and summarized in Figure 42, the here presented data identified a 
complex regulation of IL-10 secretion from human M. Apoptotic cell-derived S1P 
activates S1PR. The resulting signaling via src is a requisit for TRKA translocation to the 
plasma membrane. Membrane-associated TRKA is stimulated by autocrine NGF, which 
results in induction of IL-10 mainly through PI3K/AKT signaling. However, an unknown 
ACM-derived factor, signaling through p38, is additionally required for the full M 
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5.4  Regulation of TAM markers of mice and men 
5.4.1  ACM induces differentially regulated TAM markers 
Within  the  tumor  environment,  tumor-associated  macrophages  express  various 
enzymes,  transcription  factors,  receptors  and  soluble  mediators  to  establish  and 
maintain  a  tumor-favourable  environment  (depicted  and  summarized  in  the 
introduction, Figure 6 and Figure 7). To verify the relevance of my in vitro model of 
ACM-treated  M  in  comparison  to  the  in  vivo  situation  of  TAM,  I  screened  for 
induction and regulation of well-described TAM markers in ACM-treated M.  
  Interestingly, already within  3 h ACM induced  a variety of TAM markers and 
targets of ACM-derived S1P signaling in M (115, 130, 133, 134, 237), such as VEGF, 
ADORA2A, IDO, IL-8, HIF-1, and IL-1ra, but had no effect on mRNA expression of 
mannose receptor 1 (MRC-1) (Figure 36 A).  
 
Figure 36:  TAM markers in ACM-stimulated M 
(A) mRNA regulation of TAM markers IL-10, VEGF,  ADORA2A, IDO, IL-8, HIF-1, IL-1ra and 
MRC-1 after 3 h stimulation with ACM compared to unstimulated control cells was quantified 
against ribosomal 18S RNA by qRT-PCR. The ratio of TAM marker mRNA versus ribosomal 18S 
in ACM-treated cells was set to 1 (B) IL-10, IL-6, IL-8 and TNF- protein was measured in M-
supernatants after 24 h-incubation with ACM, using CBA.  
In addition to mRNA expression profiles, I noticed drastically enhanced secretion of 
tumor-promoting cytokines, such as IL-6, IL-8 and TNF- by ACM treatment, whereas 
pro-inflammatory,  anti-tumoral  IL-12p70  was  not  detectable  (Figure  19  and  Figure 
36 B).  Now  the  question  arose  whether  the  augmented  TAM  markers  shared  the RESULTS  81 
regulation  patterns  I  had  identified  for  IL-10.  Consequently,  I  employed  inhibitors, 
which had shown suppressive effects on IL-10 induction. Of note, inhibition of S1P 
signaling reduced expression of all markers except IL-1ra, which confirmed previous 
reports for some of the here investigated TAM markers (133, 134). Interestingly, TRKA 
signaling seemed only to be important for cytokine release (Figure 37), but no marker 
showed exactly the same response as IL-10. 
 
Figure 37:  Mechanistic analogy of TAM marker regulation 
(A) TAM marker mRNA and 18S RNA were quantified by qRT-PCR after 3 h of incubation with 
ACM and JTE-013 (20 µM), PP2 (10 µM), K252a (250 nM), Wortmannin (100 nM) or SB203580 
(5 µM). The ratio of TAM marker mRNA versus ribosomal 18S in ACM-treated cells was set to 
1, n  3. (B) Cytokines were measured by CBA in M supernatants after 24 h incubation with 
ACM with or without inhibitors, as in (A). ACM treatment was set to 1, n  5. Inhibitors were 
pre-incubated for 45 min. Data are means ± SEM. Statistics were performed using one-way 
ANOVA and Bonferroni’s post test. *, p  0.05; **
/##, p  0.01; ***
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  Of note, although inhibition of S1P signaling reduced secretion of all investigated 
cytokines, authentic S1P alone or in combination with VCM showed no effect (Figure 
38). This again argues for a modulatory function of S1P in combination with other, yet 
unidentified, AC-derived factors.  
 
Figure 38:  Authentic S1P has no effect on cytokine production 
M were stimulated for 24 h with ACM, VCM with or without S1P or S1P alone and secreted 
IL-10, IL-6, IL-8 and TNF- were measured in the supernatant by CBA, n = 4 – 5. Statistics were 
performed using one-way ANOVA and Bonferroni’s post test. Data are means ± SEM. n.s., not 
significant; ***, p  0.001. 
5.4.2  TRKA signaling is required for cytokine release by murine TAM 
I  wondered  whether  the  discovered  signaling  pathway  was  also  active  in  primary 
tumor-infiltrating M. Therefore, I isolated TAM from primary murine breast cancer 
tissue of PyMT transgenic mice and investigated spontaneously secreted cytokines as 
well  as  putative  mechanistic  parallels  to  human  ACM-stimulated  M.  In  a  first 
approach, I isolated CD11b
+ cells and exposed them to pharmacological inhibitors used 
in the ACM/M approach. After 3 and 24 h, supernatants from CD11b
+ cells, which 
were pre-dominantly CD11b
high, HLA-DR
high, F4/80
high M (238), were collected and 
cytokine release (IL-10, IL-6, TNF-, MCP-1, IL-12p70 and IFN-) was assessed. At both 
time points, the cells produced significant amounts of IL-10, IL-6, TNF- and MCP-1 
without prior stimulation, whereas, as expected, the classical inflammatory IL-12 or 
IFN- were not detectable (Figure 39 A and B). Indeed, K252a and SB203580 markedly 
suppressed IL-10 release from primary TAM. Although the TRK inhibitor K252a was 
surprisingly potent in regulating cytokine secretion at 24 h, I exclude toxicity since the 
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stress. In contrast, src inhibition was only effective at the 24 h time point. This might 
reflect a situation where TRKA is already localized at the plasma membrane due to 
activation of CD11b
+ cells e.g. by dying tumor cells within the tumor. Compared to IL-
10, IL-6 and TNF- were regulated in a similar manner, being also dependent on TRKA. 
Interestingly,  the  PI3K  inhibitor  Wortmannin  did  not  block  cytokine  production  by 
CD11b
+ cells (Figure 39 C - F), except for MCP-1, contrasting its potent suppression of 
IL-10 in the human setup (Figure 12 C).  
 
Figure 39:  TRKA signaling is operating in murine CD11b
+ cells of PyMT tumors 
(A, B) CD11b
+ cells were isolated from PyMT tumors and cultured for 3 or 24 h. Spontaneous 
cytokine secretion (IL-10, IL-6, TNF-, MCP-1, IL-12, IFN-) was measured. IL-12 and IFN- were 
not detected. 3 h: n = 3, 24 h: n = 5. (C-F) CD11b
+ cells were isolated from PyMT tumors and 
cultured for 3 or 24 h with or without inhibitors PP2 (10 µM), K252a (250 nM), SB203580 (10 
µM), Wortmannin (100 nM) and secreted cytokines were measured. For statistical analysis, 
DMSO (0.1%) solvent-treated cells were set to 1, 3h: n = 3, 24h: n 4. All data are means ± 
SEM. Statistics were performed using one-way ANOVA and Bonferroni’s post test.*
/#, p  0.05; 
**
/##, p  0.01; ***
/###, p  0.001.  
  CD11b
+  immune  cells  are  not  a  homogenous  cell  population,  as  they  are 
comprised of CD11b
+, Ly6G
+ granulocytes, CD11b
+, F4/80
-, HLR-DR
-, Ly6C
+ monocytes; 
CD11b
+, F4/80
-, HLR-DR
-, Ly6C
- monocytes and CD11b
+, F4/80
+, HLR-DR
+ TAM, which 
are all potentially capable of secreting the above measured cytokines. To corroborate RESULTS  84 
the earlier findings and to verify the importance of TAM in cytokine secretion I sorted 
the four distinct CD45/CD11b
high immune cell sub-populations mentioned above from 
PyMT  tumor  single  cell  suspensions.  TAM  were  the  major  cell  population  (80%) 
within the sorted CD45/CD11b
high cells (Figure 40 A). The four cell populations were 
seeded at identical densities (6000 cells/well) and 24 h  later cytokines were again 
measured in supernatants. IL-12p70 and IFN- were not detected. IL-10 was measured 
in all four fractions, whereas only TAM showed the previously observed regulation by 
inhibitors PP2 and K252a. IL-6 and TNF- secretion was only pronounced by the TAM 
population  and  responded  to  the  used  inhibitors.  When  I  seeded  TAM  at  higher 
density  (20,000  cells/well)  the  observed  effects  were  verified  and  MCP-1  was  also 
detectable, its release being dependent on src and TRKA (Figure 40 B and C).  
 
Figure 40:  TAM are the main CD11b
+ cytokine producing cells in PyMT tumors 
(A) Distinct CD45
+/CD11b
+ immune cell populations were isolated from PyMT tumors and the 
relative amounts (%) of sub-populations within the CD45
+/CD11b
+ population are shown. (B, C) 
Cells were cultured at the indicated densities for 24 h with or without inhibitors PP2 (10 µM), 
K252a  (250  nM)  and  spontaneous  cytokine  secretion  (IL-10,  IL-6,  TNF-,  MCP-1)  was 
measured. MCP-1 was only detected at higher cell density, n = 3. All data are means ± SEM. 
Statistics were performed by student’s t-test. *, p  0.05; **, p  0.01. 
  In conclusion, the combined presented data suggests a very tight and specific 
regulation  of  IL-10,  as  no  other  investigated  marker  responded  identically. RESULTS  85 
Additionally,  signaling  pathways  activated  downstream  of  TRKA  might  be  species-
specific. However, TRKA was involved in cytokine secretion from both human tumor 
cell-activated M and isolated murine TAM, which were primed by tumor cells in vivo, 
giving room for further research and possible translation to future cancer therapies. 
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6  Discussion 
The milestone review  by Hanahan and Weinberg, ‘The Hallmarks of Cancer’  (239), 
summarized six characteristics of cancer cells enabling them to malignantly outgrow. 
Cancer therapy predominantly focuses on targeting cancer cells directly, and so far not 
much attention has been paid on the tumor microenvironment as therapeutic target. 
This gradually changed over the last ten years as marked by the expansion of cancer 
hallmarks,  including  new  aspects  of  tumor  biology,  namely  avoiding  immune 
destruction and tumor-promoting inflammation ((103, 240) , Figure 41).  
 
Figure 41:  Hallmarks of cancer 
Adopted from (240) 
  Due to a lack of nutrients, diminished oxygen supply, chemotherapy or radiation, 
a high apoptosis index is found within tumors. The impact of dying cancer cells on 
fueling cancer growth was recently connected to M polarization in tumors (16, 241, 
242). However, as early as 1956, Révész described that inoculation of a mixture of 
dead and viable cancer cells drastically augmented tumor growth and reduced overall 
survival  in  mice  compared  to  viable  cells  only  (243).  Mechanistic  proof  for  this 
observation comes from interaction of apoptotic tumor cells with neighboring cancer 
cells,  as  well  as  immune  cells.  Cell  death  and  concomitant  caspase-3  activation  in 
tumors was recently shown to stimulate growth and survival of tumor cells by the 
release of PGE2 (244), and vaccination of M with apoptotic but not necrotic cancer DISCUSSION  87 
cells acted as a strong priming factor for rapid growth of tumor xenografts in mice 
(245).  
  In  this  scenario,  direct  cell-cell  contact  of  apoptotic  cells  and  M  was  not 
required for phenotypical changes in M (130). Earlier studies from our lab (133-135, 
241, 246), as well as the presented data herein, show pronounced induction of tumor-
promoting  cytokines  and  expression  of  well  established  TAM  markers  in  M 
challenged  with  supernatant  of  apoptotic  cancer  cells.  Since  especially  in  breast 
cancer, TAM exert powerful tumor-promoting functions by driving immune as well as 
tumor cells to promote tumor growth (98, 131), I chose dying MCF-7 breast cancer 
cells for my studies. Of note, supernatant from other solid tumor cell  lines, which 
respond to apoptotic stimuli, e.g. A549 lung cancer cells or DU145 prostate cancer 
cells, show comparable  responses in M. This simplified model to investigate and 
understand  aspects  of  M  activation  in  tumors  certainly  does  not  reflect  the 
complexity of TAM plasticity and diversity in different stages of cancer progression (98, 
247) but may serve as an acceptable starting point.  
  With  the  intention  to  characterize  the  nature  of  macrophage  responses  to 
apoptotic  cancer  cell  supernatant,  I  investigated  in  detail  the  production  of  the 
immunosuppressive cytokine IL-10: 
 
1)   I  started  to  evaluate  the  impact  of  S1P  and  common  intracellular  signaling 
pathways in IL-10 production. 
2)   Knowing  that  S1P  was  not  the  only  ACM-derived  factor  responsible  for  M 
responses,  I  performed  an  adenoviral  RNAi  high-throughput  screen  to  reveal 
novel regulators of M polarization.  
3)   Following screen validation of several targets of a distinguished IL-6/IL-10 co-
regulatory cluster, I chose TRKA as candidate to perform mechanistic in-depth 
analysis of IL-10 regulation. 
4)   Finally,  having  elucidated  the  complex  S1PR/src/TRKA/AKT-signaling  circuit 
resulting in IL-10 release after ACM stimulation, I investigated the involvement of 
this signaling axis on other tumor-associated markers in ACM-stimulated human 
M and in primary murine immune cells infiltrating PyMT mammary carcinoma.  DISCUSSION  88 
6.1  The facets of S1P signaling in M 
The  decision  to  study  mechanisms  of  IL-10  secretion  in  detail  evolved  from 
observations  that  IL-10  release  from  M  was  subject  to  complex  regulation  as 
compared to e.g. IL-8 and TNF-. Co-cultures of M with cancer cells followed by 
stimulation with LPS/IFN- resulted in enhanced IL-8 and reduced TNF- production 
compared to LPS/IFN-alone. The effect of co-cultures was dependent on cancer cell 
death and SK2 in cancer cells. Interestingly, LPS/IFN--induced IL-10 secretion was not 
influenced  by  cancer  cells,  but  when  treating  Mwith  ACM  or  ACM-siSK2  in  the 
absence  of  LPS/IFN-,  IL-10  production  was  cell  death  and  SK2  dependent  (130).  I 
therefore  concentrated  on  ACM-mediated  IL-10  induction  without  further  M 
activation by LPS/IFN-. In early experiments, I verified M as the exclusive source of 
IL-10  in  my  system,  as  cancer  cells  are  also  capable  of  IL-10  production  (143). 
Furthermore, I asked whether cancer cell death was necessary to trigger IL-10 release. 
I was able to reproduce previous results from our lab (130) showing S1P dependancy, 
but  neither  authentic  S1P  alone  nor  in  combination  with  supernatant  from  viable 
cancer cells provoked IL-10 secretion. During that time, we published data  from a 
MCF-7  xenograft  study  in  nude  mice,  emphasizing  the  potent  role  of  S1P  on  M 
functions within tumors by regulating M polarization but not infiltration. A drastically 
reduced tumor  burden of MCF-7-siSK2 tumors compared to MCF-7-wt tumors was 
observed,  probably  due  to  the  inflammatory,  anti-tumor  M  phenotype  in  siSK2 
tumors (207).  
  S1P is a multipotent signaling molecule and, by binding to its 5 receptors, can 
activate  multiple  signaling  pathways  dependent  on  expression  profiles,  interaction 
with specific signaling molecules and cross-talk with other receptors (see 3.2.2.4 and 
5.3.3.1). Of the five receptors, S1PR4 is primarily expressed by immune cells (248) and 
might be the dominant S1P receptor on human M (129). There are yet few functional 
studies concerning S1PR4 in immune cells. Interestingly, forced expression of S1PR4 in 
T cells inhibited proliferation accompanied by reduced secretion of IL-2 and IFN- but 
enhanced IL-10 release (56). In my work, supportive evidence for the importance of 
S1PR4 emerged from immunofluorescence data. I observed pronounced retraction of 
pseudopodia following ACM treatment and incubation with the S1PR2/4 inhibitor JTE-
013  markedly  restored  pseudopodia  expression.  This  finding  correlates  with DISCUSSION  89 
observations  from  Koh  et  al.,  who  reported  that  S1P  initiates  retraction  of 
pseudopodia in NIH3T3 clone 7 cells (249). Furthermore, overexpression of S1PR4 in 
chinese  hamster  ovary  cells  (CHO-K1)  stimulated  with  S1P  showed  cytoskeleton 
rearrangement  and  rounding  of  cells  (250).  However,  involvement  of  other  S1PRs 
alone or in combination cannot be excluded, as JTE-013 at concentrations used here 
not  exclusively  affects  S1PR4.  Moreover,  previous  studies  on  ACM-stimulated  M 
have shown involvement of other S1PRs. In murine M, S1PR2 accounted for ACM-
induced arginase-2 expression (135), and S1PR1 led to augmented heme oxygenase-1 
in ACM-stimulated human M (133). Authentic S1P was sufficient to reproduce ACM-
mediated HO-1 (133), Arg-2 (135), Bcl-2 and Bcl-xl expression, protected M from 
chemotherapeutic-induced cell death and repressed NFB activity (34). On the other 
hand, HIF-1 expression (134) and, regarding the here presented data, overall cytokine 
production  were  S1P-dependent  but  required  an  additional  yet  unidentified  factor 
(6.4.1). 
6.2  Validation of IL-6/IL-10 co-regulation 
To affect M polarization during tumor development, the goal must be to identify 
regulators impinging on more than one phenotypical and preferable functional aspect 
of these cells. Therefore, after completion of the HTS on IL-10 regulation, I screened 
for additional cytokines (IL-6, IL-8, IL-12), which are positively (IL-6, IL-8) or negatively 
(IL-12) associated with macrophage-dependent tumor promotion (97). Interestingly, a 
pronounced cluster of shRNAs, reducing both IL-10 and IL-6 secretion was identified. 
  This revealed co-regulation spurred my interest, as IL-10 and IL-6 signal through 
STAT3 (251) to promote tumor outgrowth, although by different mechanisms. IL-10 is 
usually  connected  to  suppression  of  anti-tumor  immune  responses.  IL-6  is  rather 
associated with promoting survival and proliferation of tumor cells as well as tumor 
angiogenesis (252, 253). Therefore, targeting a common regulator of tumor-associated 
production of these cytokines might be advisable. Focusing on this cluster, I verified 
five of the identified targets in a different set-up in vitro, one being IL-4R, which has 
been  described  to  contribute  to  TAM  generation  in  mouse  models  (110,  254). 
However, I also identified a multitude of new genes that were not previously linked to 
TAM generation or M polarization. During validation, two out of five targets affected DISCUSSION  90 
release of IL-10 and IL-6, two targets influenced either IL-10 or IL-6, whereas one target 
was not confirmed. Keeping in mind the complex screening procedure using primary 
cells and the different selection and maturation stimuli for M (CD14
+ selection and 
M-CSF vs. selection by adherence and human serum), the comparatively high level of 
reproducibility strengthens the credibility of the identified genes regulating cytokine 
expression in this particular setting. Nevertheless, the putative targets identified in the 
HTS require independent validation in vitro as well as in vivo in relevant assays in the 
future.  
6.2.1  IL-4 receptor alpha 
One of the identified IL-10 and IL-6 co-regulators was IL-4R/IL-4RA, one subunit of the 
receptor for both IL-4 and IL-13 (255). These two cytokines play pivotal roles in M 
phenotyping  relevant  for  wound  healing  and  allergic  inflammatory  diseases. 
Additionally, both cytokines are established inducers of IL-10 (95, 256). However, the 
source and the identity of the ligand for IL-4R was unknown, since IL-4 was produced 
by  neither  MCF-7  cells  nor  M  stimulated  with  ACM.  Interestingly,  human  M 
produced low levels of IL-13 (80 pg/ml). Therefore, IL-13 released by M themselves 
(257) rather than cancer cells (258) might trigger IL-10 and IL-6 in an autocrine fashion 
(Figure  43).  A  possible  intermediate  in  this  mechanism  might  be  IL-13-dependent 
TGF- production (255) augmenting IL-6, which has been described for PBMCs and 
endothelial cells (259, 260). In line, TGFBR3, TGFBI and other TGF-related genes in 
connection  with  IL-10  production  emerged  from  the  screen  (refer  to  6.4.1). 
Identification of the well known IL-4RA-dependent IL-10 production can be regarded as 
verification of the screening approach. In addition, diminished IL-6 production, which 
was to my knowledge not described before, adds novelty.  
6.2.2  Cannabinoid receptor 2 
Besides IL-4RA, I validated the cannabinoid receptor 2 (CBR2) to be involved in IL-10 
and IL-6 secretion by ACM-stimulated M. Endocannabinoids are potent regulators of 
immune  responses  (261).  Under  inflammatory  conditions  they  may  provoke  anti-
inflammatory effects in M and are described to be directly synthesized by M (212, 
262).  It  was  shown  that  in  murine  M,  cannabinoids  reduced  oxLDL-mediated 
inflammatory responses (263). Additionally, LPS/IFN- activated murine M (264) and DISCUSSION  91 
glia cells replied to endocannabinoids with enhanced IL-10 secretion (265). Regarding 
IL-6 regulation, CBR2-dependent suppressive effects have been reported (212),  but 
respective experiments were consistently being performed using inflammatory LPS-
stimulated  M  (266)  and  are  therefore  not  directly  comparable  to  my  approach. 
Importantly,  ACM-stimulated  M  did  not  produce  enhanced  levels  of 
endocannabinoids, as determined  in preliminary experiments in our  lab  using  lipid 
mass spectrometry. Therefore, the ligand for CBR2 must be generated by the tumor 
cells  (Figure  43).  With  regard  to  lipids  as  signaling  molecules,  cannabinoids  were 
shown to induce S1P synthesis, and S1P itself functionally interacts with CBR2 (267). 
On  the  other  hand,  sphingosine  was  shown  to  antagonize  cannabinoid  receptor  1 
signaling (268). An interaction of the cannabinoid- and S1P-signaling system might be 
one of the regulatory circuits in ACM-stimulated M. Although I did not identify S1PRs 
in the screening procedure, S1PR4 was associated with IL-10 induction in the primary 
screen, but failed to score in the rescreen. One might argue for activation of multiple 
S1P receptors on M by ACM but also an interaction with the CBR system might be 
possible, which would explain the absence of S1PRs in the final hitlist. 
6.2.3  HMG-CoA reductase 
Unexpectedly,  3-hydroxy-3-methylglutaryl  coenzyme-A  (HMG-CoA)  reductase 
(HMGCR) was identified as a regulator of IL-10 and IL-6 in the screen and was validated 
for  regulating  IL-10  in  ACM-stimulated  primary  human  M  using  a  knockdown 
approach. HMGCR is the rate-limiting enzyme for mevalonate synthesis, essential for 
production of steroids, cholesterol, ubiquinones, and prenylation of GTPase proteins 
(214). I wondered whether statins, widely used HMGCR inhibitors, would reproduce 
the  effect  of  the  HMGCR  knockdown.  However,  the  two  statins  cerivastatin  and 
atorvastatin,  mimicked  the  effect  of  the  HMGCR  knockdown  only  at  certain 
concentrations. This might be explained by off-target side-effects of these drugs, which 
curb the potential benefit of interfering with HMGCR via statins for interfering with 
cancer. As opposed to my limited and defined  system, primarily anti-inflammatory 
effects of statins were observed in large clinical trials (215), and statins were shown to 
reduce radiotherapy-induced pro-inflammatory cytokines and DNA damage (214). On 
the  other  hand,  zoledronic  acid,  a  nitrogen-containing  bisphosphonate  used 
therapeutically against bone resorption, inhibits the farnesyl pyrophosphate synthase DISCUSSION  92 
in  the  mevalonate  pathway.  Zoledronic  acid  was  shown  to  repolarize  anti-
inflammatory TAM towards an inflammatory anti-tumor M1 phenotype with reduced 
IL-10  secretion,  augmented  IFN-,  iNOS  and  NFB  activation  (269).  This  report 
correlates with my findings where statins reduce IL-10 secretion by ACM-stimulated 
M. Thus, it seems that effects of statins might largely depend on the studied cell 
type,  stress  stimulus  or  disease.  However,  interfering  with  HMGCR  might  potently 
impact immunological processes, which have to be closely investigated, as statins are 
widely used and often by patients with multiple morbidities. 
6.3  TRKA involvement in IL-10 production 
An extensive part of my studies focused on the elucidation of TRKA involvement in M 
polarization by ACM (Figure 42). I had chosen TRKA as a target for detailed validation 
of  the  IL-6/IL-10  cluster.  TRKA  and  its  ligand  NGF  were  previously  controversially 
associated with supporting and suppressing tumor growth (187, 220), and especially 
breast cancer cells can benefit from NGF signaling (177, 188, 189, 220). Furthermore, 
TRKA was shown to modulate immune cell function, but until now only a handful of 
studies  have  been  performed  investigating  NGF  effects  on  murine  and  human 
monocytes and M. Inflammatory properties of TRKA activation by NGF are described 
for murine M, as enhanced NO and TNF- production were reported (270). Murine 
peritoneal M showed increased phagocytosis in response to NGF stimulation as well 
as enhanced killing of ingested pathogens (271). Moreover, NGF treatment of mouse 
peritoneal M increased IL-1β release. However, these effects were not observed in 
human M (272). Importantly, with  regard to  my studies, TRKA was shown to be 
highly  expressed  on  human  monocytes  but  largely  down-regulated  upon 
differentiation to M (273). Under unstimulated conditions, my experiments revealed 
that TRKA is not associated with the plasma membrane of M. This observation is 
corroborated by the assumption that low TRKA expression in mature M compared to 
monocytes might enhance the sensitivity of TRKA activity regulation, since TRKA is 
prone  to  auto-activation  when  highly  expressed  (274).  Interestingly,  in  human 
monocytes  and  monocyte-derived  dendritic  cells,  NGF  seems  to  elicit  anti-
inflammatory  properties.  Bracci-Laudiero  et  al.  showed  that  LPS-stimulated  human 
monocytes  responded  to  neutralization  of  endogenous  NGF  with  reduced  IL-10 DISCUSSION  93 
secretion (224). Along this line, NGF alone was sufficient to induce IL-10 in human 
monocyte-derived dendritic cells (275), which I did not observe in human M. Thus, 
limited  availability  of  TRKA  might  regulate  its  signaling  in  M,  as  I  observed 
pronounced constitutive NGF secretion by unstimulated M, which therefore cannot 
be the limiting factor. Contrary to my observations, Samah et al. previously reported 
enhanced  gene  expression  of  NGF  upon  virtually  any  kind  of  activation,  but  no 
detectable secreted protein in M-CSF/GM-CSF-differentiated human M (272). These 
data point to a macrophage-specific receptor regulation among human myeloid cells, 
which might be sensitive to different M differentiation protocols. 
  My data on TRKA biology reinforce the importance of S1P in M polarization. 
Immunofluorenscence stainings strongly support S1PR/src-mediated shuttling of TRKA 
to the plasma membrane of human M. This finding might be of relevance not only 
with regard to M activation by dying tumor cells. Activation of sphingosine kinase 1 
by LPS or other pro-inflammatory stimuli in monocytes/M is well established (123, 
276). Thereby, newly generated S1P might be transported to the outside of cells and 
thus,  induce  shuttling  of  TRKA  to  the  plasma  membrane,  finally  modulating  the 
response to LPS.  
  All five S1P receptors have been linked to activation of the PI3K/AKT pathway, 
which was rapidly activated after ACM stimulation. Direct S1P/S1PR signaling could 
partially explain fast AKT phosphorylation in M already 5 min after activation with 
ACM. As TRKA translocation to the plasma membrane reached its amplitude after 10 
min, the rapid AKT phosphorylation was unrelated to TRKA activation and thus, not 
related to the studied IL-10 induction. However, as seen by phosphorylation-sensitive 
Western  blot  analysis  and  the  use  of  pharmacological  inhibitors,  AKT 
phosphorylation/activation at 30 min, after TRKA shuttling had occurred, was clearly 
dependent on S1PR, src and TRKA signaling; the same pathways that were critically 
involved in IL-10 induction by ACM. These findings strongly suggest that the autocrine 
NGF  loop  and  the  preceding  S1PR/src-dependent  translocation  of  TRKA  were 
necessary for AKT phosphorylation. Literature reinforces this src-mediated interaction 
as  src  kinases  are  known  to  be  important  mediators  between  G  protein-coupled 
receptors  and  tyrosine  kinase  receptors,  where  they  associate  with  the  latter  to 
influence  functional  responses.  Furthermore,  src/TRKA  interaction  was  shown  to DISCUSSION  94 
facilitate  and  enhance  NGF  signaling  (277).  My  data  add  a  different  facet  to  this 
important  interaction  by  showing  that  TRKA  shuttling  depends  on  src  kinases.  In 
analogy, fibroblast growth factor receptor 1, another tyrosine kinase receptor, also 
requires  src  for  endosomal  activation,  trafficking  to  the  plasma  membrane  and 
signaling (278).  
 
Figure 42:  Scheme of IL-10 induction by ACM in macrophages 
S1P, generated by apoptotic cells, induces src-dependent TRKA translocation to the plasma 
membrane, where autocrine NGF accesses its receptor to signal through PI3K/AKT and p38 
provoking IL-10 production. Besides S1P, at least one other factor signaling through p38 is 
necessary for IL-10 induction. Abbreviations: AKT, protein kinase B; IL, interleukin; NGF, nerve 
growth factor; p38, mitogen-activated protein kinase p38; PI3K, phosphoinositide 3-kinase; 
S1P,  sphingosine-1-phosphate;  S1PR,  S1P  receptor;  src,  sarcoma  tyrosine  kinase;  TRKA, 
tyrosine kinase receptor A. 
  Another interesting aspect of S1P/NGF interaction is their shared chemotactic 
potential. NGF increases chemotaxis in murine and human M (272, 279), which has 
also been reported for S1P (33, 128, 280). One might speculate that S1P, derived from 
damaged  tissue,  potentiates  NGF-dependent  recruitment  of  M  to  sites  of  tissue 
damage  and  both  synergistically  promote  tissue  regeneration  or,  in  the  case  of 
neoplastic lesions, cancer outgrowth. Thus, NGF as well as S1P influences functional 
properties of M depending on the local microenvironment.  
6.4  Differential regulation of TAM marker in mice and men 
Although  most  TAM  attributes  correlate  with  an  in  vitro  M2  phenotype,  clear 
differences are described in literature. Recent investigations showed heterogeneous 
activation states of M in cutaneous squamous cell carcinoma, where M expressed 
traditional M1 and M2 marker (96). This observation stresses the differences of in vivo DISCUSSION  95 
compared to in vitro work on M polarization. The model used here has an advantage 
over other in vitro models as it uses crude cancer cell supernatant, i.e. ACM, imitating 
multiple stimuli present in the micro-environment of a tumor. This explains why my 
data  and  others  show  up-regulation  of  inflammatory  (TNF-a)  as  well  as  anti-
inflammatory mediators (IL-10) together with multiple other factors important in pro-
tumoral  functions  of  TAM,  e.g.  IL-6,  IL-8,  PGE2,  VEGF  ((133,  246),  Figure  43).  The 
question arose whether the investigated cytokines (IL-10, IL-6, IL-8, TNF-) and the 
induced mRNA of other TAM-associated markers (VEGF, ADORA2A, IDO, HIF-1, IL-8 
and IL-1ra) were regulated by the same ACM-derived factors and signaling pathways. 
As observed in the screen, this did not seem to be the case as no shRNA reduced IL-10, 
IL-6 and IL-8. Indeed, when looking closely at the detailed pathway of IL-10 regulation, 
i.e.  the  S1P/src/TRKA/PI3K/AKT-axis,  use  of  respective  inhibitors  did  not  reveal  a 
similar  regulation  pattern  for  any  of  the  investigated  markers.  Nevertheless,  TRKA 
inhibition was affecting cytokine secretion, and S1P signaling seemed to be necessary 
for induction of all markers, whereas PI3K/AKT signaling appeared to be restricted to 
IL-10 induction. In line, S1P-neutralizing antibodies resulted in reduced VEGF-mediated 
blood vessel formation in mice (65). In contrast to my data, neuronal cells showed 
requirement of NGF/TRKA signaling for HIF-1-dependent VEGF induction (281). This 
might  be  due  to  analysis  at  different  time  points  and  cell  type-specific  regulation 
patterns, as I had observed for M and neuronal progenitor PC-12 cells. 
  To  validate  my  results  obtained  in  ACM-stimulated  human  M  and  to 
corroborate  my  data  in  a  more  physiological  context,  I  used  CD11b
+  cells  freshly 
isolated from PyMT mammary tumors. These cells were primarily TAM, as observed by 
FACS  staining  and  FACS-based  cell  sorting.  After  24  h-culture,  I  analyzed  secreted 
cytokines and found a similar regulation pattern as in ACM-stimulated human M. 
One major difference was the PI3K/AKT-independent regulation of IL-10. However, all 
measured cytokines (IL-10, IL-6, MCP-1 and TNF-) were dependent on src and TRKA 
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Figure 43:  Summary of TAM marker regulation and autocrine factors 
Apoptotic cancer cells secrete S1P and potentially endocannabinoids to induce TAM markers in 
primary human macrophages. Besides S1P signaling, NGF/TRKA, as well as CBR2, IL-4R and 
likely autocrine factors such as IL-13, FGF and EGF are involved. Factors, receptors marked with 
‘HTS’, were discovered in the RNAi screening procedure. Abbreviations: ADORA2A, adenosine 
receptor A2A; CBR2, cannabinoid receptor 2; EGF, epidermal growth factor; FGF, fibroblast 
growth factor; HTS, high-throughput screen; IDO, indolamine 2,3-dioxygenase; IL, interleukin; 
IL-4R,  interleukin  4  receptor-alpha;  NGF,  nerve  growth  factor;  PI3K,  phosphoinositide  3-
kinase; S1P, sphingosine-1-phosphate; S1PR, S1P receptor; src, sarcoma tyrosine kinase; TNF-
, tumor necrosis factor-alpha; TRKA, tyrosine kinase receptor A. 
  The complexity of the tumor environment and even of ACM is until now not fully 
understood,  and  the  interaction  of  the  various  factors  either  secreted  by  viable, 
apoptotic  or  necrotic  cancer  cells  or  by  the  associated  immune  cells  themselves 
represent a challenge for further in-depth research. My obtained data grant an inside 
into the regulation of M function. M themselves are effective producers of growth 
factors (e.g. EGF, FGF, VEGF, IL-8) influencing tumor cell function and possibly possess 
autocrine activity (119, 282), as shown herein for NGF. In the HTS, the IL-6/IL-10 cluster 
contained  fibroblast  growth  factors  (FGF)  8  and  23  and  knockdown  of  EGF  and 
pharmacological  inhibition  of  EGFR,  although  not  reaching  statistical  significance, 
resulted in IL-10 reduction (Figure 43). These autocrine signals could account for the DISCUSSION  97 
distinct  regulation  patterns  of  TAM  markers,  which  are  observed  besides  overall 
importance on S1P signaling. In addition to that, S1P receptors are well known to 
interact  with  several  growth  factor  receptors,  controlling  and  fine-tuning  their 
responses. For instance, extensive data on interaction of S1P and EGF signaling has 
been published (please refer to 3.2.2.4 and 5.3.3.1).  
6.4.1  TGF- - the missing AC-derived protein factor? 
Opposed to AKT, p38 phosphorylation was only mildly reduced by the TRK inhibitor 
and independent of S1PR and src. Hereby, p38 might signal from activated TRKA in 
endosomes, whereas AKT activation preferably occurs at the plasma membrane, which 
is well-described for AKT and ERK activation downstream of TRKA and other tyrosine 
kinase growth factor receptors (232, 283). Additionally, it is plausible that p38 signaling 
is mediated by a so far unidentified AC-derived protein factor, as I had observed a 
pronounced reduction of IL-10 mRNA when using deproteinated ACM, which resulted 
in comparable IL-10 levels as ACM in combination with p38 inhibitor SB203580.  
  It is difficult to speculate about the identity of this factor. To name a few critical 
questions, which have to be answered: Besides S1P, is there only one more factor 
necessary to establish the phenotype I observed in ACM-treated M? If there is more 
than one factor involved, how do they interact? Do they all depend on apoptotic cell 
death  or  are  some  constitutively  secreted  by  cancer  cells?  Do  the  factors  need 
subsequent processing after release? And finally, besides NGF, are there additional 
autocrine secreted factors from M necessary for the full response? Furthermore, 
none of the ACM-induced TAM markers showed the same regulation as IL-10. Which 
leads to the final question, whether there is really another “global player” comparable 
to S1P? 
  Well-established protein factors released by apoptotic cells, as discussed under 
3.1.2.1, are TGF- and lactoferrin. Chemotactic and immunomodulatory responses are 
established  for  lactoferrin  (reviewed  in  (284)).  It  was  shown  that  lactoferrin  has  a 
strong affinity to LPS and modulates TLR4 responses (285). Therefore experimental 
data on lactoferrin are difficult to interpret as LPS contaminations often cannot be 
excluded,  and  obtained  results  show  high  variability  (286).  On  account  of  the 
conflicting literature and the results of the preformed HTS, where no evidence for DISCUSSION  98 
lactoferrin, TLR4, and fortunately LPS involvement was observed, I exclude lactoferrin 
as a potential mediator of the response to ACM in the presented set-up. 
  Regarding TGF-, Herr et al. have previously identified a role of S1P and TGF- in 
HIF-1 induction in ACM-stimulated M, although the factors were not sufficient to 
induce HIF-1 when added exogenously, and it remained unclear, whether TGF- was 
produced by apoptotic cancer cells or by M themselves (134). This fact as well as 
hints from the HTS point to TGF- or a member of the TGF- superfamily to contribute 
to  the  powerful  effects  of  ACM  on  M.  TGF-  is  secreted  as  part  of  an  inactive 
complex consisting of the homodimer TGF-, a latency-associated dimeric propeptide 
(LAP) and a latent TGF- binding protein (LTBP). The TGF--LAP complex is sufficient 
for  TGF-  release  from  cells  and  function.  Nevertheless,  in  the  presence  of  LTBP, 
secretion  as  well  as  correct  disulfide  bond  formation  of  TGF-  is  enhanced. 
Additionally, by binding of LTBP to the extracellular matrix, the complex serves as a 
TGF- reservoir, and LTBPs may regulate the sequestration of the TGF--LAP complex 
and  thereby  TGF-  function.  The  complex  can  be  cleaved  by  plasmin,  matrix 
metalloproteinases (MMP)-2, -9, thrombospondin 1 and integrin v6 to make TGF- 
available for receptor binding (287, 288). In line with my hypothesis, TNF--dependent 
MMP-2 and MMP-9 production was shown in M co-cultured with cancer cells (289), 
and the HTS revealed urokinase plasminogen activator receptor (UPAR, PLAUR) to be 
necessary for ACM-induced IL-10 production. In regard to TGF- activation, UPAR is 
necessary for activation of plasmin and MMPs (290) and was shown to be induced by 
NGF and was required for NGF-dependent cell differentiation (291). Concomitantly to 
LTBP-4  and  PLAUR,  knockdown  of  TGF-  receptor  3  (TGFBR3),  also  known  as 
betaglycan, suppressed ACM-induced IL-10 production during the HTS. TGFBR3 binds 
LTBP-4-released  TGF-  as  well  as  other  activating  or  inhibiting  TGF-  superfamily 
members, e.g. inhibin or bone morphogenetic  proteins  (BMPs). Lacking a signaling 
domain, TGFBR3 presents the bound ligand to TGFBR2, which subsequently forms the 
signaling  complex  with  TGFBR1.  As  TGFBR3  binds  different  classes  of  the  TGF- 
superfamily  ligands,  it  takes  part  in  the  fine-tuning  of  cellular  responses,  and  its 
functional  impact  depends  on  receptor  expression  and  ligand  availability  (292). 
Furthermore, S1P has been shown to transactivate TGFBR and induce SMAD activation 
in renal mesangial cells (293). This transactivation might also occur in M. To further DISCUSSION  99 
speculate, S1P might sensitize TGFBRs or release TGFBR3 from suppressive effectors 
such as inhibins.  
  Artemin and persephin are members of the glia cell line-derived neurotrophic 
factor (GDNF) family, a distant member of the TGF- superfamily. Work on artemin 
postulates  its  oncogenic  potential  in  various  cancer  types,  and  especially  in  breast 
cancer patients, its expression correlates with decreased overall survival (294). The 
two  neurotrophic  factors  bind  to  the  glycosylphosphatidylinositol  (GPI)-anchored 
GDNF family receptor  (GFRA) 3 and 4, respectively. The receptors share the trans-
membrane  tyrosine  kinase  receptor  RET  (295)  and  signal  via  multiple  pathways 
including src, PI3K/AKT and p38 (296, 297). As reported, GDNF family members show 
similar effects as NGF on neuronal development and survival (298, 299), which might 
also be true for functions on M. In the HTS, IL-10 production was dependent on 
GFRA3  as  well  as  GFRA4.  Interestingly,  GDNF-family  members  were  described  to 
require  TGF-  as  co-factor  for  RET-dependent  signaling  (300-302),  and  NGF/TRKA 
signaling was shown to activate RET tyrosine kinase receptors (303). The hypotheses 
are summarized in Figure 44. DISCUSSION  100 
 
Figure 44:  Theoretical regulation in regard to TGF- signaling 
TGF- is secreted in a latent complex from apoptotic cancer cells or macrophages. Several 
proteases  are  known  to  free  TGF-  for  binding  to  TGFBR3,  with  subsequent  activation  of 
TGFR1/2-signaling,  potentially  inducing  IL-10  via  p38.  In  addition,  interactions  of  S1PR  or 
GFRA3/4 with TGFBR1/2 are hypothesized to regulate intracellular signaling and NGF/TRKA 
signaling  potentially  activates  RET.  Artemin  and  Persephin,  derived  from  cancer  cells 
potentially bind GFRA3/4 to induce IL-10. Furthermore, TGF- as well as S1P signaling leads to 
HIF-1  and  VEGF  induction.  In-depth  validated  IL-10  regulation  is  depicted  in  gray,  and 
factors/receptors  marked  with  ‘HTS’  were  discovered  in  the  RNAi  screening  procedure. 
Abbreviations: AKT, protein kinase B; GFRA, glycosylphosphatidylinositol (GPI)-anchored glia 
cell line neurotrophic factor (GDNF) family receptor ; HIF-1, hypoxia inducible factor-1alpha; 
HTS, high-throughput screen; IL, interleukin; LAP, latency-associated dimeric propeptide; LTBP, 
latent TGF- binding protein; MMP, matrix metalloproteinase; NGF, nerve growth factor; PI3K, 
phosphoinositide  3-kinase;  PLAUR/UPAR,  urokinase  plasminogen  activator  receptor;  RET, 
rearranged  during  transfection;S1P,  sphingosine-1-phosphate;  S1PR,  S1P  receptor;  src, 
sarcoma  tyrosine  kinase;  TGF-,  transforming  growth  factor-beta;  TGFBR,  TGF-  receptor; 
TRKA, tyrosine kinase receptor A; VEGF, vascular endothelial growth factor. 
6.5  Future cancer therapies 
Classical cancer therapies - namely surgery, radiation and chemotherapy - are to a 
great extent limited in their ability to target metastatic and minimal residual cancer. 
Immunotherapy employing monoclonal antibodies or small molecule tyrosine kinase 
inhibitors  is  an  evolving  field,  which  will  hopefully  improve  existing  conventional DISCUSSION  101 
therapies  to  target  cancer  cells.  Furthermore,  over  the  last  years,  the  tumor-
microenvironment gained acceptance as putative therapeutic target with the goal to 
overcome  tumor-mediated  immunosuppression  and  to  activate  potent  and  well 
directed cytotoxic immune responses. In this respect, targeting the inhibitory cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA-4) with ipilimumab (Yervoy) to potentiate 
antitumor  T  cell  responses  was  recently  approved  by  the  U.S.  Food  and  Drug 
Administration  (FDA)  and  European  Medicines  Agency  (EMA)  for  patients  with 
unresectable melanoma (304).  
  Focusing  on  M,  efforts  have  been  undertaken  to  define  gene  expression 
profiles of TAM in different mouse models of cancer (305-307). However, functional 
conclusions are often difficult to draw when looking at gene expression signatures. 
This strengthens my approach of looking at functional readouts to elucidate important 
mediators in TAM biology. Interestingly, a few studies indicate that these functional 
properties of TAM can be reversed to promote anti-tumor immunity leading to tumor 
regression (308, 309). In a recent phase 1 trial, an agonistic CD40 monoclonal antibody 
in combination with gemcitabine was tested on surgically incurable pancreatic ductal 
adenocarcinoma patients. CD40 is a co-stimulatory protein on antigen-presenting cells, 
important for their activation. The authors of the study observed CD40-dependent 
tumor regress in some patients, in line with their hypothesis of CD40-mediated T cell-
dependent antitumor responses. Surprisingly, by subsequent mechanistic analysis in 
mouse models, the group discovered CD40-activated infiltrating anti-tumor M to be 
the effector cells. These M were characterized by enhance MHC II expression and 
elevated  levels  of  IL-12  and  TNF-but  not  IL-10  (309).  This  study  highlights  the 
potential of new immuno-based therapies activating the innate immune system, not 
only as an initiator of cytotoxic T-cell responses, but as a powerful primary effector. 
These promising results on the recruitment and functional properties of M as targets 
in cancer therapy may give rise to further clinical studies on these cells as they are 
highly  abundant  in  a  variety  of  solid  human  tumors,  and  their  presence  is  often 
associated with poor patient survival (310-312). 
  In regard to the here presented work, multiple aspects of S1P and NGF/TRKA 
biology  are  under  current  investigation  for  innovative  therapies.  ASONEP 
(sonepcizumab), a S1P-neutralizing antibody from LPath, Inc is scheduled to advance to DISCUSSION  102 
phase 2 trials against renal cell carcinoma (as stated on www.lpath.com), and Safingol, 
a multikinase inhibitor targeting sphingosine kinase 1, was recently tested for its safety 
in a clinical phase 1 trial. It was well tolerated and reduced S1P levels in patients’ blood 
(313).  This  opens  the  way  for  further  trials  on  SK/S1P-mediated  tumor-promoting 
effects, both on cancer as well as cancer-associated immune cells. In the field of small 
molecule  tyrosine  kinase  inhibitors,  Milciclib  (PHA-848125),  a  TRKA/CDK  (cyclin-
dependent  kinases)  inhibitor,  drastically  reduces  xenograft  growth  of  various  solid 
tumor  cell  lines  (314).  Concomitantly,  a  phase  1  PHA-848125AC  tolerability  and 
pharmacokinetics study in patients with advanced/metastatic solid tumors (315) was 
performed  and  a  phase  2  trial  on  thymic  carcinoma  patients  is  recruiting  at  the 
moment (www.clinicaltrials.gov). Additionally, Pfizer is recruiting bone metastases pain 
patients  for  a  clinical  phase  2  trial  with  the  anti-NGF  antibody  Tanezumab 
(www.clinicaltrials.gov),  although  in  summer  2010,  all  trials  on  Tanezumab  against 
osteoarthritis pain were stopped due to cases of arthritis worsening (316). Thus, S1P as 
well  as  NGF  hold  great  potential  as  novel  therapeutic  targets  in  cancer  and  other 
diseases, simultaneously addressing tumor and immune cell biology. 
6.6  Concluding remarks 
In summary, the here presented study emphasizes the complex and tightly regulated 
biology of M function. The highly versatile cells respond to their environment by 
activation of divers signaling pathways, which are often interlinked. Supernatant of 
apoptotic breast cancer cells, as the tumor microenvironment, contains a variety of 
signaling molecules of lipid and protein origin. The performed adenoviral shRNA screen 
brought forward a list of until now underappreciated gene products involved in the 
corresponding  M  answer.  The  exact  characterization  and  identification  of  the 
secreted factors and their functions on M provides much potential for further studies 
of  mechanistic  and  potential  therapeutic  interest.  Moreover,  the  functional  assay 
might have significant benefits over microarray gene expression studies, which usually 
provide only information concerning expression of genes on mRNA level at a given 
time point, without considering a functional aspect.  
  The  detailed  analysis  of  TRKA  signaling,  with  regard  to  IL-10  production  in 
macrophages contributes to the growing body of evidence concerning the importance 
of NGF/TRKA signaling in cancer. Whereas an impact of this signaling axis on tumor cell DISCUSSION  103 
survival in vitro is known (317), its impact on the microenvironment has not yet been 
defined. My work provides first important findings to the involvement of NGF/TRKA in 
M function in a TAM-like model. Thus, further studies are justified to dissect the 
impact of NGF on tumor-infiltrating immune cells. This might be of great value for 
cancer therapy, by providing a common target on both cancer cells and the tumor-
supportive microenvironment. REFERENCES  104 
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Buffers for cell biology 
Erythrocyte lysis buffer    Phosphate buffered saline (PBS) 
NH4Cl  155 mM    NaCl  137 mM 
KHCO3  10 mM    KCl  2.7 mM 
EDTA  0.1 mM    Na2HPO4  8.1 mM 
    KH2PO4  1.5 mM 
Leukocyte running buffer    pH  7.4 
EDTA  2 mM       
BSA  0.5% (w/v)    Tumor lysis buffer 
in PBS      Collagenase 1A  3 mg/ml 
      DNAse 1  1 U/ml 
Leukcocyte washing buffer      in DMEM   
EDTA  2 mM       
in PBS         
 
Buffers and solutions for Immunoprecipitation and Western analysis  
BSA-TBS buffer      4 x SDS-PAGE sample buffer 
BSA  5% (w/v)    Tris-HCL  125 mM 
in TBS      SDS  2% (w/v) 
      Glycerin  50% (v/v) 
10 x blotting buffer       Mercaptoethanol  10% (v/v) 
Tris/HCl   250 mM    Bromphenol blue  0.002% (w/v) 
Glycine  1.9 M    pH  6.9 
pH   8.3       
      SDS-running buffer 
1 x blotting buffer      Tris/HCl  25 mM 
10 x blotting buffer  10% (v/v)    Glycine  190 mM 
Methanol  20% or 30%    SDS  3.5 mM 
      pH  8.3 
IP buffer         
Tween-20  0,02% (v/v)    1 x TBS    
in PBS      Tris/HCl   50 mM 
    NaCl   140 mM 
Milk-TBS buffer      pH  7.4 
Milk powder  5% (w/v)       
in TBS      TTBS   pH 7.4 
      Tris-HCl   50 mM 
      NaCl   140 mM 
      Tween-20  0.05% (v/v) APPENDIX  125 
NP40 Cell Lysis Buffer, Invitrogen    Urea lysis buffer    
Tris/HCl  50 mM    Tris-HCL pH 6,8  10 mM 
Nonidet P40  1% (v/v)    Urea  6.65 M 
NaCl  250 mM    Glycine  10% (w/v) 
EDTA  5 mM    SDS  1% (w/v) 
NaF  50 mM    pH  7.4 
Na3VO4  1 mM    Add freshly prior use:   
NaN3  0.02% (w/v)    PIM  1 x 
Freshly added prior to use:      Mercaptoethanol  10% (v/v) 
PMSF  1 mM    PhosSTOP  2 x 
PIM  1 x    Na3VO4  7 mM 
PhosSTOP  2 x       
      4 x Upper Tris buffer   
      Tris-HCL  0.5 M 
      pH  6.8 
         
      4 x Lower Tris buffer   
      Tris-HCL  1.5 M 
      pH  8.8 
 
Sodium dodecyl sulfate (SDS)-polyacrylamide gels 
  Separating gels  Stacking gel 
  6%  10%  15%  4% 
40% Acrylamide/Bis-acrylamide 
(37.5% : 1.0% w/v) 
1.5 ml  2.5 ml  3.75 ml  300 µl 
Lower tris buffer (4 x)  2.5 ml  2.5 ml  2.5 ml   
Upper tris buffer (4 x)        750 µl 
H2O distilled  5.9 ml  4.9 ml  3.65 ml  1.92 ml 
10% SDS (w/v)  100 µl  100 µl  100 µl  30 µl 
TEMED  10 µl  10 µl  10 µl  5 µl 
10% (w/v) ammonium persulfate  100 µl  100 µl  100 µl  50 µl 
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Buffers and solutions for ELISA 
ELISA blocking buffer      ELISA dilution buffer   
BSA  2% (w/v)    BSA  0.5% (w/v) 
in PBS      Tween-20  0.01% (v/v) 
      in PBS   
         
ELISA coating buffer      ELISA washing buffer   
Na2CO3  50 mM    Tween-20  0.01% (v/v) 
NaHCO3  50 mM    in PBS   
pH  9.6       
         
 
Buffers and solutions for Immunofluorescence 
IF binding buffer      IF permeabilization buffer 
FCS  2% (w/v)    Triton X-100  2% (v/v) 
in PBS      in PBS   
         
IF blocking buffer    IF washing buffer   
FCS  30% (w/v)    Triton X-100  0.01% (v/v) 
Triton X-100  0.01% (v/v)    in PBS   
 
Buffers and solutions for molecular biology and microbiology 
Annexin-V binding buffer      SOC medium   
HEPES  10 mM    Tryptone  20 g/l 
NaCl  140 mM    Yeast extract  5 g/l 
CaCl2  2.5 mM    NaCl  0.5 g/l 
pH  7.5    MgCl2  10 mM 
      MgSO4  10 mM 
DEPC-water    Glucose  2 mM 
1 ml Diethylpyrocarbonate (DEPC) in        
1 l distilled H2O       
 stirred over night and autoclaved       
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